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Abstract 
 
 The identification of risk loci in the Human Leukocyte Antigen (HLA) region 
using single-SNP association tests has been hampered by the extent of linkage 
disequilibrium (LD). Penalised regression via Least Absolute Shrinkage and Selection 
Operator (LASSO) can be used as a method for selection of variables in multi-SNP 
analysis, and to deal with the problem of multi-collinearity among predictors. This 
method applies a penalty that shrinks the estimates of the regression coefficients 
towards zero. This is equivalent to applying a double exponential (DE) prior 
distribution to the coefficients with a mode at zero, corresponding to the prior belief 
that most of the effects are negligible in a Bayesian approach. Parameter inference is 
based on the posterior mode, with non-zero values indicating marker-disease 
associations. 
 Single-SNP, stepwise regression and the LASSO approach were applied to 
case-control studies of rheumatoid arthritis, a disease which has been associated with 
markers from the HLA region. A generalisation of the LASSO called the HyperLasso 
(HLASSO), which uses the normal-exponential-gamma prior in place of the DE, was 
also investigated. These approaches were applied to data from the Genetics of 
Rheumatoid Arthritis (GoRA) study. Genotype imputation was used as a means to 
jointly analyse the GoRA and the Wellcome Trust Case Control Consortium 
(WTCCC) HLA SNPs. The North American Rheumatoid Arthritis Consortium 
(NARAC) study was used to validate the findings. 
 After controlling for type-I error, the penalised approaches greatly reduced the 
number of positive signals compared to single-SNP analysis, suggesting that 
correlation among SNP loci was better handled. The HLASSO results were sparser 
but similar to the LASSO results. One SNP in HLA-DPB1 was replicated in the 
NARAC study. In both models, the robustness of the retained variables was verified 
by bootstrapping. The results suggest that SNP-selection using LASSO or HLASSO 
shows a substantial benefit in identifying risk loci in regions of high LD.  
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Chapter 1. Introduction 
 
 
 
 
1.1 Overview of the HLA system 
 
1.1.1 Molecular structure of the HLA system 
 
The major histocompatibility complex (MHC) is a gene-dense region found in almost 
all vertebrates. In humans, the MHC was discovered by J. Dausset in the 1950s and was 
referred to as the human leukocyte antigen (HLA) system. This region is one of the most 
studied parts of the human genome due to its involvement in various diseases, many of them 
being autoimmune diseases.  
The classical HLA region [1], which is located on the short arm of chromosome 6 
(6p21.3), is a 3.6Mb region that contains many genes with varying functions that are essential 
to the immune system. The classical HLA genes encode a set of antigen-presenting molecules 
that are displayed on the surface of the cell. These define the tissue-type of each individual 
and perform the important functions of lymphocyte recognition and initiation of immune 
response. Historically, the classical HLA region has been divided into class I, II and III 
regions based on the functions of the genes. The class I region contains the highly 
polymorphic genes that encode the α-chain of the antigen-presenting class I molecules, HLA-
A, HLA-B and HLA-C, as well as other genes with both immune and non-immune functions. 
The class II region contains the genes that encode the α and β-chains of the antigen-
presenting class II molecules, HLA-DP, HLA-DQ, HLA-DR, and other immune related 
genes, such as the TAP transporters that associate with the classical HLA genes [1]. 
Figure 1.1 presents the structure of the HLA class I and class II HLA molecules. The 
HLA class I genes encode the α chain of the class I HLA molecules that form a functional 
receptor on most nucleated cells.  The HLA class II genes encode the α and β chain of the 
class II HLA molecules, which combine to form heterodimeric protein receptors that are 
expressed on the surfaces of antigen presenting cells.  
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Figure 1.1 The class I and class II HLA molecules 
 
                Source: Klein et al. [2] 
 
 
Located between the class I and the class II regions, the class III region includes non-
classical HLA genes with varying immune functions such as those involved in the 
inflammatory pathways, for instance genes of the tumour necrosis factor family, TNF, LTA 
and LTB [3]. In 2004, Horton and colleagues [3] extended the HLA region to encompass loci 
with immunological functions located further than the original classical class I and class II 
boundaries [3]. The extended HLA region is a 7.6Mb region that includes the extended class I 
and the extended class II regions in addition to the three classical HLA regions. Many 
autoimmune and infectious diseases have been associated with loci in the extended HLA 
region, since approximately 28% of the expressed transcripts from this region have immune 
function [3].  Lie and Thorsby [4] recommended seeking association throughout the extended 
HLA region as many associations have been found therein with complex diseases such as 
type I diabetes (T1D). Figure 1.2 provides a genetic map of the classical and extended HLA 
region, showing the position of the classical HLA loci. 
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Figure 1.2 Genetic map of the classical and extended HLA region. 
 
 
from Lie et al. (2005) [4] 
 
1.1.2 HLA Polymorphism 
 
The classical class I and II genes that encode the antigen-presenting molecules are 
highly polymorphic, as shown in Table 1.1 and Table 1.2.  At the molecular level, these 
polymorphisms are found predominantly in the peptide-binding domains of the HLA class I 
and II molecules, which play an important role in disease resistance and transplant rejection. 
DNA sequence comparisons of the HLA genes have shown high levels of non-synonymous 
base changes, which can result in slight to major functional differences in the encoded protein 
[5]. It is believed that selective advantages, driven by resistance to pathogens, have 
influenced HLA variation since genes that are not directly involved in antigen binding, such 
as HLA-E, HLA -F and HLA -G are less polymorphic [1].  
The selective advantage of heterozygosity, which increases the repertoire of antigens 
that initiate an immune response, and frequency-dependent selection, also referred as the rare 
allele advantage, are two phenomena that are thought to improve resistance to pathogens by 
increasing the diversity of antigens that are involved in the immune response.  
Several of the most commonly studied adverse drug reactions have also been 
associated with the highly polymorphic HLA genes. HLA-B, which is the most polymorphic 
gene of the human genome [6], has been associated with several adverse drug reactions. As 
 16 
 
an example, HLA-B*5701 has been reported to induce a hypersensitivity reaction [7] and 
HLA-B*1502 has been associated with Stevens-Johnson syndrome in Han Chinese [8].  
 
 
Table 1.1 HLA class I genes 
Gene 
Number of 
Alleles 
Number of 
Encoded 
Proteins 
Number of 
Non-Expressed 
Alleles 
HLA-A 965 718 53 
HLA-B 1,543 1,230 43 
HLA-C 626 464 11 
HLA-E 9 3 0 
HLA-F 21 4 0 
HLA-G 46 15 2 
Sources: January 2010, IMGT/HLA, http://www.ebi.ac.uk/imgt/hla/stats.html 
 
 
Table 1.2 HLA class II genes  
Gene 
Number of 
Alleles 
Number of 
Encoded 
Proteins 
Number of 
Non-Expressed 
Alleles 
HLA-DRA 3 2 0 
HLA-DRB1 762 591 5 
HLA-DQA1 35 26 1 
HLA-DQB1 107 78 1 
HLA-DPA1 28 16 0 
HLA-DPB1 138 120 3 
Sources: January 2010,  IMGT/HLA, http://www.ebi.ac.uk/imgt/hla/stats.html 
 
 
1.1.3 The HLA Nomenclature 
 
Originally, serological methods were used to detect HLA gene products. The main 
method was antibody-based HLA allele assignment. With these methods, not all gene 
products were easily detected.  For instance, HLA-B*12 was later split into HLA-B*44 and 
HLA-B*45 with the advent of HLA genotyping technologies. HLA assignment is now made 
using DNA-typing that identities HLA variants at the single nucleotide polymorphism (SNP) 
level.  
Table 1.3 presents the HLA nomenclature of low and high resolution HLA typing. At 
low resolution is the two-digit HLA allele typing, which defines a group of alleles at the 
base-sequence level that encode the same antigen. The high resolution is the four-digit HLA 
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allele typing that identifies a specific base-sequence. The importance of high resolution 
versus low resolution has been shown in organ and tissue transplantation where donors and 
recipients who were matched using the four-digit resolution had a higher rate of success 
compared to the low HLA resolution [9]. Four-digit allele typing is hence recommended for 
use in tissue or organ transplants, as well as in disease association studies. 
Different typing methods are available at varying costs. Some vendors provide 
complete four-digit HLA allele resolution at high cost, whereas others can provide less 
expensive and less accurate typing based only on part of the gene. In the latter case, exons 2 
and 3 are usually used to infer the high resolution level.  
 
 
Table 1.3 The HLA nomenclature 
HLA-A A particular HLA locus 
HLA-A*03 Denotes a group of alleles, which correspond to the serological antigen 
HLA-A*0301 
Sequence variation between alleles, which results in one or more 
nucleotide substitutions that change the amino acid sequence of the 
encoded protein 
             Sources:http://hla.alleles.org/nomenclature/nomenclature_2009.html 
 
 
1.1.4 Pattern of LD in the HLA Region 
 
In addition to the high degree of polymorphism, the HLA region is characterised by 
the presence of high linkage disequilibrium (LD), the non-random association among alleles 
at closely linked loci. A number of authors have described the pattern of LD within the HLA 
region [10]. They observed the presence of long segments of conserved DNA sequences that 
are defined by specific alleles at HLA genes and shared by unrelated individuals [11, 12]. 
These are referred to as conserved extended haplotypes or ancestral haplotypes [13].  
In Caucasians from Northern Europe, the most common ancestral haplotype is 
characterised by alleles HLA-A*01, HLA-B*08, HLA-DRB1*03, HLA-DQB1*02 and HLA-
DQA1*05, and is known as the 8.1 haplotype. Many other ancestral haplotypes exist. The 
MHC Haplotype Consortium, funded by the Wellcome Trust Sanger Institute, has to date 
sequenced eight of the most common HLA haplotypes. These haplotypes were chosen to help 
disentangle the HLA contribution to diseases such as type I diabetes, multiple sclerosis and 
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rheumatoid arthritis (RA) [14]. Details of the eight haplotypes are available from the MHC 
Haplotype Project‟s web site http://www.sanger.ac.uk/HGP/Chr6/MHC/. 
The reason that these haplotypes are highly conserved is still unexplained. It has been 
hypothesised that selective advantage is gained from combinations of alleles that play an 
important role in the immune response [11, 15-18]. Genetic linkage among loci within the 
HLA region might provide functional advantages and is unlikely to have appeared by chance. 
For instance, the association of specific alleles at HLA-DQA1 and HLA-DQB1 located in 
close proximity ensures the production of a functional HLA-DQ molecule, which is 
responsible for antigen presentation and lymphocyte recognition. The clustering of 
functionally related genes and the presence of new allelic variants is not surprising within a 
region that needs to adapt to a vast array of rapidly evolving pathogens.  
 
 
1.1.5 The HLA-DR/DQ block 
 
The classical class II genes form the HLA-DR/DQ block, which is known for the 
presence of extensive LD with alleles at HLA-DRB1. Genes HLA-DRB1, -DRB3, -DRB4 and 
-DRB5 encode four beta-chains of the HLA-DR molecule but only three are possible per 
individual. The HLA-DRB1 gene is the most polymorphic and informative HLA class II 
marker. Alleles at this locus have been shown to partially predict the occurrence of alleles at 
HLA-DRB3, -DRB4, and -DRB5 [19-21]. Each individual carries one expressed HLA-DRB1 
allele and none or at least one allele at HLA-DRB3, -DRB4, or -DRB5, depending on the 
haplotype.  
Table 1.4 presents the relationship between the alleles at HLA-DRB1 and the alleles at 
HLA-DRB3, HLA-DRB4, and HLA-DRB5. 
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Table 1.4 Association between the HLA-DRB1 and -DRB3, 4 and 5 alleles  
HLA-DRB1 
allele 
Presence of a HLA-DRB3, 4, or 5 
allele 
DRB1*01 No other DRB or DRB5 
DRB1*03 DRB3 
DRB1*04 DRB4 
DRB1*07 DRB4 
DRB1*08 No other DRB 
DRB1*09 DRB4 
DRB1*10 No other DRB 
DRB1*11 DRB3 
DRB1*12 DRB3 
DRB1*13 DRB3 
DRB1*14 DRB3 
DRB1*15 DRB5 
DRB1*16 DRB5 
                   Source: GlaxoSmithKline  
 
 
1.1.6 LD between SNPs and the classical HLA genes  
 
 Recently, several groups have produced LD maps of the HLA region using dense 
panels of SNPs. Miretti et al. [10] described in detail the pattern of LD within the extended 
HLA region.  They genotyped 2,335 markers across a 4.46 Mb sub-region of the extended 
HLA region (NCBI34: 28.91Mb– 33.37Mb) with an average marker density of 1 SNP every 
1.9kb. Figure 1.3 displays the sliding window plot of the average squared Pearson coefficient 
correlation (r
2
) that was published in Miretti et al. [10]. They observed that LD fluctuates 
along the region with strong LD within the extended and classical class I region. The lowest 
LD values were found within the class II region, consistent with the presence of multiple 
known recombination hotspots [22]. On average, this figure shows moderate r
2
 values across 
the region with a maximum value of approximately 0.24. Mirreti et al. [10] also investigated 
the decay of LD as a function of distance across the HLA region. They compared their 
findings with a 10Mb region of chromosome 20 reported in [23]. They observed that on 
average the pattern of LD between the two regions was similar. From their analysis, the 
structure of LD among SNPs located in the HLA region did not seem particularly high 
compared to the rest of the human genome. There has been much debate in the literature 
about the level of LD within the HLA region.  Walsh et al. [18] also compared the LD 
structure of the HLA region with that of the rest of the human genome. They examined the 
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pattern of LD relative to both genetic and physical distances. In the classical 3.6Mb HLA 
region, they observed that LD extended over greater physical distances than elsewhere in the 
genome, but aside from the classical HLA loci, the pattern of LD was similar to that from the 
rest of the human genome.  
 The presence of conserved long-range haplotypes in the HLA region is an unusual 
phenomenon. As described earlier, these haplotypes extend over several mega-bases and 
include specific classical HLA markers. These extended-haplotype blocks are characterised 
by a high degree of polymorphism among the HLA markers, which may be challenging to 
detect from LD analysis of SNP markers. This might explain why the pattern of LD among 
the SNP markers located within the HLA region is not significantly different from the rest of 
the human genome. Recently, De Bakker et al. [24] reported that on average, the 
recombination rate across the extended HLA region was 0.44cM/Mb compared to a genome-
wide average of 1.2cM/Mb. Miretti et al. [10] estimated a very low recombination rate for the 
extended class I region (0.19 cM/Mb) and the highest rate for the classical class II region 
(1.71 cM/Mb).   
 Figure 1.4 presents the distribution of recombination estimates within the HLA region 
published in Miretti et al. [10]. This figure shows the presence of long segments of low 
recombination interspersed by peaks that correspond to rapid LD break-down within the 
extended and classical class I HLA regions. Peaks enclosed within the dashed rectangle 
indicate recombination events located between TAP2 and HLA-DMB genes and between 
BRD2 and HLA-DOA genes that were identified by Jeffreys et al. [22] using sperm-typing 
analysis. De Bakker et al. [24] examined association between the classical HLA genes and 
SNP markers from the extended HLA region using a dense genetic panel of 5,754 SNPs.  
 Figure 1.5 presents the extent of these associations as measured by the relative 
information criterion, which assesses the strength of LD between a bi-allelic SNP i and a 
multi-allelic HLA marker j. Suppose a multi-allelic HLA marker j with N alleles, the relative 
information measure of association is as follows: 
 
    
   
 
  
   
 
where               
 
    and    
      
    
      
     
    
       
        
 
    , with 
  , the frequency of the k
th
 HLA allele in the sample;   
 , the frequency of the k
th
 HLA allele 
on the x allele at SNP i and   
 , the frequency of the x allele at SNP i in the sample.  As can 
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be seen, the SNP markers from the HLA region capture most of the variation of the classical 
HLA genes. The SNPs with high relative information lie in the same regions as the classical 
HLA genes. It is thought that this information could be used to infer HLA types in disease 
association studies without complete resolution of all classical HLA typing at the base-
sequence level. While such resolution is achievable, it is associated with high financial cost 
and DNA usage. 
Despite considerable efforts to identify conserved haplotypes and the most common 
recombination events, knowledge of the structure of LD within the HLA region is still 
incomplete and divergent descriptions are found in the literature. Both selection and 
recombination could affect the pattern of LD in a region for which high variability and new 
variants ensure disease resistance. Furthermore, there remains much uncertainty in the way 
genetic variation in the HLA region is studied, including the extent to which SNP genotyping 
platforms can reliably interrogate the region for association. The SNP markers in the HLA 
region represent a small amount of the HLA variation and cannot entirely describe the level 
of LD within the region [11, 25].  
 
 
 
 
 
Figure 1.3 Plot of average r
2
 across the extended HLA region 
 
       Source: Miretti et al. [12] 
 
 
 
This plot displays the trend of LD by averaging r
2
 between pairs of markers using a 
sliding window of up to 250 kb. The blue area represents the extended class I HLA 
region. The yellow area indicates the class I HLA region. The orange and green areas 
define the class III and II HLA regions, respectively.  
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Figure 1.4 Variation of recombination rate across the HLA region 
 
                                      Source: Miretti et al. [13] 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5  Strength of LD between SNP markers and the classical class I and II HLA 
markers 
 
  Source: deBakker et al [24] 
 
 
This plot displays the estimated recombination-rate variation across the HLA region. 
Peaks correspond to areas of intense recombination activity. Enclosed in the dashed 
rectangle are recombination events that were identified by Jeffreys et al. [22] using sperm 
typing analysis.  
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In Miretti et al. [10], the high-density LD map of the extended HLA region contained 
only 14.9% of the 20,868 validated SNPs (dbSNP Build 124) [4]. Recently, Blomhoff et al. 
[25] observed significant variations in LD after classifying the subjects of the same 
population according to alleles at specific HLA genes. They showed that mapping marker-
disease associations disregarding the highly polymorphic classical HLA markers might be 
challenging as these depend also on HLA allele-defined haplotypes, which vary between 
subjects from different populations. 
The presence of segments of high LD and the complexity of analysing highly 
polymorphic markers have complicated the finding of the causal elements in disease studies 
of the HLA region. Strong hypotheses have been made about disease-predisposing loci in the 
HLA region, such as RA susceptibility conferred by some alleles at HLA-DRB1. It is thought 
that additional predisposing genes might be concealed under the strong genetic associations 
of the classical HLA markers. For this reason, it is of interest to identify statistical methods 
that can deal with the presence of LD between markers and identify genetic factors that might 
play an important role in disease susceptibility, while making adjustment for such LD.  
 
 
1.2 Overview of rheumatoid arthritis and the genetic contribution of the 
HLA region 
 
RA is a complex autoimmune disease that is caused by self-reactive antibodies, which 
lead to the progressive destruction of joints. The disease occurs usually in hands and feet and 
can cause functional disability. The prevalence of RA ranges from 0.5% to 1% in populations 
from Europe and North-America [26], with a female to male prevalence ratio of 2.5:1. Many 
studies have implicated environmental factors such as exposure to infection, cigarette 
smoking or breastfeeding after first pregnancy [26]. Twin studies have also shown that 50%-
60% of the occurrence of RA can be explained by genetic factors [26, 27]. The strongest 
susceptibility factor has been reported to be a group of alleles at HLA-DRB1.  
 
1.2.1 The shared epitope hypothesis 
 
In 1987, Gregersen et al. [28] detected a pattern of association between specific 
alleles at HLA-DRB1 and RA. They reported that some alleles at HLA-DRB1 encode a set of 
conserved amino-acid sequences at positions 70-74, namely QKRAA, QRRAA and RRRAA, 
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in the third hyper-variable region of the DRB molecule, that predispose to RA susceptibility. 
Their observation led to the now well-known shared epitope (SE) hypothesis.  
The SE hypothesis divides alleles at HLA-DRB1 into two groups, the shared epitope 
positive (SE+) alleles and shared epitope negative (SE-) alleles, based on the presence of the 
shared amino acid sequences described above, all of which confer SE+ status. Even though 
little is known about the mechanism of action of the SE, the association between the SE and 
RA is well-established and has been replicated many times [29]. The presence of SE+ alleles 
has been observed in 70% of RA patients compared to 40% of the general population [30]. In 
populations of European ancestry, the most common SE+ alleles ( > 5% population 
frequency) are HLA-DRB1*0101, *0401 and *0404 [31]. Studies have reported that some 
alleles confer a more severe form of the disease. Kilding and Wilson [32] reported that RA 
patients homozygous for HLA-DRB1*0401 or *0404, and those heterozygote for *0401, 
*0404 or *0408, had a more aggressive form with occasional organ destruction. Despite 
recent improvements in molecular biology techniques, the precise effect of SE on RA is still 
unclear.  
 
 
1.2.2 The non-classical HLA genetic factors 
 
Many studies have suggested that the SE is not the only genetic factor predisposing to 
RA [4, 32-39]. Markers in tumor necrosis factor-α (TNFα), which is located in the class III, 
region have been implicated many times [3, 30, 40]. A large British case–control study 
compared TNF haplotypes in HLA-DRB1*04-matched RA cases and controls and found 
significant differences in carriers of both HLA-DRB1*0401 and HLA-DRB1*0404 [41]. 
Among individuals with HLA-DRB1*0401, the TNF haplotype was significantly 
underrepresented in cases compared to the controls, while the opposite effect was observed 
for those carrying HLA-DRB1*0404. In another family-based association study of 164 British 
RA families, thirteen SNP markers were genotyped in the telomeric class III region and 
transmission distortion was detected after conditioning on the effect of HLA-DRB1 [32]. A 
North American study investigated 54 microsatellites in 469 multi-case families and 
identified two non-DRB1 effects [35], one of which was within a 497-kb interval in the class 
III region on a segment of the 8.1 ancestral haplotype, and the other was present in a 697-kb 
region, centromeric of the HLA–A locus in the class I region.  
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Despite the undoubted importance of the TNF protein in the pathogenesis of RA, 
other variants in the vicinity of this locus have also been implicated with RA susceptibility 
[34, 39]. A case-control study involving 116 Japanese RA patients and 97 healthy controls 
identified an association with a promoter SNP (rs2071592) of NFKBIL1 at position -62, 
which is 30kb telomeric of the TNF locus; however, linkage disequilibrium (LD) with DRB1 
alleles was not reported [37]. Another, much larger Japanese study showed a DRB1-
independent association of another NFKBIL1 promoter SNP at –293 (rs3219185) with RA 
[42]. Interestingly, these associations were not reported in subjects from European ancestry 
[43]. Hence, genetic susceptibility linked to NFKBIL1 may vary among ethnic groups. 
Although the gene is expressed at high levels in rheumatoid synovium, it does not, as 
previously proposed, function as an inhibitor of NF-κB, but is involved in RNA processing 
[44]. 
 
 
1.2.3 Anti-CCP+ as a sub-phenotype of RA 
 
Studies of patients with long-standing RA have shown substantially higher prevalence 
of immunisation against citrullinated proteins than investigations based on patients with early 
onset of RA [45]. Investigators have reported that the presence of anti-cyclic citrullinated 
peptide antibodies (anti-CCP+), which is a biomarker used in clinic for the diagnosis of RA, 
is often associated with a more severe form of the disease. Recent studies have also reported 
correlation between the SE and the anti-CCP+ sub-phenotype of RA [46]. Van der Helm-van 
Mil et al. [47] investigated whether the SE contributed to the development of anti-CCP+ RA, 
or whether they were associated solely with the presence of anti-CCP antibodies. They 
showed that the SE alleles were associated with a significantly higher level of anti-CCP 
antibodies, suggesting that the SE might contribute to the development of RA through the 
production of anti-CCP antibodies. It has been demonstrated that HLA class II molecules 
expressing the SE can bind and present citrullinated peptides to T cells [48], and that a 
combination of SE+ and anti-CCP+ is highly predictive of the presence of rheumatoid factor 
positive (RF+), a biomarker used for the diagnosis of RA [49] indicative of more severe 
disease progression [50]. Most of the studies described were performed on RA cases of 
Caucasian ethnicity. A recent study by Hughes and colleagues [51] showed that the SE+ was 
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also strongly associated with RA among African Americans who suffered from the anti-
CCP+ form of the disease.  
Many association studies have hence investigated the presence of risk loci associated 
with the anti-CCP+ form of RA. They reported associations in the class II HLA region, which 
are thought to determine the severity of immune response [33, 52]. It is possible however that 
LD with alleles conferring RA susceptibility at HLA-DRB1 might explain these results. 
 
 
1.3 The statistical challenge of analysing SNP markers from the HLA 
region 
1.3.1 Single-SNP association tests  
 
The presence of LD has complicated the finding of additional susceptibility loci in the 
HLA region. The analysis of RA-predisposing markers from this region requires statistical 
methods that can distinguish the causal variant(s) from variants that are merely due to LD 
with the SE+ allele at HLA-DRB1. Genetic studies to date have often been unsuccessful at 
reproducing findings, due to small sample size, low genetic coverage of the region, and LD 
with the SE. 
Currently, single-SNP association testing is the most widely used approach in genetic 
research. Single-SNP methods investigate whether the observed allelic or genotypic 
frequencies among affected individuals (that is, the cases) at a locus deviate from expectation 
based on a population of unaffected individuals (that is, the controls) [53]. Given a bi-allelic 
marker with alleles A and a and genotypes AA, Aa and aa, the genotype proportions in cases 
(n
(1)
) and controls (n
(0)
) may be denoted by P
(1)
AA, P
(1)
Aa, P
(1)
aa and P
(0)
AA, P
(0)
Aa, P
(0)
aa , 
respectively (Table 1.5). The null hypothesis of no association may be tested using the 2 
degree-of-freedom (df) Fisher exact test between the rows and the columns of 2-by-3 table 
that contains the counts of the three genotypes among the cases and the controls as shown in 
Table 1.5, where ni
(1) 
and ni
(0)
denotes the count of genotype i among the cases and controls, 
respectively. 
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Table 1.5 Genotype distribution in cases and controls 
 Genotypes 
 aa Aa AA Total 
Cases P
(1)
aa = n
(1)
aa / n
(1)
 P
(1)
Aa = n
(1)
Aa / n
(1)
 P
(1)
AA = n
(1)
AA / n
(1)
 P
(1)
 = n
(1)
 / n 
Controls P
(0)
aa = n
(0)
aa  /n
(0)
 P
(0)
aa = n
(0)
Aa / n
(0)
 P
(0)
AA = n
(0)
AA / n
(0)
 P
(0)
 = n
(0)
 / n 
Total Paa = naa / n PAa= nAa / n PAA = nAA / n 1 
 
 
The genotypic association of a marker is then defined as the difference between the 
proportion of cases P
(1) 
and controls P
(0)
. The odds ratio (OR) can be used to measure the 
strength of association. Taking the most common genotype AA as reference genotype, the OR 
of genotype aa and Aa can be expressed as follows:  
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)0()1(
)0()1(
/
/
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/
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AAAA
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OR


 
 
 
The 1df single-SNP test can be used to assess the allelic effect by considering a 2-by-
2 table, where each individual contributes twice to the allele counts (Table 1.6).  
 
 
Table 1.6 Allelic distribution among cases and controls 
 Alleles 
 a A Total 
Cases P
(1)
a = (2n
(1)
aa+ n
(1)
Aa) / 2n
(1)
 P
(1)
A = (2n
(1)
AA+ n
(1)
Aa) / 2n
(1)
 P
(1)
 = 2n
(1)
/n 
Controls  P
(0)
a = (2n
(0)
aa + n
(0)
Aa)  /2n
(0)
 P
(0)
A = (2n
(0)
AA+ n
(0)
Aa) / 2n
(0)
 P
(0)
 = 2n
(0)
/n 
Total Pa = (2naa+ nAa) / 2n Pa = 2nAA+ nAa) / 2n 1 
 
 
The latter procedure assumes Hardy Weinberg Equilibrium (HWE) in the combined 
cases and controls, a condition which is often unmet. In order to avoid reliance on the HWE 
assumption, the genotype-based Cochran-Armitage test, which is also known as the Armitage 
trend test, can be used [54]. This 1df association test assesses whether there is a linear trend 
in allele count, i.e. increase or decrease, in the proportions of subjects experiencing an event, 
 28 
 
which is equivalent to testing for zero slope in a logistic regression model. Complex diseases 
are often thought to be associated with an additive genetic effect, in which the risk in the 
heterozygote Aa is intermediate between the two homozygote risks. In this case, an additive 
test will have more power than the 2df general test described above, which makes no 
assumptions about underlying pattern of disease risk in relation to allele count [55]. 
 
 
Type I error in single-SNP association tests 
 
Nowadays, hundreds of thousands of SNP markers are commonly analysed using 
single-SNP association tests. P-values are used to identify marker-disease associations 
despite a number of issues [56]. Conventionally, scientists rank P-values to identify SNP 
markers that are associated with a phenotype of interest. The P-values are, however, affected 
by the power of the test to identify a true association, which also depends on the minor allele 
frequency of the SNP being analysed and the sample size of the study [57]. The analysis of 
one marker at a time is also prone to type-I error when a large number of markers are tested. 
A number of statistical methods are available to correct for multiple testing.  
One widely used approach is the Bonferroni correction, where each test is controlled 
at a 
J

 threshold, with   being the type-I error rate and J being the total number of tests. 
This method is widely used despite being very conservative. Other approaches which are 
commonly used in genetic association analyses include the permutation test [58] and the false 
discovery rate (FDR) [59], which are less conservative [60] than the Bonferroni correction. 
Simes [61] proposed an improved Bonferroni procedure, which controls the family-wise error 
rate. Let P(1) ≤…≤ P(k) be the ordered P-values of k tests. With the Simes‟s correction, the 
joint null hypothesis is rejected if      
  
 
 for at least one j = 1,..,k.  Although Simes showed 
that this method was more powerful than the Bonferroni correction, the type-I error is 
maintained at or below α only when the test statisitics are independent. Peter Kraft [62] 
showed however in a simulation study that the Simes correction provided reasonable false 
positive rate even when the tests were correlated.  
Multiple regression methods are also prone to type-I error, but contrary to single-SNP 
analysis, they can gain power by analysing multiple markers simultaneously, while still 
taking into account the effects of other covariates, such as environmental factors. 
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1.3.2 Multi-SNP association tests  
 
Logistic regression may be used to estimate marker-based disease risk, while 
accounting for the effect of other genetic and environmental confounding factors. This 
method has received some attention in the analyses of polymorphisms from the HLA region. 
Cordell & Clayton [63] and later North et al. [64] investigated the performance of logistic 
regression models when two or more loci jointly influence the risk of developing a disease. 
They showed that multivariate logistic regression performs well in determining which locus 
or combination of loci have a causal role in disease susceptibility. However, they did not 
consider the situation where associated markers were in LD with the susceptibility loci. In the 
presence of LD, highly-correlated predictors can cause problems. In addition, when the 
number of predictors is large relative to the number of observations, maximum likelihood 
estimation faces numerical and computational issues due to singularities in matrices. 
Although numerical tricks have been developed to overcome this difficulty, the estimation 
process may result in a situation where there is no unique solution due to the large number of 
predictors.  
 
1.3.3 Overview of SNP selection methods  
1.3.3.1 Tag-SNP selection approach 
 
One way to address these problems is to reduce the number of predictors analysed by 
exploiting the pattern of LD [65]. LD can be used to select a set of SNPs that retain most of 
the genetic variation of the SNPs in a given region.  The resulting SNPs are referred as 
tagging SNPs (tagSNPs).  Several methods have been proposed for selecting the tagSNPs 
based on pair-wise LD [66, 67] and haplotype structure [67-69]. The selection of tagSNPs is 
often used to reduce genotyping costs. These methods can also be used to reduce the number 
of SNPs being analysed. Ignoring the information at the non-tagSNPs might however lead to 
an increase number of false negative results if the tagSNPs do not well capture the causal 
variants.  
 
 
 
 
 30 
 
1.3.3.2 SNP selection using regression methods 
 
Automated procedures such as stepwise regression, in which terms are added or 
removed sequentially, are commonly used. The value of a parameter can be tested by the 
increase in deviance resulting from its removal [70]. However, in the presence of large 
numbers of SNPs, the variable selection process may be unstable in the sense that small 
changes in the dataset can lead to very different models [62]. Furthermore, in the presence of 
LD, the final model can retain a set of highly-correlated predictors which add little to its 
predictive power.  
Another regression method is best-subset selection, which goes through all the 
possible sub-models and selects the final model based on criteria such as the smallest residual 
sum of squares [70]. However, in the presence of a large number of predictors p, best-subset 
selection considers 2
p
 models, which is computationally demanding in genetic association 
analysis.  
Dimension reduction techniques such as partial least square (PLS) regression may 
also be used to exploit the correlation structure between the dependent variable and a large 
number of predictors, in the presence of missing data [71, 72].  PLS regression constructs a 
set of latent components, which have maximal correlation with both the trait and the SNPs. 
However, the interpretation of the latent components can be challenging in genetic 
association studies, which aim at identifying a set of causal elements. The method is however 
of interest, for example, for exploring the relationships among the expression profiles of a set 
of genes in microarray analysis, which may translate into biologically meaningful 
associations.   
Penalised regression methods have been proposed to overcome the difficulties 
described [70, 73]. Estimation of parameters is viewed as a minimisation problem under 
certain constraints. The most commonly used methods include ridge regression [74] and the 
Least Absolute Shrinkage and Selection Operator (LASSO) [73].  
 
 
1.3.3.3 SNP selection using penalised regression 
1.3.3.3.1 Ridge regression 
 
Ridge regression was introduced in the 1970s by Hoerl and Kennard [74] as a means 
to identify the most important predictors by imposing a penalty on the size of the coefficients 
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to control the large variances of the estimated parameters. Under the linear regression model, 
  XY 0 , where X is a n x p matrix, p is the number of SNPs genotyped in n 
individuals,   is the vector of coefficients to estimate,   is vector of residuals and Y is the n-
dimensional vector of phenotypic values at each subject, ridge regression estimates can be 
obtained by minimising the penalised residual sum of squares as follows:  
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where β0 denotes the intercept, λ is the penalty parameter that controls the amount of 
shrinkage and 

p
j
j
1
2 is the L2 norm penalty. For λ = 0, the equation within the brackets is 
the residual sum of square and ridgeˆ  is the vector of ordinary least square estimates. Large 
values of λ cause a great amount of shrinkage of the regression coefficients towards zero. The 
variables X and Y are usually standardised before solving the optimisation problem so that the 
penalty is invariant to the scale of the original data. Note that the penalty is not applied on the 
intercept β0. The penalisation of the intercept would have implied adding a constant c to each 
of the dependent variables yi, which would have simply resulted in modifying the predictions 
by the same amount.  
 Malo et al. [75] applied ridge regression to identify SNP markers associated with a 
continuous phenotype in a small gene region (CHI3L2) containing 26 SNP markers. Their 
simulation study showed that ridge regression out-performed traditional multiple linear 
regression in distinguishing the causal variants from those that are in LD with them. Ridge 
regression has however the disadvantage of keeping all the variables in the model, which may 
be undesirable when dealing with large datasets and in the presence of correlated predictors, 
because the estimated regression coefficients can exhibit large variances and be poorly 
estimated. They suggested instead using the LASSO regression in order to perform variable 
selection.  
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1.3.3.3.2 The LASSO regression 
 
With the LASSO, the L2 norm penalty 

p
j
j
1
2  of ridge regression is replaced by the 
L1 norm penalty 

p
j
j
1
 , which forces many parameter estimates to be exactly zero. These 
parameters are excluded from the final model. The LASSO can hence be used as a variable 
selection process that identifies a sparse model by shrinking some coefficients towards the 
origin to avoid overestimation and setting others to zero. Terms with non-zero coefficients 
indicate effects of interest and are included in the final model. The LASSO estimate is 
defined by: 
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1.3.3.4 Literature review of LASSO  
 
Several authors have explored the LASSO for model selection considering a 
quantitative trait [65, 76, 77]. Best subset selection and stepwise regression are procedures 
that result in models that are unstable and often not reproducible [78, 79]. In addition, these 
methods are computationally infeasible even for a moderate number of predictors, p > 30, as 
the number of potential models increases [73]. Tibshirani [73] showed in a simulation study 
that the LASSO outperformed slightly the prediction accuracy of ridge regression and subset 
selection in the analysis of small to moderate effect sizes. Although the LASSO selected the 
correct model only 2.5% of the time, which was less than best subset selection (24.0%), the 
remaining LASSO models included the correct model 95.5% of the time compared to 53.5% 
with best subset selection. Tibshirani used five-fold cross-validation to estimate the penalty 
parameter of the LASSO model, which could have impacted the stability of the variable 
selection process [80].  Recently, Uh et al. compared the LASSO to the stepwise procedure in 
logistic regression and observed that while the LASSO was less parsimonious than stepwise 
regression, it had a smaller average prediction rate [81].  
Various other selection methods have been introduced. Breiman [82] investigated the 
nonnegative garrotte, which is a scaled version of the least square estimate. The nonnegative 
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garrotte relies on the least square estimate and may perform poorly in situation where p >> n.  
Yuan and Lin [83] showed that the nonnegative garrotte was an effective tool for selection of 
large effects but was less accurate in identifying small associated effects compared to the 
LASSO. They proposed to use the nonnegative garrotte in combination with estimators other 
than the ordinary least square, such as the LASSO. They observed a substantial improvement 
in term of variable selection and estimation accuracy compared to the original nonnegative 
garrotte estimator. The LASSO had however a smaller average model error rate and 
performed better than the nonnegative garrotte combined with the LASSO in identifying 
associations of small effect sizes.  
Efron et al. [84] introduced the Least Angle Regression (LARS) method, which is 
closely related to the LASSO. Both methods rely on a penalty parameter that is often chosen 
to minimise the prediction error. The LARS starts by assigning all coefficients to zero. The 
algorithm then selects the predictor that is the most correlated with the response variable. 
Additional predictors entered the model if they are more correlated with the residual than the 
variables that are already in the model. The LARS is computationally faster than the LASSO 
because it identifies predictors that correspond to change points in the solution path. The 
main disadvantage is that the LARS is not path consistent. Once a variable enters the model, 
it cannot be removed and correlated variables might also be selected, which can often lead to 
large models [85]. With the LASSO, variables can enter and leave the model multiple times 
[86]. It is recommended to implement multiple runs of the algorithm as the order in which the 
predictors enter the model might impact the variable selection process [87, 88].  
With the emergence of high dimensional datasets, the LASSO is becoming an 
attractive tool for its ability to perform SNP selection. Zhou and Hastie [89] reported 
however two main limitations of the LASSO: first, the number of selected predictors is 
bounded by the number of samples, which means that the LASSO retains at most n 
associations if n < p. This might be a problem for study of small sample sizes such as 
microarray expression where the number of genes p exceeds the number of arrays n. This is 
less of a problem in the analysis of genetic markers from the HLA region, which aims at 
identifying a reasonable set of markers associated with the disease. Second, in presence of 
correlated data, regression method tends to randomly select one variable and ignore the others 
and LASSO does not overcome this problem. This might be an issue for the analysis of 
markers from the HLA region, which is characterised by the presence of LD. Alternatively it 
might help to further locate a disease association by identifying a single SNP marker among 
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many correlated SNPs, which show the same association.  An open question is the threshold 
of the correlation coefficient r
2
 at which this phenomenon might occur. 
Modifications of the LASSO have been proposed to overcome the issue of multi-
collinearity and improve variable selection [85, 89-92]. In 2005, Tibshirani introduced fused 
LASSO, which was designed to analyse a sequence of ordered predictors. Fused LASSO 
applies a L1 penalty on the size of the coefficients and a L1 on the difference between adjacent 
coefficients, 
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assigns non-zero weight to only one of the predictors, whereas fused LASSO gives similar 
regression coefficients by putting the consecutive correlated predictors near to one another. 
This method is of interest to identify an ordered group of SNP markers associated with a 
phenotype.  
In 2005, Zou and Hastie [89] proposed the elastic net, which combines the L1 penalty 
of the LASSO with the L2 penalty of ridge regression, for the analysis of unknown groups of 
predictors, 
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The elastic net encourages grouping of effects, where correlated predictors tend to be 
included or removed from the model as a group. The L1 penalty generates a sparse model, 
while the L2 penalty encourages the grouping of effects. The elastic net is a two-stage 
procedure that requires, for each fixed 2 , the identification of LASSO coefficient solution 
paths. Zou and Hastie [89] showed that by imposing a double shrinkage, the elastic net 
introduces additional bias compared to the LASSO or ridge regression.  
In some cases, it might be of interest to analyse predefined groups of variables. Yuan 
and Li [85] proposed group LASSO. Suppose that p predictors are divided into J groups, pj is 
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the number of variables in group j and matrix Xj  represents the predictors in group j with 
regression coefficient j . The group LASSO minimises 
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where jp  accounts for the size of the j
th
 group. The parameter estimates are calculated for a 
group of variables. The group LASSO performs variable selection at the group level. Groups 
of variables are hence included in the model if the group parameter estimates are non-zero. 
The group LASSO is the LASSO if all pj = 1.   
 
Fused LASSO, the elastic net and the group LASSO have been developed to deal with 
the problem of multi-collinearity. Other methods have also been proposed to improve 
variable selection, where the objective is to identify the best-fitting model as closely as 
possible at the expense of prediction accuracy. For the high dimensional situation where most 
variables are irrelevant, large-valued penalty factors are necessary to identify the best-fitting 
model. In this case, the coefficients are shrunk significantly toward zero and the estimators 
are likely to have poor prediction accuracy. If prediction is the main interest, then it may be 
acceptable for the model to include some false positive results provided that the coefficients 
of those variables are small.  
Two-step LASSO methods have been proposed to overcome these difficulties. In 
2006, Zou [92] introduced the adaptive LASSO, which first identifies an initial estimator for 
each coefficient and then defines a LASSO optimisation problem with a weighted L1 penalty, 
j
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j
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The idea is that if the coefficient of the OLS estimator is large, this variable might be 
important to the model and its corresponding LASSO coefficient should not be shrunk much. 
Some bias might be introduced in situation where p >> n since the OLS estimator is not 
unique. Meinshausen [90] proposed to use relaxed LASSO, which first performs model 
selection by identifying the LASSO model using a L1 penalty. The LASSO is next applied to 
the identified model with a smaller penalty factor, keeping all the variables in the model but 
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using less shrinkage. Meinshausen [90] showed that the relaxed LASSO produces sparser 
models with equal or lower prediction loss than the LASSO estimator for high-dimensional 
data. With this approach, model selection and estimation of the coefficients are controlled by 
two shrinkage parameters, which need to be defined. The adaptive LASSO and relaxed 
LASSO are two-stage approaches, whose objective is to reduce bias by applying less 
shrinkage to the relevant predictors. Other penalised regression variants of the LASSO 
include the Bridge regression of Franck and Friedman [93], Least Angle Regression (LARS) 
of Efron et al. [84] or the Smoothly Clipped Absolute Deviation (SCAD) penalty of Fan and 
Li [94], for simultaneously achieving variable selection and shrinkage estimation.  
The LASSO has also been applied to other models such as for example Cox 
regression [95] and logistic regression [81, 87, 96, 97] by replacing the residual sum of 
squares by the corresponding negative log-likelihood function. Tibshirani [73] showed that 
estimating j  using the LASSO algorithm was equivalent to finding the maximum a 
posteriori (MAP) likelihood estimate using a double-exponential (DE) or Laplace prior 
distribution over j  with mode zero and variance , where 2
2

  . Many authors have 
exploited this property. Uh et al. [81] explored the LASSO and a Bayesian variation of the 
LASSO in a case-control study, where parameter estimates are obtained by applying Markov 
Chain Monte Carlo techniques. They showed that the Bayesian LASSO performs well at 
identifying a simulated causal element but they acknowledged that their method might be 
challenging for large datasets as it requires estimation of the full distribution of each 
parameter. Genkin et al. [87] investigated a Bayesian-inspired version of the LASSO to 
improve text categorization techniques, where parameter inference is based on the posterior 
mode rather than the full distribution. With this approach, each regression coefficient is 
assigned a prior distribution that strongly favours zero values, so that terms with non-zero 
posterior modes indicate important variables. This approach looks promising for SNP 
selection from dense genetic panels where the effect of a large proportion of markers is 
expected to be negligible.  
 
 
1.4 Structure of the thesis 
 
In this thesis, penalised logistic regression was used to identify RA risk loci 
independent of HLA-DRB1. Two prior distributions were considered: the double-exponential 
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distribution (DE), which corresponds to the LASSO, and the normal-exponential-gamma 
distribution (NEG), which is a generalisation of the LASSO called HyperLASSO that might 
better deal with the problem of multiple correlated predictors [88]. These approaches were 
applied to the Genetics of Rheumatoid Arthritis (GoRA) case-control association study, 
which contains approximately 1,000 cases and 1,000 controls using 2,302 SNPs spanning the 
HLA region, together with genotypes from the multi-allelic HLA-DRB1 locus. Genotype 
imputation was also investigated as a means to jointly analyse correlated SNPs from the 
GoRA and the Wellcome Trust Case Control Consortium (WTCCC) [98]. The LASSO and 
HLASSO penalised regression results were compared with those obtained using single-SNP 
association testing. The robustness of the models derived was assessed using bootstrapping. 
The North American Rheumatoid Arthritis Consortium (NARAC) dataset [99] was used as a 
replication study. The structure of the thesis is at follows:  
 
- Chapter 1 presents an overview of the HLA system and the statistical challenges 
associated with analysing SNP markers from the HLA region.   
 
- Chapter 2 provides a description of the GoRA, WTCCC and NARAC case-control 
datasets. 
 
- Chapter 3 is devoted to the modelling of the well-known HLA-DRB1 effect. First, 
the SE hypothesis is discussed. Then, an improvement to the SE hypothesis is proposed using 
the GoRA study. The model derived is then tested using samples from the WTCCC study.  
- Chapter 4 presents the single-SNP association test results of the GoRA study. This 
chapter shows that single-SNP analysis can lead to a large number of false positive results 
and the analysis of SNP markers arising from the HLA region requires statistical methods 
that can analyse simultaneously a set of SNP markers and account for the genetic information 
as a whole.  
 
- Chapter 5 presents the multi-SNP analysis of the GoRA case-control study. A series 
of increasingly sophisticated methods is used starting with multiple logistic regression and 
followed by the LASSO and HyperLASSO penalised logistic regression. After controlling for 
type-I error by the choice of the LASSO penalty parameter value, fewer positive SNP 
associations were identified compared to single-point association tests, suggesting that LD 
might be better-handled. These results were supported by a simulation study, which showed 
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that the penalised regression approach provides a substantial benefit, both in terms of 
maintaining statistical power to detect multiple causal variants and in the reduction of false 
positive associations. 
 
- Chapter 6 presents a multi-SNP association analysis of the HLA region using 
imputed genotype from the combined WTCCC and GoRA studies. After controlling for the 
type-I error rate, the penalised approaches greatly reduced the number of positive signals, 
confirming that correlation between predictors might be better-handled. The HLASSO results 
were sparser but similar to the LASSO penalised regression results. Out of five associated 
SNPs, one SNP marker was replicated in the NARAC case-control study, which was used to 
assess the markers selected. In both data sets, the robustness of retained variables was 
verified by bootstrapping and 10-fold cross-validation. These findings suggest that variable 
selection using HLASSO or LASSO show a substantial benefit in identifying risk loci in 
regions of high LD through the derivation of sparse models.  
 
- Chapter 7 presents a summary of the results, followed by a discussion. Some 
possible areas for further investigation are also presented.  
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Chapter 2. The GoRA and WTCCC datasets 
 
 
 
 
2.1 Introduction 
 
 The primary datasets analysed are two disease-based case-control association studies 
of RA. The Genetics of Rheumatoid Arthritis (GoRA) dataset includes approximately 1,000 
cases and 1,000 controls who were recruited by GlaxoSmithKline and the University of 
Sheffield, UK. The second dataset is the Welcome Trust Case Control Consortium (WTCCC) 
collection [98] that includes approximately 2,000 RA cases and 3,000 un-phenotyped 
controls. The North American Rheumatoid Arthritis Consortium (NARAC) study [99], which 
contains approximately 1,000 cases with RA and 1,000 controls, was used to evaluate the 
association test results found in the analysis of the GoRA and WTCCC studies. 
 
 
2.2 The GoRA case-control dataset 
2.2.1 The RA patients and controls 
 
Patients with established RA attending outpatient clinics at the Royal Hallamshire 
Hospital, Sheffied, UK were enrolled in the study between 2001 and 2006. Research ethics 
committee approval was obtained for the study (SSREC protocol number 02/186) and all 
participants gave informed consent. All subjects were white Caucasian, and fulfilled the 1987 
American College of Rheumatology criteria for RA. All had minimum disease duration of 3 
years and at least one definite radiographic erosion in hands or feet. Radiographs were scored 
blind at study entry by a single musculoskeletal radiologist using a modified Larsen‟s score 
[100]. The control group was recruited from the same geographical region and each 
individual was 18 years of age or older with no history of an inflammatory joint disorder. 
Where possible, cases and controls were assigned SE status, i.e. whether a subject carried the 
shared epitope, i.e. SE positive (SE+) or not, i.e. SE negative (SE-), using alleles at HLA-
DRB1. Table 2.1 presents the characteristics of the RA patients and controls by SE+ and SE- 
status.  
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Table 2.1  Clinical characteristics of the GoRA patients and controls 
 SE+ SE- 
 Cases 
(N=693) 
Controls 
(N=459) 
Cases 
(N=149) 
Controls 
(N=498) 
Sex, no.(%) 
Female 
Male 
missing 
 
494 (71) 
199 (29) 
0 
 
305 (66) 
154 (34) 
0 
 
111 (75) 
38 (25) 
0 
 
328 (66) 
170 (34) 
0 
Age, years 
Mean +/- SD 
Range 
missing 
 
61.4+/- 12.1 
19.7-89.9 
0 
 
47.9+/-13.4 
19.1-82.4 
0 
 
61.4+/-12.4 
33.5-87.1 
0 
 
48.1+/-12.4 
18.4-85.9 
0 
Age at diagnosis, years 
No. of patients 
Mean+- SD 
Range 
Missing (%) 
 
676 
45.4+/-14.7 
4-80 
17 (3) 
 
 
 
 
146 
47.0+/-15.1 
14-82 
3 (2) 
 
 
 
Age at first symptom, years 
No. of patients 
Mean+- SD 
Range 
Missing 
 
676 
42.9+/-14.5 
2-80 
17 (3) 
 
 
 
146 
42.9+/-15.5 
7 -76 
3 (2) 
 
CCP status, no. (%) 
Negative 
Positive 
Missing 
 
91 (13.1) 
533 (76.9) 
69 (10) 
 
 
46 (30.9) 
80 (53.7) 
23 (15) 
 
RF status, no. (%) 
Negative 
Positive 
Missing  
 
161 (23.2) 
445 (64.2) 
 87 (13) 
 
 
46 (30.9) 
86 (57.7) 
17 (11) 
 
 
 
 
In both SE strata, more females are found amongst the RA cases than the controls, 
consistent with the fact that RA is more prevalent in women than in men. The mean age in 
controls was lower on average than among the RA cases, but similar to the mean age at 
diagnosis of the RA cases. RA being an age-related disease, it would have been preferable to 
have the controls older than the cases in order to avoid bias due to the inclusion of pre-
symptomatic controls. Because the prevalence of RA is low (~1%), this possibility is 
expected to have little impact on the association results. Among the cases, a larger number of 
RA SE+ cases were rheumatoid factor positive (RF+) and carried antibodies directed against 
cyclic citrullinated peptides (anti-CCP+), which are the two biomarkers used for the 
diagnosis of RA, the latter being also used to assess the severity of the disease. 
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2.2.2 SNP and HLA typing 
 
High resolution (4-digit) typing at HLA-DRB1 was conducted by Laboratory 
Corporation of America (LabCorp) and 2,360 SNP markers located within the HLA region 
were genotyped by Illumina Inc. The markers constituted two panels, namely the MHC 
Mapping Panel and the MHC Exon-Centric Panel. The former comprises evenly-spaced SNP 
markers with, on average, 3.8kb between each SNP; the latter focuses on SNP markers near 
or within exons. The average inter-marker distance in the combined panels is 2.1kb and 
92.4% of markers were within 5kb of a neighbouring SNP. The mean minor allele frequency 
was 0.26 and 88 markers (3.8%) had minor allele frequency < 0.05. 
All markers had more than 95.0% genotypes available, which was greater than the 
70% call rate criteria. Of the 2,360 SNP markers genotyped, fifty-four (2.3%) failed 
genotyping, i.e. no data were returned by Illumina Inc, and four markers were not analysed 
because they were monomorphic in this sample (Table 2.2). Nine markers showed significant 
departure from Hardy-Weinberg Equilibrium (HWE) at P < 0.001 (Table 2.3). Although the 
number of SNPs showing divergence from HWE was greater than expected (= 2.4), these 
markers were not excluded from the analysis; instead their association results were 
interpreted with care. It is noted that for SNPs located within the HLA region, deviation from 
HWE may be due to selection rather than genotyping errors. In total, 2,302 SNPs were 
analysed for genetic association with RA. 
 
 
Table 2.2 Monomorphic SNPs  
Gene-Region
1
 RSnumber Position (kb) 
C6ORF27 rs7769899 31850220 
SLC44A4 rs6915800 31941639 
AGPAT1, RNF5 rs2071290 32252508 
Not Assigned rs3748082 33399849 
1
A gene was defined from 2kb of the 5' UTR to 2kb of the 3' UTR.  
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Table 2.3 SNPs showing evidence of departure from HWE 
Gene-Region
1
 RSnumber Position (kb) HWE P 
Cases  
HWE P 
Controls  
HWE P 
AGER, PBX2 rs3131300 32259912 4.3x10
-15
 3.3x10
-10
 4.3x10
-15
 
Not Assigned rs2092305 33208167 7.3x10
-10
 1.9x10
-8
 7.3x10
-10
 
TAP1 rs2071481 32927843 7.2x10
-6
 2.4x10
-6
 7.2x10
-6
 
CDSN rs4713436 31192618 9.7x10
-6
 5.1x10
-5
 9.7x10
-6
 
LEMD2 rs756139 33863519 2.3x10
-5
 4.1x10
-10
 2.3x10
-5
 
HLA-G rs2916801 30018265 1.0x10
-4
 0.004 2.0x10
-4
 
Not Assigned rs2395296 33019792 2.0x10
-4
 0.850 2.0x10
-4
 
Not Assigned rs206776 33061689 4.0x10
-4
 0.132 4.0x10
-4
 
VARS rs4713488 31870290 9.0x10
-4
 0.701 9.3x10
-4
 
1
A gene was defined from 2kb of the 5' UTR to 2kb of the 3' UTR  
 
 
 
2.3 The WTCCC RA dataset 
 
 The Wellcome Trust Case Control Consortium (WTCCC) is a large project that was 
undertaken to identify genetic variants contributing to seven common diseases, i.e. bipolar 
disorder, coronary artery disease, Crohn‟s disease, hypertension, type I diabetes, type II 
diabetes and RA, through the implementation and analysis of large-scale genome-wide 
association studies [98]. For each disease, DNA samples were collected from approximately 
2,000 cases and compared against 3,000 shared controls ascertained from throughout the UK.  
 
 
2.3.1 The WTCCC RA cases and controls  
 
 Subjects from the WTCCC cohort were all white Caucasians from the UK. RA 
patients were recruited as part of the ARC (Arthritis Research Campaign) National 
Repository of Family Material from a primary care-based inception cohort or from NHS 
Rheumatologist Clinics. All cases were over the age of 18 years and satisfied the 1987 
American College of Rheumatology Criteria for RA, modified for genetics studies. 
Approximately 3,000 shared controls were available from the 1958 Birth Cohort (n = 1,500) 
and from blood donors (n = 1,500). The former is composed of subjects from England, 
Scotland and Wales who were born within the same week in 1958. The latter were recruited 
in collaboration with the UK Blood Services in England, Scotland and Wales. Subjects were 
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identified based on sex and geographical region, to reproduce the distribution of the samples 
of the 1958 Birth Cohort.   
 
 
2.3.2 The WTCCC SNP markers 
 
 Genotyping was conducted by Affymetrix using the Affymetrix 500K chip. As part of 
this study a total of 17,000 samples were genotyped for 500,000 SNPs. The WTCCC 
excluded DNA samples if any of the following criteria applied [98]:  
- Samples had more than 3% missing data across all SNPs, indicating low quality DNA. 
- Identification of DNA contamination using genome-wide heterozygosity rate. 
- Discrepancies between the WTCCC information and any external experiment that used 
the same data, for instance when the genotypes or blood types were different. 
- Subjects of non-European ancestry. 
- Presence of relatives. 
 
 Overall, 136 RA patients and 24 and 42 subjects from the 1958 Birth Cohort (58BC) 
and the UK Blood Services (UKBS) collections were excluded.  Table 2.4 describes the 
reason for exclusion by collection.  
 
 
Table 2.4 Summary of WTCC DNA samples excluded by collection 
 RA Cases 58BC Controls UKBS Controls 
SNP call rate < 97% 47 9 8 
Heterozygosity  
> 30% or < 23% across all SNPs 
 
1 
 
0 
 
0 
Genotype or phenotype discordance 0 4 5 
Subjects of non-European ancestry 26 6 14 
Duplicate 53 4 0 
Relative 9 1 15 
Total 136 24 42 
 
 
Table 2.5 presents the demographic characteristics of the subjects that passed 
WTCCC quality control filtering. The twelve geographical regions (Figure 2.1) were defined 
by postcode and do not coincide with the administrative boundaries. The WTCCC 
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investigated the effect of population structure on disease association. They found that thirteen 
loci had notable geographical variation. Among these thirteen markers were SNPs within the 
HLA region. The genomic control approach of Devlin & Roeder [101] was used to assess the 
level of population stratification among the RA WTCCC collection. With an estimated 
measure of over-dispersion λ = 1.03, the deviation from expectation was small. The WTCCC 
did not correct for population structure but advised care in the interpretation of the genetic 
associations of SNPs showing strong geographical differentiation, as these could have arisen 
due to other confounding factors such as natural selection. 
 
 
 
Table 2.5 Demographic characteristics of the WTCCC RA patients and controls  
 RA Patients 
(N=1860) 
58BC Controls 
(N=1480) 
UKBS Controls 
(N=1458) 
%Male: %Female 25 : 75 48 : 52 50 : 50 
Geographical region 
% 
Eastern 
East &West Ridings 
London 
Midlands 
Northern 
North Midlands 
Northwestern 
Southeastern 
Southern 
Southwestern 
Scotland 
Wales 
Unknown 
 
20 
10 
2 
16 
3 
8 
19 
2 
12 
1 
3 
1 
3 
 
12 
6 
5 
12 
10 
3 
11 
11 
8 
9 
9 
5 
0 
 
11 
9 
8 
9 
8 
7 
11 
7 
8 
8 
10 
5 
0 
Age band % 
<40 
40-49 
50-59 
60-69 
>70 
Unknown 
Age at Onset 
28 
20 
20 
12 
5 
14 
Age at entry  
0 
100 
0 
0 
0 
0 
Age at entry 
37 
27 
28 
8 
0 
0 
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Figure 2.1 Description of the geographical regions of the WTCCC study 
 
 
 
2.3.3 Overview of the WTCCC genome-wide association results  
 
 With an estimated measure of over-dispersion λ = 1.03, the deviation from 
expectation was small. The WTCCC did not correct for population structure but advised care 
in the interpretation. The WTCCC performed a whole genome association (WGA) on data 
from 1,860 RA patients and 2,938 shared controls that passed the WTCCC quality control. 
They confirmed the well-known genetic association at PTPN22 on chromosome 1 
(rs2476601) at P < 10
-7 
[98]. Nine additional loci were also identified at P < 1x10
-5 
(Table 
2.6). Among them, SNP rs6920220 located between OLIG3 and TNFA1P3 on chromosome 
6q23 has been replicated in independent studies [102, 103]. In addition, four SNPs from the 
HLA region were significantly associated with RA at P < 10
-4
 (Table 2.7). RA was unique 
amongst the WTCCC studies in that a strong signal was identified in females using a sex-
differentiated analysis. SNP rs2476601 on chromosome 7 had no effect on disease status in 
males (P = 0.68) but showed a strong additive effect in females (P = 6.8x10
-8
). Five other 
SNPs (rs6679677, rs6457617, rs615672, rs11761231 and rs743777) showed significant sex-
differentiated associations at P < 1x10
-5
 but no information were given about the type of 
associations, i.e. whether an association was observed in females or in males.   
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 It is worth noting that the WTCCC analyses confirmed the association at HLA-DRB1 
using SNP rs615672 (P = 2.6x10
-27
). The WTCCC did not however adjust for the strong 
effect of HLA-DRB1 in their single-SNP analysis. It is likely that the strong association at 
HLA-DQB1 (P = 3.4x10
-76
) may be due to LD with alleles at HLA-DRB1. The reported 
genetic associations within the HLA region should hence be interpreted with caution since 
many studies have demonstrated that RA associations from the HLA region are often driven 
by the effect of HLA-DRB1 [32, 35-37]. 
 
 
 
Table 2.6 Association results at P < 10
-5 
in the WTCCC WGA
 
Chromosome RSnumber P-value Sex-differentiated 
P-value 
1 rs6684865 5.4x10-6* 2.1x10-5* 
1 rs6679677 4.9x10-26* 3.8x10-24* 
1 rs11162922 1.8x10-6* 2.2x10-5+ 
4 rs3816587 9.2x10-6+ 5.6x10-5* 
6 (HLA region) rs6457617 3.4x10-76* 5.6x10-70* 
6 (HLA region) rs615672 2.6x10-27* 2.6x10-27* 
6 rs6920220 5.0x10-6* 1.8x10-5* 
7 rs11761231 1.7x10-6* 3.9x10-7* 
10 rs2104286 7.0x10-6* 9.8x10-5* 
13 rs9550642 8.4x10-6* 5.0x10-5* 
21 rs2837960 1.7x10-6+ 4.3x10-5+ 
22 rs743777 7.9x10-6* 6.3x10-7+ 
 
 
 
 
 
 
Table 2.7 Association results of HLA SNPs at P < 10
-4 
in the WTCCC WGA 
Gene region Position (Mb) SNP(rsnumber) Trend P 
HLA-DRB1 32681899 - 32682399 rs615672 2.6x10-27 
HLA-DQB1 32771829 - 32771829 rs6457617 3.4x10-76 
NRM  30765968 - 30766468 rs1075496 2.4x 10-5 
1
A gene was defined from 2kb of the 5' UTR to 2kb of the 3' UTR  
  
 
 
 
* 
Trend test association test P-value  
+
 Genotypic association test P-value  
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2.3.4 The WTCCC HLA SNP data analysed  
 
 Among the genome-wide SNP markers, 1,321 SNPs from the extended HLA region 
as defined by Horton and colleagues [3] were selected.  Among these SNPs, 229 SNPs did 
not pass WTCCC quality control criteria and were excluded from this assessment. After 
removing these markers, 1,092 remained across the 1,834 RA patients and 2,938 shared 
controls. In addition, high-resolution HLA typing at HLA-DRB1 was available for 1,555 
58BC controls. These data were provided by the Juvenile Diabetes Research Foundation 
[104].  
 
 
 
2.4 The North American Rheumatoid Arthritis Consortium (NARAC) 
study  
2.4.1 The NARAC cases and controls  
 
 Plenge et al. [99] conducted a WGA study using the NARAC study, consisting of 908 
cases and 1,260 controls matched on self-reported ethnic background. Subjects of self-
reported white ancestry were analysed. The RA patients were randomly drawn from four 
study collections: the NARAC population (464 cases), the National Data Bank for Rheumatic 
Diseases (168 cases), the National Inception Cohort of Rheumatoid Arthritis (162 cases) and 
the Study of New Onset Rheumatoid Arthritis (114 cases). These were collectively referred to 
as the NARAC case-control study. All cases were anti-CCP+ and met the criteria for 
rheumatoid arthritis adopted by the 1987 American College of Rheumatology.  
 
 
2.4.2 Overview of the NARAC genome-wide association results 
 
Case samples and 601 control samples were genotyped with Illumina Human-
Hap550, version 1.0. Of the remaining control samples, 411 were genotyped on the Human-
Hap550K, version 3.0, and 248 were genotyped on the Human-Hap300 and Human-
Hap240S. Plenge et al. [99] compared plate membership to the top ten principal components 
 48 
 
and did not find any evidence of heterogeneity in genotype call rates for the three different 
Illumina beadchips.  
 SNP markers were excluded if they had more than 5% missing data, showed deviation 
from HWE (P < 10
-5
) in controls or had minor allele frequency (MAF) < 0.01. 
 From the genome-wide NARAC dataset, 1,625 SNP markers spanning the HLA 
region were selected in addition to the high-resolution (4-digit) typing at HLA-DRB1, which 
was used to define subjects as carriers of the SE+ or SE- HLA-DRB1 alleles (Chapter 3).  
 
 
2.4.3 The NARAC WGA study  
 
 Plenge et al. [99] analysed the combined NARAC and the Swedish Epidemiological 
Investigation of Rheumatoid Arthritis (EIRA) study populations using a Cochran-Mantel-
Haenzel stratified analysis . The associated results at P < 10
-8
 were tested in an independent 
case-control association study, in which cases had the anti-CCP+ form of RA (Chapter 1). 
The authors observed marker-disease associations with variants in HLA-DRB1 (P < 10
-100
), in 
PTPN22 on chromosome 1 (P < 2x10
-11
) and with a SNP (rs3761847) on chromosome 9 (P < 
4x10
-14
). 
 The NARAC dataset was also analysed by Ding et al. [33] and Lee et al. [52]. Ding 
and colleagues [33] identified HLA-DPB1 as a DRB1-independent risk locus associated with 
the presence of anti-CCP+. Lee and colleagues [52] reported two associations with RA in the 
class I HLA region in the vicinity of HLA-C and near the ZNF311 locus, which were both 
independent of HLA-DRB1. The latter association was enhanced in individuals with the HLA-
DRB1*0404 allele. Additional association signals were also detected in HLA-DPB1 
(rs2064478, P = 0.0053), DOB1 (rs2857151, P = 1.6x10
-5
), TAP2 (rs10484565, P = 6.3x10
-
6
), and COL11A2 (rs2855430, P = 0.00058) genes. 
 In the current thesis, the NARAC study population [99] was used to evaluate the 
marker-disease associations that were detected using data from the combined analysis of the 
GoRA and WTCCC studies. 
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Chapter 3. Modelling the effect of HLA-DRB1  
 
 
 
 
3.1 Introduction 
 
 In 1987, Gregersen et al. [28] reported an association between a group of alleles at 
HLA-DRB1 and RA.  They observed that these alleles encode a similar amino-acid sequence 
QKRAA, QRRAA and RRRAA at positions 70-74 in the third hypervariable region of the 
DRB molecule, and the observation gave rise to the shared epitope (SE) hypothesis [28]. 
According to the SE hypothesis, each SE allele confers the same risk and the HLA-DRB1 
alleles can be classified into two classes of different RA risk, called shared-epitope positive 
(SE+) and shared-epitope negative (SE-) alleles, based on the presence or absence of one of 
the three sequences. Many studies have investigated the SE hypothesis and discussed the 
SE+/SE- classification [105-109].  
 Some SE+ alleles have been shown to confer a different risk from other alleles of the 
same SE class. For example, HLA-DRB1*0401 has been shown to exhibit a higher risk than 
the HLA-DRB1*0101, *0404, *1001 and *0901 alleles, also from the SE+ class [31]. This 
could be because HLA-DRB1*0401 has a directly causal effect on RA that is different from 
other SE+ alleles, or because HLA-DRB1*0401 is in LD with another variant associated with 
RA.  
 Several modifications of the SE classification have been proposed [105-108, 110]. De 
Vries et al. [105] extended the SE classification system to include the amino acids 67 to 74. 
Mattey et al. [107] reported that the amino acid residue encoded at position 70 modified the 
risk of the disease. Later, du Montcel et al. [106] postulated that RA susceptibility may be 
conferred by the amino acid sequence RAA at position 72-74 and modulated by the amino 
acids at position 70 and 71. They classified HLA-DRB1*1101, *1201, *1301, *1303 and 
*1501 as RA susceptibility alleles, whereas these alleles were originally defined as SE- [28]. 
De Vries et al. [105] observed a protective effect for HLA-DRB1*1301, *1302 and *1501, 
and a neutral effect for HLA-DRB1*1101. In the GoRA study, the latter four alleles conferred 
protection against RA (Table 3.5). Morgan et al. [108] evaluated the three modified 
classification systems outlined above, but were unable to reproduce any of these findings 
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using a large cohort of Caucasian RA cases and controls from the UK. They reported that 
although some HLA-DRB1 alleles were associated with varying levels of RA risk, the SE 
alleles as defined originally by Gregersen et al. [28] were associated with an increased risk of 
RA and risk increased with the number of allele copies of the SE.  
 Although the proposed alternative classifications differed in detail, they are 
sufficiently similar that they can all be regarded as broadly supporting the original SE 
hypothesis of Gregersen et al. [28]. In this chapter, the SE hypothesis is investigated and 
refined using data from the GoRA study. The proposed model is then assessed by replication 
in the WTCCC study of RA. 
 
 
3.2 The SE alleles in the GoRA study 
3.2.1 The SE association with RA susceptibility 
 
 In the GoRA study, HLA-DRB1 alleles were divided into SE+ and SE- as described 
according to the SE hypothesis [28] (Table 3.1). Allele calls for which only 2-digit resolution 
could be achieved were investigated using the “allele code tool” of the National Marrow 
Donor Program (http://www.nmdpresearch.org/cgi-bin/ALLELE/dnatyp.pl). If all 4-digit 
possibilities were of the same SE class, the allele was coded accordingly. In this way, 842 
cases and 957 controls of the GoRA study were successfully assigned an SE status while the 
remaining 13 cases and 20 controls were assigned SE status of „missing‟ (Table 3.2).  
Consistent with the SE hypothesis, SE+ alleles occurred more frequently in cases (82% 
carried at least one SE+ allele) than in controls (48%). 
 
 
Table 3.1 SE+ and SE- allele classification 
HLA-DRB1 SE+ alleles HLA-DRB1 SE- alleles 
*0101, *0102, *0104, 
*0401, *0404, *0405, 
*0408,  *0409, *0426, 
*0430, *0433, *0438,  
*0440, *1001, *1113, 
*1421 
*0103, *0301, *0307, *0402, *0403, *0406, *0407, 
*0438, *0701, *0801, *0802, *0803, *0804, *0806, 
*0810, *0901, *1101, *1102, *1103, *1104, *1119, 
*1201, *1202, *1206, *1207, *1210, *1301, *1302, 
*1303, *1305, *1306, *1310, *1340, *1359, *1401, 
*1404, *1435, *1501, *1502, *1601, *1602 
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Table 3.2 Distribution of the SE in the RA cases and controls  
in the GoRA study 
 
 
Cases 
(N=842) 
Controls 
(N=957) 
SE carriage SE+ : SE - 
693 : 149 
(82% : 18%) 
459 : 498 
(48% : 52%) 
SE copies 
0 
1 
2 
149 (18%) 
426 (50%) 
267 (32%) 
498 (52%) 
384 (40%) 
75 (8%) 
 
 
 
Table 3.3 Odds Ratio Estimate for SE 
 P OR (95% CI) 
SE carriage 
SE+ vs. SE - 
4.3x10
-48 5.0 (4.0; 6.3) 
SE+ allele copies  
additive effect 
 
9.9x10
-58 
 
3.5 (3.0, 4.1) 
SE+ allele copies 
1 copy vs. 0 copy 
2 copies vs. 1 copy 
2 copies vs. 0 copy 
 
3.7x10
-29 
4.0x10
-15 
1.2x10
-53 
 
3.8 (2.9; 4.7) 
3.2 (2.4; 4.3) 
11.8 (8.6; 16.1) 
 
 
 
 
 Table 3.3 displays the odds ratio (OR) estimates for the SE, and indicates an almost 
multiplicative relationship between the number of SE+ allele copies and risk of RA: subjects 
with one copy of SE+ had OR = 3.8 for RA compared to those who did not carry an SE+ 
allele; comparing two copies with one gives OR = 3.2. To confirm the adequacy of this 
apparent multiplicative relationship, a logistic regression model that included SE+ allele 
count (coded as 0, 1, or 2) as an additive term was compared with a more general model 
including an additional dominance term coded as 1 if the subject was heterozygote or as 0 
otherwise. Table 3.4 displays the analysis of deviance derived from comparing these two 
models; results show that the more general model is not significantly better than the additive 
model (P = 0.499). Thus, in the current thesis, the SE effect is modelled as the number of 
SE+ allele copies.  
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Table 3.4 Analysis of deviance comparing the SE as additive and dominant effect 
SE Effect P of the effect Residual deviance Reduction in deviance P 
Additive 9.9x10-58 2179.3 
0.499 
General 
additive term 
dominant term 
 
4.0x10
-15 
0.498 
2178.8 
 
 
3.2.2 The contribution of HLA-DRB1 alleles to RA susceptibility 
 
 In order to assess the genetic contribution of HLA-DRB1 alleles compared to the SE 
classification, each allele was first analysed separately for association with RA, without 
including a term for SE in the model. Then, for each HLA-DRB1 allele with count greater 
than 36 (1%) in the combined GoRA cases and controls, a variable X was coded to indicate 
whether or not the subject was a carrier of that allele. For instance, for HLA-DRB1*0404, X 
was coded as 1 if a subject carried at least one copy of this allele and 0 otherwise. The 
following logistic regression model was considered:  
 
XY   , 
 
where Y represents the case/control status, 0 denoting  a control and 1 denoting a case, and X 
is the presence or absence of the HLA-DRB1 allele; by definition, if X = 1, then SE+ > 0.  
 Table 3.5 presents the distribution of HLA-DRB1 alleles in the GoRA cases and 
controls as well as the association P-values, the OR and 95% CI.  All of the SE+ alleles had a 
significant risk-enhancing effect on RA at P < 0.05, while all but one SE- alleles had a 
significant risk-reducing effect. The exception, HLA-DRB1*0901 had a 95% CI for the OR 
that was wide and included 1. Overall, the classification of the alleles as SE+ and SE- in the 
GoRA study confirms the SE hypothesis in its original form [28].  Among the SE+ alleles, 
the largest OR estimate was for HLA-DRB1*0408 (OR = 4.5) but the corresponding CI is 
wide (95%CI = (2.0; 9.7)). The most significant association was observed at HLA-
DRB1*0401 with an OR = 3.1 (P = 7.3x10
-36
).  Interestingly, the SE+ allele HLA-
DRB1*0101 had a significant lower OR compared to the alleles of the same SE class (OR = 
1.4), with the exception of *1001.  
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Table 3.5 Distribution of the HLA-DRB1 alleles among the GoRA cases and controls
*
 
Alleles SE N (%) 
RA Cases 
N (%) 
Controls 
N (%) 
P OR (95%CI) 
0101 
SE+ 
453 (13%) 249 (15%) 204 (11%) 2.1x10
-4
 1.4 (1.2; 1.8) 
0401 687 (19%) 473 (28%) 214 (11%) 7.3x10
-36
 3.1 (2.6; 3.7) 
0404 216 (6%) 149 (9%) 67 (3%) 7.4x10
-11
 2.7 (2.0; 3.6) 
0408 39 (2%) 31 (2%) 8 (<1%) 1.7x10
-4
 4.5 (2.0; 9.7) 
1001 42 (1%) 27 (2%) 15 (1%) 0.024 2.1 (1.1; 3.9) 
0103 
SE- 
39 (2%) 12 (1%) 27 (1%) 0.046 0.5 (0.2; 1.0) 
0301 466 (12%) 171 (10%) 295 (15%) 3.2x10
-6
 0.6 (0.5; 0.7) 
0701 397 (11%) 130 (8%) 267 (14%) 4.3x10
-9
 0.5 (0.4; 0.6) 
0801 63 (2%) 17 (1%) 46 (2%) 0.002 0.4 (0.2; 0.7) 
0901 42 (1%) 22 (1%) 20 (1%) 0.463 1.2 (0.7; 2.3) 
1101 144 (4%) 41 (2%) 103 (5%) 1.2x10
-5
 0.4 (0.3; 0.6) 
1201 54 (1%) 16 (1%) 38 (2%) 0.012 0.5 (0.3; 0.8) 
1301 115 (3%) 41 (2%) 74 (4%) 0.018 0.6 (0.4; 0.9) 
1302 112 (3%) 37 (2%) 75 (4%) 0.003 0.5 (0.4; 0.8) 
1401 65 (2%) 22 (1%) 43 (2%) 0.035 0.6 (0.3; 0.9) 
1501 417 (12%) 141 (8%) 276 (14%) 2.2x10
-8
 0.5 (0.4; 0.7) 
 
 
 
 
 
3.2.3 The contribution of HLA-DRB1 genotypes to RA susceptibility 
 
 Several investigators have suggested that certain HLA-DRB1 genotypes, for example 
HLA-DRB1*0401/*0404 [111], convey greater RA risk than would be predicted assuming 
independent contributions from their constituent haplotypes [105, 112]. In order to 
investigate this possibility, a binary variable was created for each of the twelve HLA-DRB1 
genotypes with count > 36 (2%) in the GoRA cases and controls combined; a cut-off of 2% 
was used instead of 1% to limit the number of genotype groups. For instance, each subject 
carrying the genotype HLA-DRB1*0401/*0404 was coded as 1 and all other genotypes were 
coded as 0. Each HLA genotype was further classified as SE+/SE+, SE+/SE- or SE-/SE-. As 
in the allele-based analysis, logistic regression was used to assess the individual effect of the 
HLA-DRB1 genotypes on RA susceptibility, without including the SE in the model. Table 3.6 
*Allele frequencies and association test results are presented for the HLA-DRB1 alleles with 
allele frequencies > 1% in the GoRA samples 
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presents the frequencies of the HLA-DRB1 genotypes among the GoRA cases and controls as 
well as the association P-values, OR and 95% CI. Differences in degree of association can be 
observed among the genotypes of the same SE group, i.e. SE+/SE+, SE+/SE- or SE-/SE-. 
Among the SE+/SE+ genotypes, HLA-DRB1*0401/0404 had the highest risk effect on RA 
(OR = 6.6) followed by HLA-DRB1*0401/0401 (OR = 5.7). Both associations were 
previously reported in the literature to convey the highest risk of RA susceptibility and 
severity [113, 114].  In general however, the genotypic risk effect increased with the number 
of SE+ allele copies. Carrying two copies of the SE+ allele greatly increased the risk of RA 
compared to carrying one SE+ allele. None of the SE-/SE- genotypes was associated with RA 
susceptibility in the GoRA samples. 
 
 
Table 3.6 Distribution of the HLA-DRB1 genotypes in the GoRA cases and controls  
Genotypes 
SE 
Genotypes 
N (%) 
RA Cases 
N(%) 
Controls 
N(%) 
P OR (95%CI) 
0101/ 0401 
SE+/SE+ 
 
105 (6%) 83 (10%) 22 (2%) 3.4x10
-10
 4.6 (2.9; 7.5) 
0401/ 0401 58 (3%) 48 (6%) 10 (1%) 6.6x10
-7
 5.7 (2.9; 11.4) 
0401/ 0404 71 (4%) 60 (7%) 11 (1%) 1.3x10
-8
 6.6 (3.4; 12.6) 
0101/ 0301 
SE+/SE- 
 
57 (3%) 25 (3%) 32 (3%) 0.652 0.9 (0.5; 1.5) 
0101/ 0701 54 (3%) 29 (3%) 25 (3%) 0.302 1.3 (0.8; 2.3) 
0101/ 1501 51 (3%) 25 (3%) 26 (3%) 0.747 1.1 (0.6; 1.9) 
0301/ 0401 82 (4%) 50 (6%) 32 (3%) 0.009 1.8 (1.1; 2.9) 
0401/ 0701 69 (4%) 34 (4%) 35 (4%) 0.674 1.1 (0.7;1.8) 
0401/ 1501 75 (4%) 45 (5%) 30 (3%) 0.021 1.7 (1.1; 2.8) 
0301/ 0701 
SE-/SE- 
 
65 (4%) 13 (1%) 52 (5%) 3.5x10
-5
 0.3 (0.1; 0.5) 
0301/ 1501 56 (3%) 14 (2%) 42 (4%) 0.001 0.4 (0.2; 0.7) 
0701/ 1501 49 (3%) 10 (1%) 39 (4%) 4.0x10
-4
 0.3 (0.1; 0.6) 
 
 
 
 
3.2.4 Reinvestigating the modelling of the SE 
 
 In order to investigate whether the SE hypothesis as defined by Gregersen et al. [28] 
could be refined by including the individual effect of some alleles at HLA-DRB1, alleles were 
*Genotype frequencies and association test results are presented for the HLA-DRB1 genotypes with 
frequencies > 2% in the GoRA samples.  
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jointly analysed in a backward stepwise regression, accounting for the additive effect of the 
SE. The same analysis was applied to the HLA-DRB1 genotypes.  
 The HLA-DRB1 alleles with frequency greater than 2% in the combined GoRA cases 
and controls were re-coded as additive effects based on number of allele copies. The additive 
effect rather than the presence or absence of the allele was considered since the previous 
analysis showed that the degree of association increased with the number of SE+ allele copies 
at some loci.  
 As displayed in Table 3.5, nine alleles were present in more than 2% of the GoRA 
subjects. Among them, were the SE+ alleles HLA-DRB*0101, *0401 and *0404, and the SE- 
alleles HLA-DRB1*0301, *0701, *1101, *1301, *1302 and *1501. The full logistic model 
included additive terms for these nine HLA-DRB1 alleles as well as a term representing the 
number of SE+ alleles. Backward stepwise regression was performed in order to identify 
HLA-DRB1 alleles that could improve the fit. Change in deviance was used to compare pairs 
of models differing by one term. The alleles at HLA-DRB1 were kept in the model if they 
improved the fit measured by the deviance by at least two points. 
 By this approach HLA-DRB1*0101, *0401 and *1101 were retained in the final 
model in addition to the number of SE+ allele copies (Table 3.7, Model 4). In this model, the 
marginal effects of *1101 and *0401 were not statistically significant at the type I-error α of 
0.05. The model was therefore compared to a model that excluded the least significant effect, 
i.e. HLA-DRB1*0401 (Model 3), using a 
2 test.  Analysis of deviance showed that adding 
HLA-DRB1*0401 did not improve the fit of the model (Model 4 vs. Model 3: P = 0.14). 
HLA-DRB1*0401 was hence removed from the model. Similarly, Model 3 was not 
significantly better than Model 2 (P = 0.08) and so HLA-DRB1*1101 was also omitted. 
Interestingly, RA risk was better accounted for by Model 2, which included the number of 
HLA-DRB1*0101 allele copies in addition to the SE+ allele count, compared with the SE+ 
allele count only (P = 3.9x10
-5
).  
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Table 3.7 Selection of the HLA-DRB1 alleles that may improve the well-known SE association in 
the GoRA study 
Statistical 
Model 
Estimate (se) P 
Residual 
Deviance 
Difference in 
Deviance 
Reduction in 
Deviance P 
Model 1 
SE+ copies  
 
1.25 (0.08) 
 
9.9x10
-58
 
 
2179.3 
- - 
Model 2 
SE+ copies 
*0101  
 
1.39 (0.09) 
-0.53 (0.13) 
 
8.3x10
-58
 
4.5x 10
-5
 
 
2162.4 
Model 2 vs. Model 1 
16.4 
Model 2 vs. Model 1 
4.0x10
-4
 
Model 3 
SE+ copies 
*0101,  
*1101 
 
1.38 (0.09) 
-0.54 (0.13) 
-0.35 (0.20) 
 
7.3x10
-56 
4.1x10
-5 
0.086 
 
2159.3 
Model 3 vs. Model 2 
3.1 
Model 3 vs. Model 2 
0.082 
Model 4 
SE+ copies 
*0101,  
*1101 
*0401 
 
1.25 (0.09) 
-0.41 (0.16) 
-0.35 (0.20) 
0.23 (0.15) 
 
1.9x10
-25 
0.008
 
0.088 
0.136 
2157.1 
Model 4 vs. Model 3 
2.2 
Model 4 vs. Model 3 
0.137 
 
 
 
In order to assess whether the effect at HLA-DRB1 was well represented by the 
number of SE+ allele copies, a multivariate logistic model that included the effect of the 
HLA-DRB1 alleles with frequency > 1% as additive terms was fitted as follows: 
 
             
 
where    is one of the sixteen HLA-DRB1 alleles, which were coded as 0, 1 or 2 according to 
the number of allele copies, and   .is the regression coefficients to estimate.  
 Table 3.8 presents the P-values and ORs of each of the sixteen HLA-DRB1 alleles that 
were estimated simultaneously in a multivariate logistic regression model. All SE+ alleles 
were significantly associated with RA susceptibility at P < 0.05. The OR estimates were in 
the range of 1.6 to 5.7. HLA-DRB1*0408 had the highest OR (OR = 5.7, 95% confidence 
interval [2.4, 13.2]), whereas HLA-DRB1*0101 had the smallest risk effect (OR = 1.6, 95% 
confidence interval [1.2, 2.3]). As described earlier, the additive OR of the number of SE+ 
allele copies was 3.5, 95% confidence interval [3.0, 4.1] (Table 3.3), which falls within the 
confidence interval of any SE+ HLA-DRB1 alleles other than *0101. Among the eleven SE- 
alleles, six alleles had a significant protective effect on RA at P < 0.05 and five alleles were 
not associated with RA.  
 Backward stepwise regression identified a model with the numbers of HLA-
DRB1*0101 and SE+ allele copies as the preferred model. The Bayes information criterion 
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(BIC) of five models representing the effect at HLA-DRB1 were compared in order to identify 
the model that best fit the data, i.e. the model with the lowest BIC value, where BIC = -2ln(L) 
+ k*ln(n), L being the log-likelihood of the model, k being the number of parameters in the 
model and n being the number of observations. The five logistic models were:  
1) a model that includes the effect of the sixteen HLA-DRB1 alleles as presented above: 
          . 
2) a model that includes the effect of the number of SE allele copies,    , and the eleven 
HLA-DRB1 alleles of the SE- class that were coded as indicator variables of the number 
of copies of the allele,   
   :               
   
   
   .  
3) a model that includes the SE- effect,     , and the five HLA-DRB1 alleles of the SE+ 
class that were coded as indicator variables of the number of copies of the allele,   
   :  
                
   
   
   . 
4) a model that includes the effect of the number of SE allele copies    , on its own: 
          . 
5)  a model that includes the effect of the number of SE allele copies     and *0101 allele 
copies:                          where       represents the number of *0101 
allele copies. 
 
 
Table 3.9 presents the BIC values of the different models. The model with the sixteen 
HLA-DRB1 alleles included as covariates had the highest BIC value (BIC = 2254.9). The 
model that considered all the SE+ alleles the same (BIC = 2250.9) had a larger BIC value 
than the model that considered all the SE- alleles the same (BIC = 2196.1). Introducing an 
indicator variable that account for the five SE+ alleles improves the BIC but only by a small 
amount, whereas introducing a common SE- variable for the eleven SE- HLA-DRB1 alleles 
improves the BIC greatly. With BIC = 2174.4, the model with the number of SE+ and *0101 
allele copies, which was obtained using backward stepwise regression, is to be preferred 
according to this criterion.  
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Table 3.8 ORs and P-values of HLA-DRB1 alleles from a multivariate 
logistic model 
SE Alleles OR (95%CI) P 
SE + 
0101 1.6 (1.2, 2.3) 0.002 
0401 2.9 (2.1, 3.9) 1.4x10-11 
0404 2.7 (1.8, 4.0) 9.8x10-7 
0408 5.7 (2.4, 13.2) 5.5x10-5 
1001 2.3 (1.1, 4.7) 0.025 
 
SE - 
0103 0.6 (0.3, 1.3) 0.229 
0301 0.7 (0.5, 1.0) 0.079 
0701 0.6 (0.4, 8.7) 0.005 
0801 0.4 (0.2, 0.8) 0.014 
0901 1.6 (0.8, 3.2) 0.184 
1101 0.5 (0.3, 0.7) 0.002 
1201 0.5 (0.2, 1.0) 0.045 
1301 0.7 (0.4, 1.1) 0.156 
1302 0.6 (0.4, 1.0) 0.035 
1401 0.6 (0.4, 1.2) 0.165 
1501 0.6 (0.4, 0.9) 0.006 
 
 
 
 
Table 3.9 Comparison of models accounting for the  
HLA-DRB1 effect ordered by decreasing values of BIC 
Multivariate logistic models BIC  
            2254.9 
              
   
   
     2250.9 
                
   
   
     2196.1 
           2186.7 
                      2174.4 
  
 
 
 
 A genotypic approach was next examined to investigate whether the representation of 
the SE effect could be improved compared to the allelic approach. In this case, the full model 
included the twelve genotypes with frequency greater than 2% in the GoRA samples 
(*0701/*1501, *0401/*1501, *0301/*0701, *0301/*1501, *0401/0401, *0401/0404, 
 59 
 
*0401/*0701, *0301/*0401, *0101/*0701, *0101/*0401, *0101/*0301, *0101/*1501), as 
well as the number of SE+ allele copies.  
 Table 3.10 presents the results of backward stepwise regression. The final model, 
Model 4, retained *0401/*0404, *0401/*1501 and *0301/*0401 in addition to the number of 
SE+ allele copies, but none of the genotype associations was statistically significant at a type 
I-error α of 0.05. The model was sequentially refitted with each time one variable removed, 
but in each case the more complex model was not significantly better than the simpler model, 
and so it was concluded that no HLA-DRB1 genotype terms improved the fit over the number 
of SE+ allele copies alone.  
 
 
Table 3.10 Selection of the HLA-DRB1 genotypes that may improve the well-known SE 
association in the GoRA study 
Statistical 
Model 
Estimate (se) P 
Residual 
Deviance 
Difference in Deviance 
Reduction in Deviance 
P 
Model 1 
SE+ copies 
 
1.25 (0.08) 
 
1.0x10
-57
 
2179.3 -  
Model 2 
SE+ copies, 
*0401/*0404 
 
1.22 (0.08) 
0.42 (0.35) 
 
2.0x10
-50
 
0.224 
2177.7 
Model 2 vs. Model 1 
1.6 
Model 2 vs. Model 1 
0.207 
Model 3 
SE+ copies, 
*0401/*0404 
*0401/*1501 
 
1.21 (0.08) 
0.45 (0.35) 
0.37 (0.24) 
 
1.1x10
-49
 
0.195 
0.126 
2175.3 
Model 3 vs. Model 2 
2.4 
Model 3 vs. Model 2 
0.123 
Model 4 
SE+ copies, 
*0401/*0404 
*0401/*1501 
*0301/*0401 
 
1.20 (0.08) 
0.49 (0.35) 
0.40 (0.24) 
0.44 (0.23) 
 
8.9x10
-49
 
0.159 
0.101 
0.064 
2171.7 
Model 4 vs. Model 3 
3.6 
Model 4 vs. Model 3 
0.058 
 
 
 
3.2.5 Summary of the SE hypothesis in the GoRA study  
 
 These findings show that the RA risk conferred by SE+ alleles as defined by 
Gregersen et al. [28] is confirmed in the GoRA study. Modelling the SE as an additive effect 
was also significantly better than modelling it as a general effect. Furthermore, although 
alleles from the SE+ class were all risk-enhancing, risk level varied, as also reported in the 
literature [31]. The joint analysis of the HLA-DRB1 alleles revealed that modelling the risk of 
RA could be improved by including the additive effect of HLA-DRB1*0101. The model that 
also included the number of HLA-DRB1*0101 allele copies was significantly better than a 
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model that included the SE alone. HLA-DRB1*0101, which was the second most common 
allele among the GoRA samples (12.6%), had the smallest OR among the SE+ alleles (OR = 
1.4).  
 
 
3.3 The HLA-DRB1 effect in the WTCCC dataset 
3.3.1 The effect of SE in the WTCCC study 
 
 In order to investigate the proposed approach, the model that includes the number of 
SE+ and *0101 allele copies was analysed using samples from the WTCCC study of RA. 
 Alleles at HLA-DRB1 were only available for the controls of the 1958 Birth cohort. In 
order to evaluate the association at HLA-DRB1 in the WTCCC study, the SE and HLA-
DRB1*0101 indicator variables were imputed from the HapMap (CEU parents) and the 
GoRA study using MACH [115]. The imputation process is presented in detail in Chapter 6. 
Because both variables are included additively in the logistic regression model, uncertainty in 
the imputations was accounted for by using the expected number of SE+ and *0101 alleles as 
regression predictors. As an example, a weighted mean allele score was derived for SE+ 
based on the probability of the expected SE+/SE+, SE+/SE- and SE-/SE- genotypes, which 
can be written as follows:  
 
  SESESESESESE PPPScore /// 012 , 
 
where Pi  is the probability of genotype i and score is a real number between 0 and 2. This 
score was used to measure the additive effect of the genotypes in the regression analyses.  
 Table 3.11 displays the distribution of the SE+ and SE- alleles among the RA cases 
and controls from the WTCCC. As in the GoRA study, the SE+ alleles were more frequent in 
cases compared to the controls.  The distribution of the SE+ alleles was 82% among both the 
WTCCC and GoRA cases. The similarity of the SE+ distributions between the two studies is 
unlikely to have been caused by the imputation process since the genotype data of the case 
and control samples were imputed simultaneously.   
 Table 3.12 displays the OR estimates for SE. The ORs were very similar to those 
observed in the GoRA study. The effect of the number of SE+ allele copies was 
approximately multiplicative. One copy of SE+ increased significantly the risk of developing 
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RA (OR = 3.5) compared to no copy of SE+. Similarly, two copies of SE+ increased 
significantly the risk of developing RA (OR = 2.9) compared to one copy.   
 
 
Table 3.11 Distribution of the SE in the RA cases and controls of the WTCCC study 
 
 
Cases 
(N=1834) 
Controls 
(N=2938) 
SE carriage SE+ : SE - 
1498 : 336 
(82% : 18%) 
1446 : 1492 
(49% : 51%) 
SE copies 
0 
1 
2 
336 (18%) 
945 (52%) 
553 (30%) 
1492 (51%) 
1203 (41%) 
243 (8%) 
 
 
 
Table 3.12 OR estimate of SE  
 P OR (95% CI) 
SE carriage 
SE+  vs. SE - 
3.4x10
-103 4.6 (5.3, 4.0) 
SE+ allele copies 
 additive effect 
 
1.6x10
-128 
 
3.6 (3.2, 4.0) 
SE+ allele copies 
1 copy vs. 0 copy 
2 copies vs. 1 copy 
2 copies vs. 0 copy 
 
2.8x10
-63 
2.3x10
-33 
1.3x10
-123 
 
3.5 (3.0; 4.0) 
2.9 (2.4;3.4) 
10.1 (8.3; 12.2) 
 
 
 
 The SE effect was next assessed in a general model that included a dominant as well 
as an additive effect term. As in the GoRA study, the inclusion of the additional term did not 
improve the fit of the model (P = 0.20) as seen in Table 3.13.  
 
 
Table 3.13 Analysis of deviance comparing the SE as additive and dominant effect 
SE effect P of the effect 
Residual 
Deviance 
Reduction in 
Deviance P 
Additive  2.3x10-130 5672.6 
0.200 
Dominant  
additive term 
dominant term 
 
1.3x10
-123 
0.156 
5670.5 
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3.3.2 The effect of SE and HLA-DRB1*0101 in the WTCCC study 
 
 Next, the number of HLA-DRB1*0101 alleles was included as a predictor of RA in 
the logistic regression model, in addition to the number of SE+ alleles. The analysis of 
deviance showed that the additional term significantly improved the fit (Model 2 vs. Model 1, 
P = 3.8x10
-4
) in the WTCCC study (Table 3.14), similar to the result for the GoRA study.   
 
 
Table 3.14 Analysis of deviance comparing a model with SE and *0101 to a model with SE only 
Statistical 
Model 
Estimate 
(se) 
P of the 
effect 
Residual 
Deviance 
Variation in Deviance Reduction in 
Deviance P 
Model 1: 
SE+ copies  
 
1.27 (0.05) 
 
1.6x10
-128
 
 
5685.5 
- - 
Model 2:  
SE+ copies,  
*0101 
 
1.33 (0.06) 
-0.24 (0.08) 
 
2.5x10
-122
 
3.1x10
-3
 
5676.8 
Model 2 vs. Model 1 
8.7 
Model 2 vs. Model 1 
0.003 
 
 
 
3.4 Discussion 
 
 Many investigators have tried to model the effect of the HLA-DRB1 in RA 
susceptibility [31, 105-108, 110, 116]. The majority of them have concluded that the SE 
hypothesis [28] did not fully explain the effect of HLA-DRB1 on disease susceptibility. 
Different classifications of the SE alleles have been proposed but none of them has been 
validated [108]. Across studies, the original SE classification [28], which supposed that the 
SE+ alleles have similar risk effect, has been consistently associated with RA. 
 The results from both the GoRA and WTCCC studies confirm the SE effect on RA 
risk. These findings revealed however that alleles within the SE+ and SE- classification show 
different strengths of association. Therefore, we disagree with the SE hypothesis on that the 
effect size of the HLA-DRB1 alleles is constant within each class. Correcting for the SE only 
might not entirely account for the effect at HLA-DRB1. The inclusion the number of alleles at 
HLA-DRB1*0101 improved the model of association with RA over the model that only 
includes the number of SE+ alleles. The result was observed in both the GoRA and WTCCC 
datasets. For this reason, the number of HLA-DRB1*0101 and SE+ allele copies were both 
used to model the effect of HLA-DRB1.   
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Chapter 4. Single-SNP association analysis of the GoRA 
case-control study 
 
 
 
 
4.1 Introduction 
 
 As introduced in Chapter 1, the HLA-DRB1 locus is a well-known RA 
susceptibility gene. There is however evidence of additional risk loci in the HLA 
region that are independent of HLA-DRB1 [32, 35, 36, 38, 117-119]. The objective of 
the current analysis is to identify the locations of the non-DRB1 associated markers 
via single-SNP association tests using cases and controls from the GoRA study 
(Chapter 2).  
 First, logistic regression analyses are performed unadjusted for the effect of 
HLA-DRB1. In Chapter 3, both the SE and HLA-DRB1*0101 allele count variables 
were used to account for the effect of HLA-DRB1. Here, two adjusted logistic models 
are presented: a model that adjusts for the effect of SE+ allele copies only, and a 
model adjusted for the effect of SE+ and HLA-DRB1*0101 allele counts. Multivariate 
logistic regression using backward stepwise regression is applied on the set of 
associated SNPs at P < 10
-4
. A discussion assessing the strengths and weaknesses of 
these analyses follows, highlighting the need for superior analyses that is attempted in 
subsequent chapters. 
 
 
4.2 Single-SNP association tests using logistic regression  
4.2.1 Methods 
 
 Consider a sample of n1 cases and n2 controls, and let N = n1 + n2 and ip be the 
probability that individual i is affected. Logistic regression models the disease risk as 
a function of a set of variables xij, j {1,…p}, using the logit transformation of ip . 
In the general case, the logistic model can be written as follows, 
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 and where   is the vector of the coefficients to be estimated, 0
is the intercept and j  the effect of variable j. This model is additive on the logit 
scale and multiplicative on the odds scale, and also approximately multiplicative on 
the absolute risk scale under the assumption of rare diseases; the OR being 
approximately equivalent to the relative risk.  
 Here, the xij encode the minor allele count (0, 1, or 2) of individual i at SNP j, 
where the minor alleles were identified according to their frequencies in controls. This 
coding scheme implies that the effect, on the logit scale, of having two copies of the 
minor allele was twice that of having one copy. In the following equation, βadd 
denotes the corresponding effect-size parameter. The likelihood ratio test, the Wald 
tests and the score test are typically used in logistic regression to assess the statistical 
significance of the parameters [120]. These tests are asymptotically equivalent for 
large sample sizes. To test the linear hypothesis βadd = 0, the Wald chi-square test 
statistic, which has approximately a 
2  distribution, was used: 
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ˆ 2
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 In addition, a general model was implemented to test for dominant allele effect by 
specifying an additional term xi,dom coded as 1 if the subject was heterozygote and 0 
otherwise. The general model can be written as,  
 
  domidomiaddiaddii xxp ,,,,0)(logit  
 
 Three models were fitted for each marker: one excluding any effect at HLA-
DRB1 (unadjusted analysis), and two adjusted logistic models for the effect of SE+ 
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copies only, and for the effect of SE+ and HLA-DRB1*0101 allele counts.  The latter 
model took the following form: 
 
  iidomidomiaddiaddii DRBSExxp 0101_)(logit ,,,,0  
 
 In this notation, SE is the number of SE+ alleles and DRB_0101 is the number 
of HLA-DRB1*0101 alleles. For each marker, the combined genetic effect was tested 
by comparing the null hypothesis of no association (H0: βadd = βdom= 0) to the 
alternative hypothesis that either βadd ≠ 0 or βdom ≠ 0 using the Wald chi-square test 
statistic.  
 After each marker had been tested individually for the presence of additive or 
general effects, stepwise backward logistic regression analysis was performed to 
jointly explore the relative importance of the SNPs that were significantly associated 
with RA at P < 10
-4
 in the additive or the general single-SNP association models.  
  
 
4.2.2 Results 
4.2.2.1  Unadjusted analysis  
 
 Figure 4.1 presents the association test results for the additive model, before 
adjusting for the effect at HLA-DRB1.  In summary, 443 SNPs were associated with 
RA at the type-I error α = 0.001, before adjusting for the effect at HLA-DRB1. Among 
them, 322 had P < 10
-4
, 240 had P < 10
-5
 and 121 markers had P < 10
-10
. The 
expected counts of significant results under the null hypothesis are 3 at P < 0.001 and 
none at P < 10
-4
.  Many of the statistically significant associations were observed in 
the vicinity of HLA-DRB1, the SE locus (Figure 4.1). The lowest P-values were 
observed for the three SNPs that are located close to HLA-DRB1:  rs7764856, in the 
5‟-untranslated region (5‟-UTR) of HLA-DQA2 (P = 1.1x10-40), rs660895 (P = 
3.0x10
-40
) which flanks HLA-DRB1 and rs2395175 in the 5‟ UTR of HLA-DRA (P = 
5.7x10
-40
).  
 The general model (Figure 4.2) identified 376 markers with P < 0.001.  
Among these SNPs, 283 had P < 10
-4
, 213 had P < 10
-5
 and 113 were associated at P 
< 10
-10
.  The same genetic-regions were identified as for the additive model. The 
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lowest P-values were observed for rs7764856, in the 5‟-UTR of HLA-DQA2 (P = 
1.8x10
-39
), rs660895 (P = 5.2x10
-39
), which flanks HLA-DRB1 and rs2395175 in the 
5‟-UTR of HLA-DRA (P = 1.6x10-38). All three SNPs lie in a 250kb window which 
includes HLA-DRB1. 
 Inspecting by eye, the P-value distributions of the additive and general models 
were similar across the HLA region as shown in Figure 4.1 and Figure 4.2. Figure 4.3 
shows that there was no major deviation for the highly significant SNP markers 
between the additive and general models, which means that there is no evidence for 
non-additive effects. Among the 213 significant associations at the type-I error α = 10-
5 
from the general model, one SNP marker was not significant in the additive model; 
its association was however marginally associated with RA at P = 7.0x10
-5
.  
 The Quantile-quantile (QQ) plot representing the single-SNP association test 
P-values of the dominant effects from the general model (Figure 4.4) shows no strong 
departure from the expectation under the null hypothesis of no association. Only few 
markers provide evidence of deviation from additivity in this analysis.  
 There is no consensus on which genetic model to consider, unless there is 
prior knowledge on the mode of inheritance of the risk allele. The additive model 
assumes that the disease risk changes multiplicatively with the number of copies of 
the risk allele. The general model allows deviation from the additive model and places 
no assumption on the underlying model. This model is more flexible than the additive 
model. Like the WTCCC [98], the association test results from both models were used 
in this assessment. 
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Figure 4.1 -log10(P) of the additive unadjusted association tests across the HLA region 
 
 
 
Figure 4.2 -log10(P) of the general unadjusted association tests across the HLA region 
 
  
The y-axis shows the –log10(P) for association with RA, and SNP location is shown on the x-
axis. The dashed line corresponds to a P value threshold of 10
-4
. The vertical line indicates HLA-
DRB1. 
The y-axis shows the –log10(P) for association with RA, and SNP location is shown on the x-
axis. The dashed line corresponds to a P value threshold of 10
-4
. The vertical line indicates HLA-
DRB1. 
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Figure 4.3 Comparison of the –log10(P-value) association test results 
for the additive (x-axis) and general (y-axis) models, unadjusted 
 
  
 
Figure 4.4 Quantile-quantile plot of the single-SNP association 
 test P-values of the dominant effects from the general model 
 
 
  
 
 To estimate the strength of the influence of the SE locus on the other loci, 
pairwise LD analysis was performed between each marker and the SE+/SE- allele 
groupings. Since there was no major difference between the additive and general 
 69 
 
model (Figure 4.3), the general association test –log10 P-values were compared to the 
squared Pearson correlation coefficient, r
2
, between each SNP and the SE alleles. 
Correlation with the SE impacts the association results. Figure 4.5 shows that SNPs in 
moderate to high LD (r
2 
> 0.3) with SE are the SNPs with the lowest P-values. Figure 
4.6 presents the r
2 
value between the 376 SNPs that were significant at P < 0.05 in the 
general model and the SE alleles. The pattern of LD is similar to that seen in Figure 
4.2. Figure 4.3 in which the association test P-values are given. This suggests that the 
genetic associations observed in the unadjusted analysis may be largely due to strong 
LD with the HLA-DRB1 locus.   
 
 
 
Figure 4.5 Comparison of the –log10(P-value) from the general unadjusted 
analysis and r
2
 values between each SNP and SE  
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Figure 4.6 LD (r
2
) between the SE and SNPs with P < 0.05 in the general unadjusted 
analysis 
 
 
 
 
4.2.2.2 Analyses adjusted for the SE 
 
 To investigate the presence of non-DRB1 associations with RA, logistic 
regression was applied with the number of SE+ alleles included as a covariate. Figure 
4.7 and Figure 4.8 present the association test P-value across the HLA region for the 
additive and general single-SNP association tests, respectively. As expected, the 
strong genetic associations are now no longer clustered around HLA-DRB1. The 
additive model identified 56% more positive results than the general model at P < 10
-
4
. After accounting for the number of SE+ allele copies, the additive model identified 
145 associated SNPs at P < 0.001. Of these associations, 43 had P < 10
–4
 and 10 had 
P < 10
–5
.  After accounting for the number of SE+ allele copies, 90 markers were 
significant at P < 0.001 in the general model, 18 of these had P < 10
–4
, and 3 markers 
were significant at P < 10
–5
, which is still more than the number of positive 
associations expected to arise by chance. 
 
Each cross represents the pairwise LD value (r
2
) between a SNP and the SE+/- locus. 
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Figure 4.7 -log10(P) of the additive association tests across the HLA region after 
adjustment for the SE 
 
 
 
 
 
 
 
Figure 4.8 -Log10(P)of the general association tests across the HLA region after 
adjustment for the SE 
 
 
The y-axis shows the –log10(P) for association with RA, and SNP location is shown on the x-
axis. The dashed line corresponds to a P value threshold of 10
-4
. The vertical line indicates 
HLA-DRB1. 
The y-axis shows the –log10(P) for association with RA, and SNP location is shown on the x-
axis. The dashed line corresponds to a P value threshold of 10
-4
. The vertical line indicates 
HLA-DRB1. 
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 Figure 4.9 displays the differences between the general association test P-
values (y-axis) and the additive association test P-values (x-axis). The excess of P-
values under the y = x line showed that the additive P-values were overall more 
significant than those of the general model. A group of twelve markers with P < 10
-3
 
in the general model and P > 10
-3
 in the additive model stands out. Among this group, 
the two markers that are the most associated in the general model with RA are 
rs423023 (P = 5.7x10
-5
) and rs415929 (P = 6.1x10
-5
). Interestingly the GoRA dataset 
suggests a recessive effect for both markers (Table 4.1).  
 These results show that there are many more positive additive associations 
than non-additive effects. The number of positive associations in both models is 
however far higher than one would expect by chance. The extent of LD within the 
HLA region might have contributed to this effect.  
 
 
 
 
Figure 4.9 Comparison of the general and additive association tests -log10( P) 
after adjustment the SE 
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Table 4.1 Association test P-value of the SNPs with P < 10
-4
 
in the general model and P > 10
-3
 in the additive model 
RSnumber P dominant P recessive 
rs415929 0.47 7.7x10-5
 
rs423023 0.57 5.6x10-5 
 
 
 
Backward stepwise regression analyses of the significant association at P < 10
-4 
 In an exploratory analysis, the 43 SNPs that were significant at P < 10
-4
 in the 
additive model were included, with the number of SE+ allele copies, in a backward 
stepwise logistic regression analysis.  In addition to the SE, five markers were 
retained in the final model:  rs46278, which is a non-synonymous SNP in VARS2, 
rs2442728, which is upstream of HLA–B, rs17499655, which is upstream of HLA–
DQA2, rs1592409, located in the 3‟-UTR of LOC729653, a gene with no reported 
function, and rs6934187, which encodes a synonymous change in MICA.  
 In the stepwise analysis of the markers significant at P < 10
-4
 in the single-
SNP general model, the SNP markers were included as additive effects to limit the 
number of variables. Among the eighteen SNPs with P < 10
–4
, the three SNPs that 
were previously selected rs4678, rs2442728 and rs17499655, were retained in the 
final model. Marker rs17499655, which was selected by both stepwise regression 
models, lies very close to HLA-DRB1 and might have been selected to account for 
some effect at HLA-DRB1. In order to investigate this possibility, LD between 
specific HLA-DRB1 alleles and the SNPs selected by the two stepwise analyses was 
calculated in the GoRA controls (Table 4.2).  
 Interestingly, the SE+ allele HLA-DRB1*0101 is in LD with rs17499655 at r
2
 
= 0.64. The *0101 allele is associated with the rare allele of rs17499655. 
 The association between RA and rs17499655 could be due to the effect, 
previously discussed, of HLA-DRB1*0101 that is significantly lower than the other 
SE+ alleles (Chapter 3). It is also possible that rs17499655 is truly associated with RA 
and modifies the effect at HLA-DRB1*0101. 
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Table 4.2 r
2
 between the 43 SNPs with P < 10
-4
 in the additive single-SNP association test 
and the most common HLA-DRB1 alleles (allele frequency > 0.02) in the GoRA controls 
Marker 
dbSNP127 
Alleles at HLA-DRB1 
 0101 0301 0401 0404 0701 1101 1301 1302 1501 SE 
rs1592409 * 0.01 * * * * * * * * 
rs4678 * 0.27 0.02 * * 0.01 * * 0.01 0.02 
rs6934187 0.04 0.01 * * * * * * 0.01 * 
rs17499655 0.64 0.02 0.02 * 0.03 * 0.01 0.01 0.03 0.21 
*r
2
 < 0.01 
 
 The stepwise regression was repeated, omitting rs17499655 in the set of 43 
and 18 SNPs that were significant at P < 10
-4
 in the additive and general single-SNP 
association tests. The final models included the same SNPs, which were selected in 
the previous stepwise regression, together with a marker that was in LD with the SNP 
that was removed. The additive stepwise model retained rs4248166, which was in LD 
with rs17499655 at r
2
 = 0.64 and the general stepwise model retained rs3763313, 
which was in LD with rs17499655 at r
2
 = 0.57. The inclusion of the SNPs correlated 
with rs17499655 reflects the difficulties associated with applying stepwise analysis to 
variables that are correlated and suggests that the true effect of HLA-DRB1 may not 
be fully captured by grouping alleles as SE+ and SE–. 
  
 
4.2.2.3  Adjusted analysis on the SE and HLA-DRB1*0101 
 
 In Chapter 3, the inclusion of the number of alleles at HLA-DRB1*0101 
improved the model of association with RA, over and above the use of the binary 
SE+/SE- variable on its own. To further investigate associations with RA independent 
of HLA-DRB1, logistic regression was applied with the number of SE+ and HLA-
DRB1*0101 allele counts included as covariates. Figure 4.10 and Figure 4.11 display 
the association test P-value of the additive and general single-SNP analysis after 
adjustment for the SE and *0101. A similar pattern of associations can be observed 
between the additive and general models. Most of the significant associations are 
located within the class I HLA region, between HLA-A and TNF. The highly 
associated markers (P < 10
-4
) from the additive and general models are presented in 
the Appendix. 
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 The additive model identified 44 markers associated with RA at P < 10
-4 
and 
13 with P < 10
-5
. Of the significant associations at P < 10
-4
, 33 had also been 
associated at P < 10
-4
 in the previous SE adjusted analysis. Among the ten markers 
that were no longer associated with RA (P ≥ 0.05), were the markers in high LD with 
HLA-DRB1*0101, rs4248166 (r
2 
= 0.56) and rs6930777 (r
2 
= 0.80). 
 In the general model, 26 markers were significant at P < 10
-4 
and five markers 
had P < 10
-5
. Of the 26 markers with P < 10
-4
, 12 were also associated with P < 10
–4
 
in the analysis adjusted on the SE alone. Among the remaining markers (6 out of 18 at 
P < 10
-4
), which were no longer significant at P < 10
-4
 in the SE and HLA-
DRB1*0101 adjusted analysis, three markers were in LD with HLA-DRB1*0101 at r
2
 
= 0.56 (rs4248166), r
2
 = 0.46 (rs3763313) and r
2
 = 0.64 (rs17499655). The latter 
marker was also previously retained in the stepwise regression of both the additive 
and general models adjusted on the SE only.  
In order to assess the degree of correlation among the most associated SNPs, LD 
among the significant markers (P < 10
-4
) from the additive and general models was 
plotted using Haploview [9] in the GoRA controls. The results are presented in Figure 
4.12 and Figure 4.13 , respectively. In both analyses, the associated markers exhibit 
substantial inter-correlation and block structure, despite the interval spanning around 
2Mb. There was however no LD between the SNP markers and the SE and HLA-
DRB1*0101 alleles (r
2
 ≤ 0.05 for SNPs from the additive model and r2 ≤ 0.03 for 
SNPs from the general model). As expected, there was some LD between the SE and 
HLA-DRB1*0101 (r
2  
= 0.30).  
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Figure 4.10 -log10(P) of the additive association test across the HLA region after 
adjustment for the SE and HLA-DRB1*0101 alleles 
 
 
 
 
 
 
Figure 4.11 -log10(P) of the general association tests across the HLA region after 
adjustment for the SE and HLA-DRB1*0101 alleles 
 
 
 
 
The y-axis shows the –log10(P) for association with RA, and SNP location is shown on 
the x-axis. The dashed line corresponds to a P value threshold of 10
-4
. The vertical line 
indicates HLA-DRB1. 
The y-axis shows the –log10(P) for association with RA, and SNP location is shown on 
the x-axis. The dashed line corresponds to a P value threshold of 10
-4
. The vertical line 
indicates HLA-DRB1. 
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Backward stepwise regression analyses of the significant association at P < 10
-4
 
 As in the previous analyses, markers with P < 10
-4
 were analysed jointly using 
a backward stepwise regression analysis. Of the 44 SNPs that were associated with 
RA in the additive model (P < 10
-4
), three markers in addition to the SE and HLA-
DRB1*0101 effects were retained in the stepwise model. The three SNPs included the 
two SNPs, rs2442728 and rs1592409 that were retained in the stepwise analysis that 
included the effect of the SE on its own, and an additional marker rs2532934, which 
is in the 3‟-UTR of VARS2. None of these SNPs was in LD (r2 ≤ 0.05) with any of the 
HLA-DRB1 alleles. It is hence unlikely that these markers were selected to account for 
some of the effect at HLA-DRB1. 
 Once again, the SNPs from the general model were analysed as additive 
effects in order to limit the number of variables. Among the 26 associated markers (P 
< 10
-4
) from the general model, two SNPs, rs4678 and rs2442728, were retained in the 
final model in addition to the effects of SE and HLA-DRB1*0101. These markers 
were also retained in the stepwise regression that included the SE effect on its own. 
Interestingly, marker rs2442728 was retained in both stepwise analyses that were 
adjusted for the effects of SE and HLA-DRB1*0101. Markers rs2532934 and rs4678, 
which were retained in the different stepwise analyses, were both in VARS2; these 
markers were however moderately correlated with each other (r
2
 = 0.33). Overall, 
both stepwise models retained markers within the same genes, i.e. BAT1/MICA and 
VARS2.  
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Figure 4.12 LD (r
2
) among the 44 most highly associated SNPs (P < 10
-4
)
 
in the additive association tests adjusted on the SE and *0101 
LD (r
2
) among the most highly associated SNPs (P < 10
–4
) in the additive adjusted analysis on the SE and *0101. Markers are shown in map 
order, as indicated across the top. r
2
, which were calculated using data from the controls, are indicated in the individual boxes and are reflected by 
the intensity of shading with darker shading corresponding to higher r
2
values. 
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Figure 4.13 LD (r
2
) among the 26 most highly associated SNPs (P < 10
-4
)
 
in the general association tests adjusted on the SE and *0101 
LD (r
2
) relationships among the most highly associated SNPs (P < 10
–4
) in the additive adjusted analysis on the SE and *0101). Markers are 
shown in map order, as indicated across the top. r
2
, which were calculated using data from the controls, are indicated in the individual boxes and 
are reflected by the intensity of shading with darker shading corresponding to higher r
2
values. 
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4.3 Discussion 
 
 The unadjusted analysis identified a large number of positive results and confirmed 
the influence of the HLA-DRB1 locus on the marker-disease associations within the HLA 
region.  After adjusting for the effect of the SE, 43 SNPs in 30 genes were associated with 
RA at P < 10
-4
 in the single-SNP additive model and 18 SNPs in 14 genes were associated 
with RA at P < 10
-4
 in the single-SNP general model. Results from the latter model are 
presented in Vignal et al. [121]. Backward stepwise regression of the markers that were 
significant at P < 10
-4
 in the additive model retained the SE and the following markers: 
rs6934187, which encodes a synonymous change in BTNL2, approximately 1.1Mb of HLA-
DRB1, rs1592409 upstream of an unknown gene, approximately 3.0Mb from HLA-DRB1, as 
well as the same three markers as for the general model rs4678, a non-synonymous change in 
VARS2 , approximately 1.7Mb telomeric of HLA-DRB1, rs2442728, upstream of HLA-B and 
approximately 1.2Mb telomeric of HLA-DRB1, and rs17499655, which is located in the 
5‟UTR region of HLA-DQA2, only 0.1Mb centromeric of HLA-DRB1.   
 The latter association was particularly intriguing, since it lies within 38kb of HLA-
DQB1, very close to HLA-DRB1. Genetic studies to date have yielded conflicting results 
regarding the role of HLA-DQ in RA [122, 123]. In the GoRA study, the apparent association 
with this marker arose through an indirect effect of HLA–DRB1. Although rs17499655 was 
not in LD with the SE, further investigation revealed that this SNP was in LD with allele 
HLA-DRB1*0101 (r
2
 = 0.64).  
 The effect of HLA-DRB1 on RA is complex as Brown and colleagues [41] pointed out 
in their reply to Vignal et al. [121]. This is due to the presence of long segments of LD and 
high levels of polymorphism in the HLA region. The picture is further complicated by the 
different strength of association of the SE alleles with RA. The inclusion of the HLA-DRB1 
effect as a binary SE+/SE- classification rather than specific HLA-DRB1 alleles might have 
introduced biases by ignoring LD with specific alleles. Spurious associations could arise if 
one of the HLA-DRB1 allele conveyed a different level of risk than others of the same SE 
class.  
 In the GoRA dataset, rs4678 and rs244278 were in low LD with the SE. They were 
however in moderate LD with HLA-DRB1*0301, which is the most common SE- allele (r
2
 = 
0.27 for rs4678 and r
2
 = 0.12 for rs244278). Further assessment showed that the protective 
effect of HLA-DRB1*0301 is well captured by the SE- category. The OR for SE+ vs. SE- was 
2.93 (95% CI (2.55; 3.37)), and the OR for SE+ vs. *0301 was not significantly different 
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from this (OR = 2.68, 95% CI (2.16; 3.35)). Similarly, the findings of a logistic regression 
model treating SE as a factor with three levels, i.e. “SE+”, “SE- excluding *0301” and 
“*0301”, were not significantly different from the two level SE+/SE- model (P = 0.29). 
Together with the modest degree of LD, this leaves little scope for LD with HLA-DRB1*0301 
to contribute to the observed SNP associations with RA.  
  In Chapter 3, a modification to the modelling of the SE in genetic studies of RA was 
proposed. In addition to the number of SE+ allele copies, the inclusion of the number of 
alleles at HLA-DRB1*0101 improved the model of association with RA, over and above the 
use of the binary SE+/SE- variable on its own. The logistic regression model with the  effect 
of SE+ and HLA-DRB1*0101 allele copies as covariates led to the identification of 44 SNPs 
with  P < 10
-4
 in the additive single-SNP association model and 26 SNPs with P < 10
-4
 in the 
general single-SNP association model. Backward stepwise regression was used to assess the 
effect of the most highly associated markers (P < 10
-4
) in both the additive and general 
single-SNP models. One marker rs2442728, which is located in the vicinity of HLA-B and 
HLA-C, was retained by both stepwise approaches. The gene location of this marker is 
ambiguous. Some transcripts place it in the 3‟-UTR of HLA-B; others place it intergenic 
between HLA-B and HLA-C. Using the HapMap data on Caucasian subjects, this marker is 
not in LD with any other HapMap SNPs, so no other genes are implicated by this route. The 
HLA-B protein is central in antigen presentation to CD8-T cells, and HLA-B27 is a major 
genetic determinant in the genetic background of the spondylarthritides, particularly 
ankylosing spondylitis. A role of HLA-C as a risk factor for severe RA has also been 
previously reported [124].  
 Interestingly, the stepwise regression analysis of the highly significant markers from 
the additive and general models identified two different markers in VARS2: rs2532934, which 
lies in the 3‟-UTR of VARS2 and rs4678, which encodes a non-synonymous change also in 
VARS2. A study of the expression of 11,000 genes in inflamed and non-inflamed paws from 
mice with collagen-induced arthritis reported 187 to be up-regulated and 36 down-regulated; 
of note was a 4-fold increase in VARS2 expression in affected joints [125]. The possibility 
that VARS2 may have non-canonical functions is also consistent with available expression 
data indicating the highest levels in white blood cells (online at http://genome.ucsc.edu/). 
Determining whether VARS2 possesses alternative functions in addition to its probable valyl-
tRNA synthetase activity is thus a prerequisite to understanding its possible role in RA. 
Results from the stepwise analysis have to be interpreted with caution since the method is 
unstable in presence of multi-collinearity as is the case here. Furthermore, the SNP markers 
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from the general model were included as additive effects in order to limit the number of 
predictors.  
In these unadjusted and adjusted single-SNP analyses, the additive P-values tended to 
be more significant than the general single-SNP P-values as expected given the fewer model 
degrees of freedom. This also provides little evidence for the presence of non-additive 
effects.  
Although there is evidence of additional risk loci beyond the HLA-DRB1 effect, 
inference using single-SNP analysis has been hampered by the presence of LD. Geneticists 
have often preferred single-SNP association tests over multivariate regression approaches but 
this simplification can lead to many positive results, even after including the effect of well-
known risk factors such as the SE. The analysis of markers from the HLA region requires 
methods that can efficiently assess the effect of multiple markers simultaneously, while 
controlling for the confounding effect of other covariates. Variable selection methods can be 
used in genetic association studies in order to identify the set of SNP markers that might be 
associated with the disease. Penalised regression using a variation of the Least Absolute 
Shrinkage and Selection Operator (LASSO), which is presented in the next chapter, is one 
such approach [73].  
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Chapter 5. Multi-SNP association analyses of the GoRA study 
using penalised logistic regression 
 
 
 
 
5.1 Introduction 
 
Multi-SNP logistic analysis using stepwise regression was attempted as a variable 
selection approach but failed to identify optima due to the large number of predictors 
compared to the number of observations. Forward stepwise regression could have been used 
instead, but the parameters that are retained depend on the order in which they enter the 
model, which makes the final model unstable.  
In this chapter, penalised regression using the LASSO was investigated as a variable 
selection method for multi-SNP association analysis of case-control studies. With this 
approach, the estimation of the parameters is performed while applying a penalty that shrinks 
the regression coefficients towards zero. This is equivalent to applying a double exponential 
prior distribution (DE) to the coefficients, with a mode at zero corresponding to the prior 
belief that most of the markers have effect sizes close to zero. Parameter inference is based 
on the posterior mode, with non-zero values indicating marker-disease associations. The 
LASSO approach was applied to SNP selection for markers from the HLA region. A 
generalisation of the LASSO called the HyperLasso (HLASSO), which uses the normal-
exponential-gamma (NEG) prior in place of the DE, was also investigated. 
With these methods, the aim is to identify RA predisposing SNPs, beyond the HLA-
DRB1 effect. The performance of the LASSO in terms of identifying causal variant(s) in 
presence of LD is assessed using two simulation studies. Results of the LASSO and 
HLASSO SNP selection approaches are discussed and compared with those obtained using 
single-SNP association tests.  
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5.2 LASSO logistic regression  
5.2.1 Model formulation 
 
Multi-SNP analysis using logistic regression is a natural extension to single-SNP 
association tests, where the disease risk of each individual is estimated based on the linear 
combination of several predictors. Environmental, demographic, and clinical characteristics 
may also be included as covariates to account for confounding factors. The parameters β = 
(β1,…βj,…βp), where βj is the regression coefficient of SNP j can be estimated by minimising 
the negative log-likelihood,  
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The minimisation of the log-likelihood is however problematic when the number of 
variables p exceeds the number of observations n, or in the presence of multicollinearity 
among the predictors. The estimation process then requires the inversion of a non-invertible 
singular matrix, which results in no solution for the estimated parameters.  
 Tibshirani [73] proposed to overcome this difficulty by using the LASSO, which adds 
a L1 norm penalty term, namely 

p
j
jj
1
 , to the negative log-likelihood, corresponding to 
the sum of the absolute values of the regression coefficients. The LASSO estimates are 
obtained by solving the constrained optimisation problem, 
 








p
j
jj
LASSO l
1
)(minargˆ 

, 
 
where LASSOˆ  is the vector of shrunk parameters that minimises the penalised log-likelihood 
and j  is the penalty factor of SNP j, 0j . 
Tibshirani [73] showed that estimating j using the LASSO is equivalent to finding 
the maximum a posteriori (MAP) estimate using a DE prior distribution over j  with mode 
zero,  
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Assuming that jj   , the prior on β can be expressed as the product of the p independent 
DE densities  
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The DE distribution can be expressed as a two-level hierarchical model [126], which 
corresponds to a mixture of normal distributions [127, 128]. In these models, the first level 
assumes that j  follows a normal distribution with mean zero and unknown variance
2 , 
such as 
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p  . At the second level, the hierarchical model assumes that the variances 
2
j  follow independent exponential prior distributions,  
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With the two level priors stated above, the DE distribution for the coefficients j  is a scale 
mixture of normal distributions, 
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Figure 5.1 displays the densities of the DE distribution for a penalty factor λ of 0.5 and of 1. 
As λ increases, the DE places more mass near zero, which means that the coefficients βj have 
a high probability of being near zero. This is reflected by the sharp peak at the origin. 
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The penalty factor λ plays an important role by controlling the amount of shrinkage. In the 
optimisation problem, a large value of   penalises highly the L1 norm of   leading some 
MAP estimates to be exactly zero, whereas as λ approaches zero, the coefficient estimates 
tend to the maximum likelihood estimates. In a Bayesian framework, large values of   
correspond to the prior belief that most of the predictors have no effect, i.e. j  are close to 
zero, and are unlikely to be retained in the model, whereas small values of   correspond to 
weaker beliefs about the effect sizes. This approach is Bayesian-inspired in the sense that it is 
based on the prior distribution of the parameters. However, it is not fully Bayesian because 
the parameter estimates is determined without evaluation of the full posterior distribution.  
 
 
Figure 5.1 The DE density function 
 
 
 
5.2.2 CLG Algorithm for finding the MAP estimate 
 
 Assuming a priori that all j  are independent, the MAP estimate of   is obtained by 
minimising the negated log-posterior objective function )(minarg 

lassol [87]. Traditionally, 
the Newton-Raphston method is used to infer the MAP estimates [129]. This algorithm is 
however computationally intensive in the presence of a large number of predictors. Zhang 
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and Oles [130] applied a cyclic coordinate descent algorithm, which is a one dimensional 
optimisation, with inherent speed and simplicity.  
CLG (Coordinate Logistic Gradient) is a cyclic coordinate descent optimisation 
algorithm that is used for fitting a logistic regression model with a Gaussian prior. The 
algorithm requires an objective function that is convex and has continuous first and second 
order derivatives. At each iteration, the algorithm minimises the objective function relative to 
one coordinate before going to the next parameter, while the remainders are held constant. 
Zhang and Oles [130] applied an adaptation of the Newton-Raphston algorithm that uses a 
quadratic function as an approximation to the objective function, which is faster and more 
stable than other methods [76]. In order to avoid regions where a quadratic is a poor 
approximation of the objective function and to improve the speed of the algorithm, they 
calculated the upper bound on the second derivative of the objective function for an interval 
around the value of the parameter that is being estimated.  
Let )( jf   be the objective function, which is minimised as a function of one 
parameter j , assuming the remaining predictors are fixed. The value that minimises (.)f is 
given by, 
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Genkin et al. [87] modified the cyclic coordinate descent algorithm for fitting the 
logistic model with the DE prior. The objective function of the LASSO being not 
differentiable at zero, the algorithm can be applied as long as it operates within strictly 
positive or strictly negative values of the estimated parameters. The estimation of j  is 
performed by an update in both directions from j , i.e. 0
+
 and 0
-
, the limits from above and 
below. In the case where the calculated value of the parameter estimate crosses over 0, the 
updated newj is set to zero; otherwise the corresponding update, which is different from zero, 
is accepted. This process is repeated iteratively for each variable, until convergence criteria 
are met.  
 The CLG algorithm described above has been implemented by Genkin and colleagues 
[87] in the Bayesian Binary Regression (BBR) package and is publicly available at 
http:/www.stat.rutgers.edu/~madigan/BBR.  
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5.2.3 The GoRA association study using the LASSO logistic regression 
 
LASSO logistic regression was applied to a subset of the GoRA study, consisting of 
774 RA cases and 945 controls with no missing genotypes, since the BBR software of Genkin 
et al. [87] could not handle missing data. SNP markers were modelled as additive effects for 
the reasons described in Chapter 4. Genotypes were standardised to have mean zero and unit 
variance, so that the penalty was invariant to the scale of the predictors. This standardisation 
also has the effect of incorporating the prior belief that the effect sizes are larger at SNPs with 
low minor allele frequency. The associated markers, i.e. those with non-zero posterior mode, 
were compared to those significant by the additive single-SNP association test after 
adjustment for the effect of the number of SE+ and HLA-DRB1*0101 allele copies. For 
consistency, the Bonferroni P-value threshold of 4.3x10
-4
, which corresponds to one false 
positive association among the total number of SNPs analysed, i.e. 1/2,302, was used to 
compare the two methods. 
 
 
5.2.4 Estimating the penalty factor λ 
 
 The choice of the parameter λ is a key component of the LASSO logistic regression. 
As λ decreases, the penalty is relaxed and more parameters can enter the model. Although 
there is no consensus on the best way to select the penalty factor λ, cross-validation has been 
widely used [70] to find the optimal value of λ despite being computationally intensive.  
 
 
5.2.4.1 k-fold cross-validation 
 
 With k-fold cross validation, the original dataset is divided into k sub-datasets of equal 
size. The parameters are estimated k times for a given value of λ, leaving one sub-dataset out 
at each iteration. Each time, the estimated regression coefficients are used to calculate the 
error rate in the omitted dataset, which can be the prediction error in case-control studies. The 
average error rate is then computed across the k omitted subsamples for a fixed value of λ. 
The value of λ that gives the minimum average error rate is selected as the constraint 
parameter.  
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 The advantage of cross-validation is that all the samples are used to estimate the 
parameters and assess the prediction error of the fitted model. A disadvantage is that the 
process has to be repeated k times for different values of λ, which can be time consuming for 
a large dataset. Furthermore, Leng and Wahba [80] showed that when the penalty factor λ 
was chosen to minimise the prediction error, the probability of the LASSO at correctly 
identifying the important set of predictors was less than one. A permutation approach was 
used instead in order to let the false positive rate drive the selection of λ.  
 
 
5.2.4.2 Permutation approach 
 
The individuals were first classified into three SE groups based on the number of SE+ 
alleles they carried. The labels of the cases and controls were permuted a hundred times 
within each group in order to retain the effect of the SE. The smallest value of   that gave 
less than one false positive result per dataset, corresponding to a SNP-wise type I error of 1/p, 
with p being the number of predictors, was selected as the value of the penalty factor λ. The 
permutation approach requires one to test different values of , which can also be 
computationally intensive for large dataset, but is less demanding than cross-validation. In 
this experiment, a combination of bracketing and bisection was used to select the value of   
that gave on average less than one false positive result per hundred permutations. The 
bracketing and bisection approach is as follows.  
The approach starts by defining a λu and λl with λu large enough to have on average 
strictly less than 1 false positive, where ul 
2
1
 . The interval I is defined as I = [λl, λu]. The 
false positive rate is then calculated for λl, λu and for λm with 
2
ul
m



  . If the false 
positive rate associated with λm is greater than one, then λl is replaced by λm; if the false 
positive rate associated with λm is smaller than one, then λu is replaced by λm. The bracketing 
and bisection process continues until an optimal point is reached, i.e. the value λm for which 
the false positive rate is less than one. 
Figure 5.2 presents the type-I error rate that was obtained as a function of λ in the 
GoRA study, using the permutation approach described above. The y-axis displays the 
averaged number of false positive results per model that were observed for the different 
values of   ranging from 40 to 84. In this experiment,   of 62 was the smallest integer value 
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that gave less than one false positive result per dataset and was selected to perform the main 
penalised logistic regression analyses.  
 
 
 
Figure 5.2 Selection of the prior parameter λ 
 
 
 
 
5.2.5 The LASSO logistic regression analysis  
 
LASSO logistic regression was applied to the GoRA dataset using a penalty factor   
of 62 as described above over the entire set of markers and the number of SE+ and *0101 
allele counts. In the case where n < p, the posterior density of the DE can be multi-modal and 
the posterior modes might depend on the order in which the parameters are estimated.  The 
LASSO logistic model as implemented in BBR was hence performed hundred times with the 
columns randomly permuted at each run.  The same nine SNPs were selected at each run with 
unchanged MAP estimates, which shows that BBR always converged to the same posterior 
likelihood.  
The LASSO logistic model identified nine marker-disease associations, in addition to 
the effect of the SE+. Interestingly, HLA-DRB1*0101 was not selected in the final model. 
Table 5.1 presents these nine SNPs as well as the single-SNP additive P-values after 
adjustment for the effect of the SE and HLA-DRB1*0101 that were presented in Chapter 4. 
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Table 5.1 Single-SNP association P-value of the SNPs selected by the LASSO logistic 
regression 
Marker 
dbSNP127 
Position (kb) 
NCBI36 
Gene (location) Padj
  r2SE r
2
*0101 
rs2523428 29599902 LOC729653 (3‟UTR) 6.3x10-5 * * 
rs886422 30972258 DDR1 (intron) 9.6x10-7 0.02 * 
rs4678 31001920 VARS2 (coding) 4.9x10-7 0.03 * 
rs2442728 31427334 HLA-B (3‟UTR) 7.3x10-6 0.01 * 
rs2844513 31496193 BAT1 (intron) 0.002 * 0.02 
rs2395150 32434023 C6orf10 (intron) 0.021 0.03 0.08 
rs4321864 32507165 HLA-DRA (5‟UTR) 0.258 0.22 * 
rs2395175 32513004 HLA-DRA (5‟UTR) 0.297 0.41 0.05 
rs660895 32685358 HLA-DRB1 (5‟UTR) 0.739 0.74 0.05 
 
 
 
 
 Among the nine SNP markers that were retained, four were significant at P < 4.3x10
-4
 
in the single-SNP association analysis (α = 1/2,302) (Chapter 4). Two markers, namely 
rs4678, which is a coding SNP in VARS2 and rs244278, which lies in the 3‟-UTR of HLA-B, 
had also been selected in the stepwise regression analysis which followed the single-point 
analysis. It is of interest to note that three SNPs were selected by the LASSO although they 
were not significant in the single-SNP analysis after adjustment for the effect of the SE and 
HLA-DRB1*0101 (P ≥ 0.05). All lie very close to HLA-DRB1: rs660895, which is 
downstream of HLA-DRB1, rs2395175, which is a non-coding SNP in C6orf10 and 
approximately 82kb centromeric of HLA-DRB1, and rs4321864, which is upstream of HLA-
DRA and approximately 89kb telomeric of HLA-DRB1.  
 From these results, it appears that although the number of SE+ allele copies was 
included in the LASSO logistic model, the posterior mode of the SE effect might have been 
shrunk too severely by the penalty factor λ, and additional SNPs could have been selected 
merely due to LD. In order to investigate this possibility, pairwise LD between the selected 
SNP markers and the SE were calculated. The values of the correlation coefficient r
2
 are 
shown in Table 5.1; r
2 
values with the non selected variable HLA-DRB1*0101 is also 
presented. None of the selected SNPs were highly correlated with the number of HLA-
DRB1*0101 allele copies. As expected, the SE is correlated with the three SNP markers 
(rs660895, rs2395175 and rs4321864), which were not significant in the adjusted single-point 
analysis.  
 
Padj
 
is the single-SNP association test P-value adjusted for the effect of the SE+ and *0101 
alleles 
*r
2
 values < 0.01 
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5.2.6 The effect of over-shrinking  
 
 To investigate this phenomenon, the SE was included twice in the LASSO logistic 
model as SEreal and SEfake. When the DE prior distribution with a penalty factor λ was applied 
to SEreal and SEfake, both variables were retained in the final model suggesting that shrinking a 
strong effect might cause correlated SNPs to be selected as well. When SEreal was not shrunk, 
only SEreal was retained in the final model, which shows that correlated SNPs could be 
eliminated from the final model even if they are in high LD with a strong effect. Therefore, 
subsequent LASSO logistic analysis was performed without applying a DE prior distribution 
to the SE or HLA-DRB1*0101 (λ = 0). From a Bayesian perspective, this corresponds to 
assigning an improper uniform prior to these two parameters. 
 
 
5.2.7 LASSO logistic regression analysis with no prior on the SE and *0101  
 
 In this analysis, LASSO logistic regression retained six SNP markers in addition to 
the SE and HLA-DRB1*0101 (Table 5.2). Among them were the two markers, rs4678 and 
rs2442728, which were previously retained in the stepwise regression; rs886422, which 
encodes a synonymous change in DDR1; rs1264308, which encodes a synonymous change in 
GTF2H4; rs1592409, which is upstream of an unknown gene; and rs7750641, which encodes 
a non-synonymous change in TCF19. All were highly significant in the single-SNP 
association analysis after adjustment for the effect of the SE and HLA-DRB1*0101 (P < 
4.3x10
-4
). However, they were masked by many other significant results in the single-SNP 
analysis, whereas in the LASSO analysis they stand out. 
In order to investigate the degree of correlation between these SNP markers, LD 
between the markers was calculated using samples from the GoRA controls. The r
2
 values are 
displayed in Table 5.3. None of the selected SNPs were correlated with either the SE effect or 
the number of HLA-DRB1*0101 allele copies but a group of four markers, rs4678, 
rs7750641, rs1264308 and rs886422 show some intercorrelation (r
2
 > 0.5).  
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Table 5.2 Single-SNP association test P-value adjusted for the effect of the SE and *0101 for 
SNPs selected by the LASSO logistic regression 
Marker 
dbSNP127 
Position (kb) 
NCBI36 
Gene (location) Padj r
2
SE r
2
*0101 
rs1264308 30987966 GTF2H4 (intron) 1.0x10-6 0.02 * 
rs1592409 29599902 LOC729653 (3‟UTR) 6.3x10-5 * * 
rs7750641 31237289 TCF19(coding) 2.2x10-6 0.03 * 
rs2442728 31427334 HLA-B (3‟UTR) 7.3x10-6 0.02 * 
rs886422 30972258 DDR1(intron) 9.6x10-7 0.02 * 
rs4678 31001920 VARS2 (coding) 4.9x10-7 0.03 * 
 
 
 
 
 
Table 5.3 r
2
 among the six selected SNPs using the LASSO logistic regression 
 rs1592409 rs886422 rs1264308 rs4678 rs7750641 rs2442728 SE 0101 
rs1592409 1 0.09 0.09 0.05 0.08 * * * 
rs886422 
 
1 1 0.66 0.89 0.19 0.02 * 
rs1264308 
 
1 0.66 0.88 0.19 0.02 * 
rs4678 
 
1 0.59 0.14 0.03 * 
rs7750641 
 
1 0.20 0.03 * 
rs2442728 
 
1 0.02 * 
SE 
 
1 0.19 
0101  1 
 
 
 
 
LASSO logistic regression identified some SNPs in high LD, but the presence of far 
fewer associations suggests that LD might be more effectively handled by LASSO than by 
single-SNP association tests, even after accounting for the well-known risk effect at HLA-
DRB1. Among the six SNPs that were retained, four exhibited intercorrelation.  
In order to investigate the performance of LASSO logistic regression at identifying 
causal variants, two analyses were undertaken. Firstly, power to identify a single variant was 
assessed and compared to single-SNP association analysis. Secondly, the power and the error 
rate for causal SNPs in LD was evaluated using simulated risk effects correlated with the SE.  
 
Padj is the SNP additive association P–value after adjustment for the SE+ and *0101 alleles 
*r
2
 values < 0.01 
SNP markers are ordered by map position 
* r
2
< 0.01 
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5.2.8 Simulation study 
5.2.8.1 The power of LASSO logistic regression to identify a single causal variant 
 
A simulation study was performed to investigate the power of LASSO logistic 
regression at identifying a causal variant using the   value of 64, chosen as described above. 
A causal SNP, uncorrelated with the other markers, was simulated with minor allele 
frequency (MAF) of 0.05, 0.1 and 0.3 respectively, and genotypes formed assuming HWE. 
Cases and controls status were assigned so that the heterozygote relative risk (RRhet) ranged 
from 1.1 to 1.5, while RRhom = (RRhet)
2
, corresponding to a multiplicative model. The 
simulated causal SNP was added to the 2,302 SNPs under investigation. The process was 
repeated one thousand times for each value of MAF and RRhet. LASSO logistic analysis was 
performed on each simulated dataset and the number of times the causal SNP was retained in 
the final model was recorded. Results were compared to single-SNP association tests using an 
armitage trend test (ATT) adjusted on the number of SE+ allele copies, by assessing the 
number of times the simulated causal SNP was detected at P < 4.3x10
-4
, corresponding to 
approximately one false positive result under the null hypothesis of no association.  It is noted 
that for an additive effect, logistic regression is asymptotically equivalent to ATT. ATT is 
also more robust at extreme allele frequency compared to logistic regression and since the 
LASSO is meant to be robust at low allele frequencies, ATT is the appropriate benchmark in 
this assessment.  
Figure 5.3 shows the power of LASSO logistic regression and ATT to detect a marker-
disease association as a function of MAF and RRhet. LASSO logistic regression performs 
better than ATT for identifying an additive causal variant that was simulated independently 
of the other loci; especially at low RRhet and low MAF (≤ 0.1). In term of error rate, LASSO 
logistic regression produced 0.06% false positive results, which was slightly more to than 
ATT (0.04%) at a type I error α = 4.3x10-4.  Overall, these results show that the penalised 
regression approach is a good alternative to the widely-used single-SNP association, which is 
known to be limited in presence of multi-collinearity.  
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Figure 5.3 Power simulation of the LASSO and ATT  
 
 
5.2.8.2 The power of LASSO logistic regression to identify a variant correlated with 
the SE 
 
Hundred simulations were performed to evaluate the power and type-I error of 
LASSO logistic regression to identify a causal variant in the presence of LD.  ATT was not 
considered as it was shown earlier that LASSO logistic regression performed better than the 
single-SNP analysis at identifying a causal variant.  
Four SNP markers in different degrees of LD with the SE (r
2
 = 0.1, 0.3, 0.5 and 0.7) 
were selected from the GoRA study. The dataset was divided into three sub-datasets based on 
the number of SE+ allele copies. Within each SE group, the number of genotypes of the 
selected marker were calculated for the cases and controls in order to achieve different sizes 
of odds ratio (rare homozygote OR ~ 1.6, 3, 5 and 7), while maintaining the margins of the 
genotype by case-control frequency table, and hence the LD structure with the SE. The 
genotypes were then distributed randomly between the cases and controls using a 
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multinomial distribution. The remaining 2,301 SNPs were added maintaining the LD 
structure with the simulated causal marker, which is equivalent to randomly distributing their 
genotypes among the cases and controls. The three sub-datasets, corresponding to 0, 1 and 2 
allele copies of the SE+, were merged and the LASSO logistic regression was applied to each 
of the hundred simulated datasets. Power was assessed by calculating the number of times the 
simulated causal SNPs were retained in the final models. The type-I error was evaluated by 
calculating the number of SNPs that were falsely selected beyond the effect of the SE and the 
simulated causal SNPs. Figure 5.4 and Table 5.4 describe the simulation study.  
As an example, consider the group with 0 SE+ allele copies, which is made up of 138 
cases and 492 controls (Table 5.4). Let xAa and xaa be the number of subjects to add to or 
remove from the Aa and aa genotype groups in order to reach a given OR with genotype AA 
denoting the reference category. In this setting, the constraints are: 0≤ xAa< NAa, 0≤ xaa< Naa, 
xAa+xaa=z and 0≤ z< min(NAA, xAa+xaa). The left-hand side of Table 5.4 describes the initial 
genotype distribution where the OR of Aa vs. AA is 0.5 and the OR of aa vs. AA is 1.6. The 
right-hand side of Table 5.4 shows the number of cases and controls that are added or 
removed from each genotype category to achieve an homozygote OR (aa vs. AA) of 
approximately six with the constraint that the heterozygote OR of Aa vs. AA has a risk effect 
between one and six. An ideal value would have been ORAa vs. AA =   , however it has proved 
impossible to obtain in this simulation process and the nearest it could achieve was a value 
between 1 and 6. By adding one case to the aa group and sixteen cases to the Aa group, the 
homozygote OR of aa vs. AA is 5.8 and OR of Aa vs. AA is 1.4.  
 
 
Table 5.4 Simulation of a causal SNP at a fixed ORaa vs. AA of 6, and with  
1< ORAa vs. AA < ORaa vs. AA, among individuals with 0 SE+ allele copies 
 original association simulated association 
 Controls Cases N Controls Cases N 
AA 382 + z 120 - z NAA = 502 382 + 17 120 - 17 NAA = 502 
Aa 106 - xAa 17 + xAa NAa = 123 106 - 16 17 + 16 NAa = 123 
aa 4 - xaa 1 + xaa Naa = 5 4 - 1 1 + 1 Naa = 5 
N N0 = 492 N1 = 138 N = 630 N0 = 492 N1 = 138 N = 630 
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Figure 5.4 Simulation of a causal SNP in LD with the SE using  
data from the GoRA study 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
   
 
 
Figure 5.5 displays the power of the LASSO logistic regression at identifying four 
simulated SNPs associated with RA and in LD with the SE at r
2 
of
 
0.10 (blue line), 0.30 (pink 
line), 0.50 (green line) and 0.70 (red line). The y-axis presents the power of the LASSO 
logistic regression and the x-axis presents the effect size of the simulated association, with the 
homozygote OR ranging from 1.2 to greater than 7.  
SNP markers in low to moderate LD with the SE (r
2 ≤ 0.50) were selected most of the 
time for small effects with homozygote OR of 1.6. The causal SNP in high LD with the SE 
(r
2 ≥ 0.70) was selected for homozygote OR greater than 5. As expected, when r2 is high, a 
higher OR is needed in order to achieve a particular level of power.  
With respect to type-I error, Figure 5.6 presents the proportion of false positives, 
which corresponds to non-simulated SNPs that were selected beyond the SE effect among the 
2,302 SNP markers. On average, LASSO logistic regression generated one to two false 
positive results per analysis. It is noted that under the null hypothesis of no association, the 
expected number of false positive was one per analysis using the LASSO logistic model with 
a penalty factor λ of 64.  
 
 
 
 
 
Select SNP in LD with SE 
within SE genotype 
Shuffle the genotypes AA, Aa and aa among the cases & controls 
to obtain specific ORaa , with 1< ORAa< ORaa 
within SE genotype 
Distribute the genotypes AA, Aa and aa among the cases & 
controls using a multinomial distribution 
add the remaining 2,301 SNPs and  
merge SE sub-datasets 
Perform the LASSO 100  
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Figure 5.5 Power of the LASSO logistic regression at identifying causal variants in the 
presence of LD 
 
 
 
 
Figure 5.6 Error rate of the LASSO logistic regression at identifying causal variants in the 
presence of LD 
 
 
 
 
5.2.9 Discussion of LASSO logistic regression 
 
LASSO logistic regression identified fewer positive associations than did single-SNPs 
association tests. Besides being computationally efficient, this method yielded similar power 
to single-SNP analysis in identifying a causal SNP that was simulated independently of the 
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other loci. The simulations of causal SNPs in moderate to high LD with another strong effect 
confirmed reasonable power and error rate in a situation where two predictors were 
correlated. These results showed however that the effect of the number of SE+ allele copies 
may not be well-handled by the DE prior. Applying the penalty factor to all the predictors 
and disregarding the strong association of the SE led to the selection of markers correlated 
with the SE. When the penalty factor was applied to the entire set of SNPs as well as the 
effect of the SE and HLA-DRB1*0101, three out of nine SNPs selected were in LD with the 
SE, and may have been retained because they compensated for the over-shrunk effect of the 
SE. When the DE prior distribution was only applied to the SNP markers but not to the SE 
and HLA-DRB1*0101, the LASSO logistic analysis identified six SNP markers associated 
with RA. None of them was in LD with the SE or HLA-DRB1*0101. Two markers, rs4678, 
which encodes a non-synonymous change in VARS2, and rs244278, which is upstream of 
HLA-B, were identified previously by stepwise logistic regression (Chapter 4). The presence 
of a group of four markers that exhibited some intercorrelation was, however, intriguing. It is 
possible that LD with particular alleles at HLA-DRB1 might have driven these associations. 
In order to investigate this phenomenon, r
2 
values were calculated between each marker and 
the common HLA-DRB1 alleles (allele frequency > 2%) using data from the GoRA controls. 
Table 5.5 shows that there is moderate LD (0.01 < r
2 
< 0.50) between each of the four 
correlated markers and HLA-DRB1*0301, which is the most common SE- allele. As 
discussed in Chapter 4, the effect of *0301 was well captured by the SE+/SE- classification 
in the GoRA study. It is unlikely that the effects of these four markers were due to LD with 
*0301. It is however possible that one of these four markers is the causal SNP and that three 
additional SNPs were selected to account for its over-shrunk effect. 
 
 
Table 5.5 r
2
 between the six SNPs selected by the LASSO logistic regression and alleles at HLA-
DRB1 (frequency > 2%) 
 Allele at HLA-DRB1  
Marker 
dbSNP127 
0101 0301 0401 0404 0701 1101 1301 1302 1501 
rs1592409 * 0.01 * * * * * * * 
rs886422 * 0.40 0.02 * 0.01 * 0.01 * 0.01 
rs1264308 * 0.40 0.02 * 0.01 * 0.01 * 0.01 
rs4678 * 0.27 0.02 * * 0.01 * * 0.01 
rs7750641 * 0.45 0.2 * 0.01 * * * 0.01 
rs2442728 * 0.12 0.01 * * * * * 0.03 
 
SNP markers are ordered by map position 
* r
2
< 0.01 
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Although LASSO logistic regression seems to provide substantial benefit over single-
SNP association analysis in terms of identifying fewer positive results, the selection of a 
group of markers in LD is intriguing. Ideally, the prior distribution of the penalised model 
should retain only parameters that are independent and important to the model. It was 
postulated by Hoggart et al. [88] that by using a prior with flatter tails and a sharper peak than 
the DE prior, parameter estimates with non-zero effect size might be shrunk less severely, 
resulting in fewer correlated variables being selected to account for the over-shrunk estimates 
of some parameters. Hoggart et al. [88] proposed the use of the normal-exponential gamma 
distribution (NEG), which is a generalisation of the DE, in order to achieve this goal.  
 
 
 
5.3 The HLASSO logistic regression 
5.3.1 Model formulation 
 
 The NEG is a generalisation of the DE prior distribution, which can be represented as 
a scale mixture of normal distributions [126]: 
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where ),( dc  is the gamma density with shape parameter c and scale parameter d. In the 
case of the NEG, H  and   are the shape and scale parameters that control the intensity of 
the peak and the gradient of the tails;   is the integrating constant and D is the parabolic 
cylinder function. Computation of D is described in Zhang and Jin [131]. Figure 5.7 presents 
four NEG density functions with λH values of 0.05, 1, 3 and 10, and scale parameters γ = 
0.13, 0.026 and 1, respectively, which were defined as a function of type-I error [88]. For λH 
values of 0.05 and 1, the NEG has a sharp peak at the origin and heavy tails. As with the DE, 
the spike around zero reflects the prior belief that the effects have a high probability of being 
close to zero. The flat tails correspond to little prior information about the effect sizes of the 
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non-zero estimates. As λH decreases, the non-zero parameters are less penalised towards zero. 
As λH increases, the NEG is less peaked around zero and converges to the DE distribution 
(green NEG density) [88].  
 
 
Figure 5.7 NEG density function with shape parameters λH of 0.05, 1 and 10 with scale 
parameters γ = 0.13, 0.026 and 1, corresponding to 1 false positive result 
 
 
 
5.3.2 Finding the posterior modes 
 
 As with LASSO logistic regression, SNPs are considered significant if the MAP 
estimate of the regression coefficient exceeds zero. The CLG optimisation algorithm is used 
to maximise the penalised log-likelihood and estimate the parameters. The posterior density 
being multi-modal, the algorithm is run several times with the order of the predictors 
permuted at each run. The model with the largest posterior mode corresponds to the preferred 
model [88]. The main difference between the models, which are selected at each iteration, is 
the order in which the correlated variables are included in the fitted model. When a group of 
SNPs carry the same information, the NEG will choose one of the SNP markers, whereas the 
DE might select more than one. 
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5.3.3 Estimating the SNP-wise type I error 
 
 In Hoggart et al. [88], the SNP-wise type-I error is defined by:  
 
           
     
    
   
 
where n1 and n0 denote the number of cases and controls,   is the derivative of the –log NEG 
density function at the origin, which is also the derivative of the DE distribution and   is the 
cumulative distribution function of the normal distribution. For the DE prior, at the origin 
                   where    is the DE penalty parameter; hence    can be expressed to 
control the type-I error  , such as     
     
    
      
 
 
 .   being also the derivative of 
the –log NEG density function at the origin, the NEG shape parameter    and NEG scale 
parameter   can also be fixed to control the type-I error   with           . In this 
analysis, λL, λH  and γ were set for α = 4.3x10
-4
 , corresponding to less than one false positive 
results.  
 
 
5.3.4 Setting the prior parameter λH 
 
Hoggart and et al. [88] showed in a simulation study that a shape parameter λH of 0.05 
was suitable to identify the causal variants given a reasonable type-I error. Larger λH values 
resulted in several SNPs being brought into the model to account for the positive signals at 
tightly-linked and correlated loci. Stephens and Balding [57] suggested a NEG prior 
distribution with a shape parameter λH between 1 and 2 in order to identify SNPs with non-
zero effect sizes, as smaller values tend to give more weight to large effects, which rarely 
occur.  
Table 5.6 presents the probabilities of a SNP having an estimated effect size θ above a 
given threshold using the NEG distributions with shape parameters λH of 0.05 and 1, 
respectively and with scale parameters γ of 0.001, 0.01 and 0.1.  
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With λH = 0.05 and irrespectively of γ, SNPs with an effect size |θ| > 0.05, 
corresponding to OR > 1.05 or < 0.95, have a high probability of being detected. These 
probabilities decreased only slowly for SNPs with large effect sizes, which rarely arise. SNPs 
with |θ| > 1, corresponding to OR > 2.72, have unrealistically high probabilities of being 
identified (5
th
 row of columns 1, 3 and 5 of Table 5.6). The probabilities of detecting non-
zero parameter estimates using λH of 1 are more realistic than with λH of 0.05. With a shape 
parameter λH of 1 and γ = 0.001, the expected number of SNPs with a moderate effect size |θ| 
> 0.2, corresponding to OR > 1.22 or < 0.82, per 100,000 tested was approximately 2. As the 
scale parameter γ increases, the NEG is less peaked around zero, resulting in a higher 
probability of retaining non-zero SNPs of small effect size. A shape parameter λH of 1 was 
hence selected to perform the HLASSO logistic regression analyses. 
 
 
Table 5.6 Tail probabilities of the NEG distributions with λH = 0.05 and 1 and γ = 0.001, 0.01 and 
0.1 
 
γ = 0.001 γ = 0.01 γ = 0.1 
 λH = 0.05 λH = 1 λH = 0.05 λH = 1 λH = 0.05 λH = 1 
P[|θ| > 0.05] 0.64 3.9x10-4 0.80 0.03 0.95 0.56 
P[|θ| > 0.1] 0.59 9.9x10-5 0.75 9.7x10-3 0.92 0.34 
P[|θ| > 0.2] 0.55 2.5x10-5 0.70 2.5x10-3 0.87 0.16 
P[|θ| > 0.4] 0.52 5.9x10-6 0.65 6.2x10-4 0.82 0.05 
P[|θ| > 1] 0.47 6.2x10-7 0.59 9.9x10-5 0.75 9.7x10-3 
 
 
5.3.5 Setting the prior parameter γ 
 
 The values of the prior parameter γ were calculated for a type-I error α of 4.3x10-4, 
corresponding to one false positive result per model as a function of λL, and λH. The formula 
in Hoggart et al [88] gave a penalty factor λL of 72, which is higher than the λL value that was 
obtained using the permutation approach. In the LASSO logistic regression analysis, a 
penalty λL of 62 was estimated to provide on average one false positive per model (Figure 
5.2). It was noted that stringent penalty factors (λL > 62) might result in many variables being 
shrunk too severely to zero. In addition, in the previous analysis, the penalty λL was estimated 
while controlling for the effect of the SE. For these two reasons, the value of λL was set to 62.  
 104 
 
 A scale parameter γ of 0.026 was applied based on the values of λH  = 1 and λL = 62 as 
described by Hoggart and colleagues [88]. Table 5.7 presents the probabilities of a SNP 
having a small to large effect size |θ|, given λH = 1 and γ of 0.026. With these settings, SNP 
markers have a 2% chance of having a moderate effect size |θ| > 0.2, corresponding to OR > 
1.2 and OR < 0.8. At first sight, the identification of one in fifty SNPs seems an excess of 
positive results given the size of this study, but this is not too many as we expect non-causal 
SNPs to be selected due to LD with the causal variant.  
 
 
Table 5.7 Tail probabilities under NEG  
distributions with λH = 1 and γ = 0.026 
 
λH = 1 and γ = 0.026 
P[|θ| > 0.05] 0.166 
0.057 
0.016 
4.2x10
-3 
6.7x10
-4 
P[|θ| > 0.1] 
P[|θ| > 0.2] 
P[|θ| > 0.4] 
P[|θ| > 1] 
 
 
5.3.6 Findings of the HLASSO logistic regression 
 
 The software HyperLasso [88] was used to perform the HLASSO logistic regression 
using the NEG prior distribution. This software requires one to define a prior distribution 
over the covariates. A Gaussian prior distribution with a large variance, corresponding to a 
small penalty factor of 10
-4
, was applied to the number of SE+ allele copies and the number 
of HLA-DRB1*0101 allele copies in order to give a weak constraint to these parameters.  
With λH of 1, four SNPs in addition to the SE and HLA-DRB1*0101 were selected 
(Table 5.8): rs1592409, which is upstream of an unknown gene, approximately 3.0Mb from 
HLA-DRB1; rs4678, which is a coding SNP in VARS2 and approximately 1.5Mb telomeric of 
HLA-DRB1; rs2442728, which is upstream of HLA-B and approximately 1.2Mb telomeric of 
HLA-DRB1; rs2844513, which is upstream of MICA and also approximately 1.2Mb telomeric 
of HLA-DRB1; and rs3130188, which is a upstream of HLA-DPB1, approximately 0.5Mb 
centromeric of HLA-DRB1. It was noted that three markers, rs1592409, rs4678 and 
rs2442728, were also associated with RA in the stepwise regression analysis (Chapter 4). 
There was no deviation from HWE among the selected markers.  
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Table 5.8 Markers selected by the HLASSO logistic regression with  
prior λH = 1 and γ = 0.026 
Marker 
dbSNP127 
Position (BP) 
NCBI 36 
Gene (location) HWE P MAF 
rs1592409 29599902 LOC729653 (3‟UTR) 0.019 0.42 
rs4678 31001920 VARS2 (coding) 0.609 0.21 
rs2442728 31427334 HLA-B (3‟-UTR) 0.298 0.40 
rs3130188 33165154 HLA-DPB1 (3‟-UTR) 0.337 0.29 
 
 
 
 
 
 
 
 
 Figure 5.8 shows the location of these four markers across the HLA region, as well as 
the seven SNPs that were retained by the LASSO logistic regression. Each dot corresponds to 
the P-value of a SNP from the additive single-SNP association test after adjustment for the 
effect of the SE and HLA-DRB1*0101. The LASSO and HLASSO identified SNPs within the 
same genetic regions. Interestingly, marker rs3130188 was significant at P < 4.3x10
-4
 in 
neither the additive single-SNP association test (P = 1.8x10
-3
) or in the general test (P = 
5.5x10
-3
) (Chapter 4).  
In an exploratory analysis, the four markers that were selected by the HLASSO 
logistic regression were jointly analysed in a multi-SNP regression analysis. The logistic 
model included these four SNP markers as additive effects as well as the number of SE+ and 
HLA-DRB1*0101 allele copies.   
 
Table 5.9 displays the multi-SNP association test P-values of these four SNPs. None 
of the SNP markers were significant at the type I error α of 4.3x10-4. Interestingly, marker 
rs3130188, which is upstream of HLA-DPB1, had the strongest association. Although the 
effect of the retained SNP markers were moderate compared to the effect of the SE, these 
markers were either non-synonymous or located upstream the nearest gene. These markers 
may hence play an important role in RA susceptibility. 
 
 
 
Shown are the SNP accession number, map position on chromosome 6 from National Centre 
for Biotechnology information Build 36 (NCBI36), gene annotation, HWE P-value, Padj and 
minor allele frequency (MAF). Padj is the SNP additive association P–value after adjustment 
for the SE+ and *0101 alleles. 
† SNPs that were selected by the LASSO logistic regression.  
‡ rs3130188 was not in LD (r2 < 0.01) with any of the markers that were selected by the 
LASSO logistic regression 
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Table 5.9 Multi-SNP association test P-value of the SNPs selected by the HLASSO logistic 
regression 
Marker 
dbSNP127 
Position (BP) 
NCBI36 
Gene (location) Estimate (se) Multi-SNP P 
rs1592409 29599902 LOC729653 (3‟UTR) 0.22 (0.08) 3.4x10-3 
rs4678 31001920 VARS2 (coding) 0.32 (0.10) 2.0x10-2 
rs2442728 31427334 HLA-B (3‟-UTR) 0.26 (0.08) 2.2x10-3 
rs3130188 33165154 HLA-DPB1 (3‟-UTR) -0.30 (0.08) 5.5x10-4 
SE 32654526 HLA-DRB1 1.55 (0.09) 1.2x10-58 
*0101 32654526 HLA-DRB1 -0.60 (0.13) 2.3x10-6 
 
 
 
Figure 5.8 Location of the SNPs selected by the LASSO and HLASSO logistic regression across 
the HLA region  
 
 
 
 
 
 
Shown are the –log10(P) of the SNPs from an additive single-SNP association test after adjustment 
for the SE and HLA-DRB1*0101 (grey dots). The position of each SNP on chromosome 6 is 
indicated on the x-axis. Data points above the dashed and dotted lines represent markers significant 
at P < 4.3x10
-4 
and P < 2.2x10
-5
; the former corresponding to 1 false positive per analysis and the 
latter corresponding to a Bonferroni correction with a type-I error α = 0.05. The vertical line 
indicates the position of HLA-DRB1. The positions of other genes of interest are indicated across 
the top. 
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5.4 The prior HLASSO parameters in the GoRA study 
 
Different values of the shape parameter λH were assessed, with λH =1, 1.5, 3, 10 and 
25, and with the scale parameter γ such that the derivative of the density at the origin was the 
same as for the DE prior based on the λL value of 62, corresponding to a type-I error α of 
4.3x10
-4
. The Bayesian information criterion (BIC) was used to compare the HLASSO 
logistic models that were obtained for different values of the shape parameters, where 
 
)ln(ln2 nkLBIC  , 
 
where L is the maximised likelihood, k is the number of SNPs and n is the number of 
observations in the fitted model. The BIC penalises the complexity of the model, with large 
BIC values indicating that parameters do not improve the fit of the model. The model with 
the lower value of the BIC is hence to be preferred. Since a model with a small shape 
parameter applies less shrinkage to large effects, the BIC value of such a model is expected to 
be artificially improved. In order to account for this phenomenon, the likelihood was taken 
from fitting a traditional multi-SNP logistic model including the selected SNP markers.   
Table 5.10 presents the SNP markers that were selected using a NEG prior 
distribution with a shape parameters λH of 1, 1.5, 3, 10 and 25. As the shape parameter λH 
increases, fewer variables were selected for λH < 10. Six predictors were selected for a shape 
parameter λH of 1, whereas five were retained with a shape parameter λH of 10. With a prior 
shape parameter λH of 25, the NEG gave similar results as the DE prior distribution. 
Interestingly, the HLASSO logistic models with a shape parameters of 1.5 and 3, which 
selected only one predictor in addition to the SE and *0101, had high BIC values compared 
to the model with a shape parameter of 10.  The lowest BIC value was observed for the 
model with the smallest shape parameter λH of 1, even though this model included more 
variables than those with larger shape parameter values.  
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Table 5.10 Shrunk estimates of the SNP markers retained in the HLASSO logistic models using 
λH = 1, 1.5, 3, 10 and 25 
Marker 
dbSNP127 
λH = 1 
BIC*=2051.5 
λH = 1.5 
BIC*=2057.9 
λH = 3 
BIC*= 2059.9 
λH = 10 
BIC*= 2056.1 
λH = 25 
BIC*=2063.4 
rs2844657   0.28   
rs1592409 0.13   0.02 0.02 
rs4678 0.29 0.38  0.17 0.13 
rs7750641     0.03 
rs2442728 0.16   0.03 0.03 
rs3130188 -0.18     
SE 1.51 1.48 1.46 1.43 1.44 
*0101 -0.59 -0.58 -0.57 -0.57 -0.56 
 
 
 
 
 
The three markers, rs1592409, rs4678 and rs2442728, which were previously 
associated with RA in the stepwise regression model (Chapter 4) and with the LASSO 
logistic regression, were consistently selected for different values of λH. Marker rs7750641, 
which was also selected by the DE, was only selected in the model with the largest shape 
parameter. This marker, which lies between rs4678 and rs2442728, was in LD with these two 
markers at r
2 
= 0.56 and 0.20, respectively. As discussed earlier, as λH increases, the lighter 
tails of the NEG distribution resulted in correlated SNPs being brought into the model to 
explain some effect of the over-shrunk predictors.  
The regression coefficient of rs2442728, which was higher in a model with a shape 
parameter of 1 than the models with λH of 10 and 25, was shrunk more severely towards zero 
as λH increased. The presence of LD between rs4678 and rs2442728, which lie ~425kb apart, 
might have caused the effect at rs2442728 to be spread out over rs4678.  
 It is intriguing to note that a model with a prior shape parameter of 3 included only 
one SNP marker (rs2844657), in addition to the effect of the SE and HLA-DRB1*0101. The 
LD between this marker and rs4678 (r
2 
= 0.79) might explain this result (Figure 5.9).  
 Surprisingly, marker rs3130188 in HLA-DPB1, which was also selected by the 
LASSO logistic regression, was only retained in a model derived with a shape parameter of 1. 
This marker was not in LD with any other markers that were retained in the HLASSO models 
with higher shape parameters (Figure 5.9).  
 
*The BIC values were calculated from regressing the NEG selected SNPs using a standard multi-
SNP logistic model  
†SNPs that were selected by the LASSO logistic regression 
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Figure 5.9 LD plot of the SNPs markers that were selected by the HLASSO logistic regression 
using λH of 1, 1.5, 3, 10 and 25 
 
 
 
 
 
5.5 Discussion 
 
 In the current analysis, penalised logistic regression approaches identified fewer 
positive results than the commonly used single-SNP association test. Six and four SNP 
markers were selected in addition to the SE and HLA-DRB1*0101 by the application of 
LASSO and HLASSO logistic regression respectively. Of these, three associations were 
retained by both methods; these were independent associations in the HLASSO model. Those 
SNPs markers that were only retained in the LASSO logistic model, were correlated with at 
least one of the other selected SNPs. The lighter tails of the DE distribution caused correlated 
SNPs to be brought into the model to account for the over-shrunk estimates of the 
informative SNPs. By selecting SNPs in low LD, the HLASSO improved the localisation of 
the positive signals.  
 The three markers that were selected by both the LASSO and HLASSO logistic 
models were also identified in the stepwise analysis of the significant markers at P < 10
-4
 and 
including the SE and *0101 (Chapter 4).  These markers were as follows: rs4678, which 
encode a non-synonymous change in VARS2; rs244278, which is upstream of HLA-B; and 
SNPs are shown in map order, as indicated across the top. Correlation coefficients using 
r
2
(x100) are shown in the individual boxes. Grey shading denote 0<r
2 
<1 with white 
boxes corresponding to r
2
=0 and black boxes corresponding to r
2
=1. To illustrate the 
correlation with the SE and *0101, these two markers are also shown. 
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rs1592409, which is upstream of an unknown gene. The HLASSO logistic regression in 
addition selected rs3130188, which is located upstream of HLA-DPB1. 
 There is evidence in the literature that markers in HLA-DPB1 might be associated 
with RA, and in particular with anti-CCP+, a sub-phenotype of RA [33, 52] (Chapter 1). Ding 
et al. [33] reported that marker rs3117213, also in HLA-DPB1 was highly associated with 
anti-CCP+ in a single-SNP association study adjusted for HLA-DRB1. Since this marker was 
not genotyped in the GoRA study, further investigation was performed using the HapMap 
Caucasian subjects from Utah (CEU). This revealed that this marker was in high LD with 
rs3130188, also in HLA-DPB1, which was selected by the LASSO and HLASSO models (r
2 
= 0.96) [132].   
 The HLASSO logistic regression, which identified four independent associations (r
2 
< 
0.3), appears to perform better than the LASSO in the presence of multicollinearity, provided 
that the prior parameters are chosen with care. Contrary to the results reported in Hoggart et 
al. [88], the HLASSO selected fewer predictors as the prior shape parameter λH increased 
from 1 to 25. This unexpected result might be due to the presence of segments of LD in the 
HLA region. As the prior shape parameter increased, the first SNPs that entered the model 
might have explained enough of the variation in the model, while adding little information to 
its predictive power, resulting in fewer informative predictors being retained.  
 With the NEG, a sensible value of the shape parameter λH should allow one to identify 
the important markers without shrinking too severely their regression coefficients, but while 
removing the associations that are due to LD. Hoggart et al. [88] reported that a prior shape 
parameter of 0.05 could reliably identify causal variants . However, Stephens and Balding 
[57] suggested a prior shape parameter of between 1 and 2 as smaller value might give 
excessively high prior probabilities to large effects due to the heaviness of the tails. We 
considered different shape parameters λH, and showed that a prior shape parameter of 1 
improved the fit of the model, despite selecting more variables that with higher value of λH in 
the GoRA study. The NEG distribution with a prior shape parameter λH of 1 was hence 
selected to identify the set of markers associated with RA. A scale parameter γ of 0.026 was 
applied based on the values of λH  = 1 and λL = 62 to allow one false positive result [88]. 
 The LASSO and HLASSO logistic regression approaches appear to provide notable 
advantage for analysing simultaneously a large number of SNPs, while accommodating the 
presence of LD. In addition, by using the MAP estimates of the mode, these penalised SNP 
selection methods do not suffer from the multiple testing issues that are associated with 
testing the null hypothesis of no association in traditional regression settings. One could 
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argue that because of being multi-modal, the LASSO and HLASSO might not produce 
accurate results. This assessment revealed that the HLASSO tends to retain the same genetic 
information across the different models. The HLASSO seems hence a good approach for 
estimating the number of risk loci that might be associated with the disease, even in the 
presence of LD as is the case here.  
 Overall, the results from these analyses suggest that apparent benefit can be gained 
from jointly analysing multiple genetic variants, even in presence of LD. With the emergence 
of genotype imputation techniques, scientists face the problem of analysing extremely dense 
genetic regions by combining SNP data from different platforms. In order to evaluate the 
performance of LASSO and HLASSO logistic models in such a situation, these two penalised 
methods were applied to the combined samples from WTCCC and the GoRA studies.
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Chapter 6. Genotype imputation analysis of the combined 
WTCCC and GoRA studies using the LASSO and HLASSO 
logistic regression 
 
 
 
 
6.1 Introduction 
 
 In Chapter 5, it was shown that the LASSO and HLASSO can be used for variable 
selection in multi-SNP association analysis. In this chapter, these penalised regression 
approaches are applied to a dense panel of imputed markers from the HLA region.  
 First, genotype imputation methods are reviewed. The method MACH [115] is then 
used to impute the missing data at ungenotyped and genotyped SNP markers. The HapMap 
Caucasian subjects from Utah (CEU parents) are used as a means to jointly analyse SNPs 
from the WTCCC [98] and the GoRA studies. Results from LASSO and HLASSO logistic 
regression are compared with those obtained using single-SNP association tests. The 
robustness of the markers retained by the LASSO and HLASSO approaches is verified by 
bootstrapping. Cross-validation is used to assess the prediction performance of the models 
derived. In addition, samples from the NARAC study are used to evaluate the reproducibility 
of the results. 
 
 
6.2 Overview of genotype imputation methods 
 
 Imputation-based approaches are becoming more important in association studies for 
testing ungenotyped markers and combining genotype data from different platforms. Novel 
effective programs such as MACH [115], IMPUTE [133], fastPHASE [134], BIMBAM 
[135], BEAGLE [136], and PLINK [137] are available. They all are based on the idea that 
unrelated individuals share haplotype-segments from common ancestors. Hence, by 
exploiting the SNP correlation structure among densely-genotyped individuals, missing 
genotypes at ungenotyped or partially genotyped markers can be inferred. This is done by 
comparing the haplotypes of study samples with those of subjects from a reference panel 
[133, 138].  
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 To date, subjects from the HapMap have served as a commonly-used reference panel. 
Nothnagel and colleagues [139] assessed the accuracy of the imputation-based methods when 
using a reference panel. They showed that imputation programs using the HapMap CEU 
samples can reliably infer missing genotypes in a northern European population even in 
highly variable genetic region such as the HLA complex. 
 The most commonly used genotype imputation programs are based on two models: 
the cluster-based model  and the product of approximate conditionals (PAC) model [140]. 
These two statistical models use hidden Markov models (HMMs) to infer phase and impute 
missing genotypes among unrelated individuals by making the assumption that the state of a 
process is dependent on a set of hidden states, corresponding to the phased haplotypes.  
 The model parameters of the HMMs include the transition probabilities that reflect 
changes between pairs of consecutive markers due to recombination events, and the emission 
probabilities, which correspond to differences at a specific position between haplotypes due 
to factors such as mutation or genotyping error. 
 
 
6.2.1 The cluster-based imputation models 
 
 In cluster-based models, haplotypes are organised into clusters based upon their 
similarities at a particular position. Because of recombination events, the membership of a 
cluster changes along the chromosome. HMMs determine membership iteratively based on 
the estimation of the emission probabilities and transition probabilities to jump from one 
cluster to another. BEAGLE, fastPHASE and BIMBAM are haplotype-clustering algorithms.  
 With fastPHASE, missing genotypes are sampled based on the estimation of the allele 
frequencies within the cluster. The expectation maximisation (EM) algorithm is then used to 
estimate the parameter values of interest, namely the probability of a genotype i at a marker 
m where gi = x and x   (0, 1, 2), the allele frequencies, the emission probabilities and the 
transition probabilities.  
 The main differences between BEAGLE and fastPHASE are that 1) fastPHASE uses 
a fixed number of clusters, whereas BEAGLE allows the number of clusters to vary 
according to the data; and 2) fastPHASE uses an EM algorithm to estimate the emission and 
transition parameters that are needed in the configuration of the cluster, whereas BEAGLE 
does not require their estimation. With BEAGLE, two haplotypes with different alleles at a 
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particular locus will not be in the same cluster, whereas they may be with fastPHASE if the 
two haplotypes are similar at nearby markers [136]. BIMBAM uses the FastPHASE 
algorithm to impute the missing genotypes.  
 
 
6.2.2 The PAC imputation models 
 
The PAC model of Li and Stephens [140] computes the likelihood of the observed set of 
haplotypes H, },...{ 1 HhhH   with H the number of haplotypes, using the “product of 
approximate conditional” probabilities to be estimated. The likelihood of Li and Stephens 
[140] can be written as, 
 
)...,/(ˆ)......,/(ˆ).../(ˆ)(ˆ),( 121211121  nnkkPAC hhhhphhhhphhphpHL  , 
 
where )...,/(ˆ 211 kk hhhhp   is the approximate conditional probability of the k+1 haplotype, 
relative to the k
th
 haplotypes, as a function of the parameter  , the recombination rate that 
varies along the region. The PAC model assumes that the k+1 haplotype is likely to be an 
exact copy of one of the first k haplotypes, unless a recombination event or a mutation occurs. 
In the latter case, a novel haplotype is sampled from the uniform prior distribution on the first 
k previously sampled haplotypes. The haplotype k+1 is then formed of different segments 
that are copied from the already simulated first k haplotypes. This is done using HMMs 
[141]. At each site, corresponding to a marker, haplotype k+1 is an imperfect copy of one of 
the first k haplotypes. A large set of possible sequences is hence available. For instance, at a 
site j, there are H
2 
possible states. One disadvantage of this model is that the PAC likelihood 
depends on the order in which the haplotypes are processed [140].  
 Despite being slower than cluster-based imputation models, the PAC model as 
implemented in MACH and IMPUTE captures more information on haplotypic variation than 
BEAGLE and fastPHASE. In terms of software based on the PAC model, PLINK performed 
consistently more poorly than MACH and IMPUTE [139, 142], which produce similar results 
[16, 139, 142].  
 IMPUTE uses a set of reference haplotypes that are phased haplotypes from the 
HapMap project as the hidden states of the Markov chain. It then updates the haplotypes and 
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missing genotypes according to these hidden states. The recombination and mutation rates are 
calculated from the HapMap data, which is considered as the reference panel.  
 MACH, on the contrary, combines data from the reference panel with those from the 
study samples. It then estimates the parameters of the HMMs, i.e. the recombination and 
mutation rates, and infers the haplotypes and missing genotypes for each of the individuals in 
turn. The estimated haplotypes become the reference haplotypes. These are used to infer the 
pair of haplotypes of each individual, once removed from the reference set.  
 Pei et al. [142] reported that strong LD at untyped markers produces higher accuracy 
rates for both MACH and IMPUTE compared to other software. MACH was however more 
efficient than IMPUTE under low LD and high marker density. IMPUTE, which relies on 
pre-specified recombination and mutation rates, has the benefit of saving computation time 
with the disadvantage of being less accurate.  
 In this study, MACH v1.0.16 [115] was used to impute the missing genotypes at 
ungenotyped and partially genotyped markers in the combined WTCCC and GoRA datasets. 
Genotypes from the HapMap CEU founders were included as a reference panel.  
 
 
6.2.3 Genotype imputation using MACH 
 
 The algorithm starts by assigning pairs of haplotypes to each individual based on their 
observed genotypes. Alleles at ungenotyped markers are assigned using population 
frequencies. Let S define a series of indicators that denote the unobserved states underlying 
the unphased genotypes, with },...,{ 21 LSSSS  a Markov chain, and let L denote a locus. At 
a state j, Sj = (xj, yj) corresponds a pair of haplotypes xj and yj. The objective is to infer the 
sequence of states S underlying the observed genotypes. The probability of the observed 
genotypes conditional on the underlying haplotype states is defined as follows:  
 
 

L
j
L
j
jjjj SGPSSPSPSGP
2 1
11 )/()/()(),( , 
where )( 1SP  denotes the probability of the initial state, )/( 1jj SSP  denotes the transition 
probability between two states, reflecting the likelihood of recombination events between the 
states j and j-1 and )/( jj SGP  is the probability of the observed genotypes at position j 
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conditional on the underlying state at the same position, which reflects the effects of factors 
such as gene conversion, mutation or genotyping error.  
 At each position j, the pair of haplotypes of an individual is removed from the dataset. 
The remaining haplotypes are then estimated and used to update each individual in turn. This 
procedure is repeated for several iterations until a stable pair of haplotypes is found for each 
individual. Missing genotypes are then inferred based on the most likely genotypes, i.e. those 
that were sampled most of the time. 
 
 
 
6.3 The WTCCC and GoRA imputed dataset 
 
6.3.1 Combining genotypes from Affymetrix and Illumina 
 
 Genotype imputation was performed by applying MACH to data from the GoRA, 
WTCCC and HapMap subjects. The HapMap subjects comprised 60 CEU parent samples. 
Genotype data from these three studies were combined in one dataset making sure that the 
strand orientation of the alleles was consistent across the genotyping platforms.  
 An important prerequisite for an imputation-based approach is the consistent labelling 
of alleles across studies. In this evaluation, there was an issue with the orientation of the 
assay used. The WTCCC reported that the genotype data from the Affymetrix 500K chip 
were reoriented to correspond to the positive strand of the Affymetrix assay. However, 
approximately 30% of the WTCCC alleles did not match the alleles reported for the reference 
polymorphisms using NCBI36. This estimation was highly conservative, as the effect was 
only detectable for SNPs whose alleles were not complementary. It is conceivable that the 
WTCCC may have reported genotypes corresponding to the strand assayed by Affymetrix, 
and not the reference strand from dbSNP. In order to match the alleles corresponding to the 
reference strand as maintained by NCBI in the dbSNP database, the WTCCC genotype data 
were flipped to obtain the alleles of the reference genomic strand reported by Affymetrix. We 
subsequently checked that this strand matched the dbSNP reference strand. The observed 
allele frequencies from the HapMap database were used to validate this process [143]. The 
recoded alleles were all consistent with those reported by HapMap.  
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6.3.2 The combined HapMap, WTCCC and GoRA genotypes 
 
Genotype imputation was performed on 9,884 genetic markers, i.e. 9,882 SNP 
markers, plus the SE and HLA-DRB1*0101, with the latter recoded as bi-allelic markers 
according the presence of SE+ and *0101.  
Figure 6.1 presents the counts of the genetic markers across the GoRA, WTCCC and 
HapMap samples. The majority of the loci were genotyped in the HapMap samples (67%). 
Approximately 3% of the markers were common to the WTCCC and GoRA samples.  
 
 
6.3.3 Assessing the quality of the imputed genotypes  
 
 The estimated R
2
MACH provided by MACH was used to assess the quality of the 
imputed genotypes. The estimated R
2
MACH compares the variance of the estimated genotypes 
with what would be expected if the genotypes were observed without errors based on HWE. 
Li et al. [138] reported that an estimated R
2
MACH value of 0.3 excluded most of the poorly 
imputed markers without removing many of the successfully imputed ones. A more stringent 
threshold of 0.6 was applied since a large number of SNPs were only present in the HapMap 
dataset (Figure 6.1).   
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Figure 6.1 SNP coverage of the GoRA, WTCCC and HapMap SNPs from the HLA 
region  
 
 
 
 
6.3.4 Evaluation of the imputation process parameters 
 
 Before starting the imputation, a key step is to define the number of Markov chains 
that are necessary for accurate genotype imputation. In this study, the number of chains 
required was evaluated by comparing the proportion of SNPs with an estimated RMACH
2
 
greater than 0.3, 0.6 and 0.8 using 0, 25, 50, 100 and 200 iterations. The performance of the 
imputation process was evaluated using a 25-step burn-in process prior to starting the 
genotype imputations.  
 Table 6.1 presents the results from this assessment. As expected, the quality of the 
imputation process increased with the number of Markov chains. Among the 9,884 imputed 
SNPs, the proportion that exceeded any specified R
2
MACH value was greater when the number 
of chains was greater. The inclusion of 25 burn-in steps improved the results substantially. A 
model with 100 Markov chains, including 25 burn-in steps prior to starting the genotype 
imputations, gave similar results to a model with 200 iterations with the advantage of being 
 
 
  
WTCCC 
N=1,195 
CEU 
HapMap 
N=9,738 
GoRA 
N=2,305 
6,681 
(67%) 
34 
(<1%) 
104 
(1%) 
865 
(9%) 
1,904 
(19%) 
8 
(<1%) 
288 
(3%)) 
The diagram provides the number (N) and percentage (%) of 
markers that are either unique to the GoRA, WTCCC and 
HapMap studies or shared by any two or all three studies. 
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less computationally intensive. Genotype imputation was hence performed using 100 Markov 
chains with 25 burn-in steps.  
 
 
Table 6.1 Assessment of the imputation process as a function of the number of Markov 
chains    
Number of  
burn-in steps 
Number of 
iterations 
R
2
MACH > 0.3 R
2
MACH > 0.6 R
2
MACH > 0.8 
0 25 8165 (83%) 3125 (32%) 1263 (13%) 
 50 9099 (92%) 6121 (62%) 2188 (22%) 
 100 9326 (94%) 8279 (84%) 4437 (45%) 
 200 9384 (95%) 8779 (89%) 6873 (69%) 
25 25 - - - 
 50 9413 (95%) 8799 (89%) 7671 (70%) 
 100 9404 (95%) 8882 (90%) 7858 (79%) 
 200 * * * 
 
 
  
    
6.3.5 Evaluation of the imputation process by masking 5% of the non-missing 
genotypes  
 
 In an exploratory analysis, 5% of the data were hidden prior to starting the imputation 
process in order to further evaluate the quality of the imputation with 100 Markov chains and 
25 burn-in steps. The imputed genotypes were then compared with the hidden true values 
using the correlation coefficient r
2
.  Among the 9,882 imputed SNP markers, the mean 
correlation coefficient r
2
 was 0.99, ranging from 0.31 to 1; only 87 SNPs had r
2
< 0.9.  
 Table 6.2 presents the six SNP markers with an r
2
 < 0.6, as well as the imputed MAF 
and MACH estimated R
2
MACH. Although these SNPs were poorly imputed based on this 
assessment, the MACH estimated R
2
MACH exceeds the quality threshold (R
2
MACH > 0.6) that 
was used to filter out the badly imputed markers. These results suggest that the estimated 
R
2
MACH should not be the only measure used to identify the poorly imputed SNP markers.  
 
 
 
 
 
 
 
 
*Genotype imputation was not performed due to limitation of computation time 
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Table 6.2 SNP markers with poor genotype  
imputation quality, i.e. r
2
< 0.6  
Marker 
dbSNP127 
MAF R
2
MACH r
2
 
rs2395222 0.07 0.67 0.31 
rs391755 0.04 0.70 0.49 
rs9261380 0.04 0.65 0.49 
rs9348863 0.07 0.86 0.49 
rs9394052 0.07 0.96 0.49 
rs9394054 0.05 0.83 0.49 
 
 
 
6.3.6 The mean allele score 
 
 In order to accommodate uncertainty in genotype imputation, a weighted mean allele 
score was derived for each marker based on the probability of the imputed genotypes,  
 
AAAaaa PPPScore 012  , 
 
where Pi is the probability of genotype i, a is the rare allele, A is the common allele and score 
is a real number between 0 and 2. This score, which is equivalent to the expected count of the 
rare allele, was used to model the additive effect of the genotypes in the regression analyses. 
 
 
6.3.7 Comparison of the imputed genotypes in the WTCCC and GoRA datasets  
 
 The genotype imputation resulted in 1,001 poorly imputed SNPs with estimated 
R
2
MACH < 0.6. These SNPs were excluded from the marker set. In order to investigate further 
the genotype imputation of the combined WTCCC and GoRA datasets, the difference in the 
means of the SNP allele scores (see above) between the GoRA and WTCCC controls was 
assessed using a t-test. Genetic markers with a significant difference at P < 10
-4
 were 
excluded from the remaining analyses; at this threshold the expected number of false 
positives was less than one.  
 Of the remaining 8,885 markers, 2,703 SNPs, i.e. 30%, were removed in this way. 
Figure 6.2 presents the distribution of the difference in mean allele scores between the GoRA 
and WTCCC controls using the entire set of 8,885 SNPs that passed the MACH quality 
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control (Figure 6.2 (a)) and using the remaining 6,182 SNPs with no significant differences 
between the two studies (Figure 6.2 (b)). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 In order to investigate the nature of such deviation, the mean allele scores of the 292 
SNP markers (R
2
MACH > 0.6) that were present in both the GoRA and the WTCCC studies, 
Figure 6.2 Distribution of the mean allele scores in the WTCCC and GoRA controls 
(a) using 8,885 SNPs with R
2
MACH > 0.6, (b) using 6,182 SNPs with R
2
MACH > 0.6 and t-
test P ≥ 10-4  and (c) among the 292 SNPs with R2MACH > 0.6 that were genotyped in 
both studies  
 
 
 
 
 
(a)         (b) 
 
(c)  
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were plotted in Figure 6.2 (c). Among these 292 SNPs, only three SNPs had significant 
differences in mean allele score between the two samples (P < 10
-4
). It seems that the SNPs, 
which showed significant differences in mean allele scores (P < 10
-4
) in Figure 6.2 (a), must 
be markers with poor genotyping quality. These results suggest that the estimated R
2
MACH 
might not be good enough in identifying SNP markers that have been poorly imputed from 
different genotyping platforms. A t-test, which investigates the differences in mean allele 
score of each marker from two studies, seems a good approach to identify SNPs with low 
genotype imputation quality.  
 Hence, genotypes from 6,182 SNPs from the HLA region in 2,679 cases (nGoRA = 845, 
nWTCCC=1,834) and 3,896 controls (NGoRA = 958, NWTCCC = 2,938) were used in the regression 
analyses.  
 
 
6.3.8 Assessment of population substructure 
 
 Population substructure was next assessed using the Devlin & Roeder genomic 
control approach [101]. The marker set included 589 genome-wide markers in low LD, which 
were common to the GoRA and WTCCC, had less than 5% missing data and excluding those 
from the HLA region and chromosome X. Subjects with a missing rate greater than 5% for 
these markers were also excluded. Overall, 6,414 subjects (NGoRA=1,643, NWTCCC=4,771) 
were used to investigate the similarities and dissimilarities between the two samples.  
 Single-SNP association tests with 1 degree of freedom (df) were performed on the 
589 SNP markers. The genomic inflation factor λ was calculated as the ratio of the median of 
the observed distribution of the test statistics to the expected median of the 1 df χ2 distribution 
(0.455). In the combined GoRA and WTCCC, there was modest evidence of population 
substructure with an inflation factor λ of 1.06. Although the effect of population structure 
seems small, the inflation factor λ might be enough to introduce some bias in the regression 
analyses.  
 In order to investigate the presence of population substructure within the two studies, 
the Devlin & Roeder [101] inflation factor was also assessed for the WTCCC and GoRA 
studies separately. The over-dispersion estimates of the association trend statistics was 1.03 
and 1.02 for the WTCCC [98] and GoRA [121] studies, respectively. There was hence little 
evidence of population stratification within either the GoRA or the WTCCC studies. In order 
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to accommodate the fact that the inflation factor λ was higher in the combined WTCCC and 
GoRA datasets compared to the individual studies, a factor variable was created to indicate 
whether a subject was part of the GoRA or the WTCCC study.  
 
 
6.4 Regression analyses of the combined imputed datasets 
 
 Single-SNP association analysis, and the LASSO and HLASSO logistic regression 
methods, were applied to markers from the HLA region, including as covariates the number 
of SE+ and HLA-DRB1*0101 allele copies, sex and study of origin as described below.  
 Sex is a well known confounding factor that should be accounted for in RA 
association analyses. The GoRA cases and controls were approximately matched on sex but 
there were slightly more females among the GoRA cases (72%), compared to controls (66%). 
The proportion of WTCCC cases who were female was also high (75%) compared to the 
proportion of population controls (50%). In order to adjust for the effect of sex, while 
controlling for the effect of study, two variables were created according to whether the 
subject was male and from the WTCCC and whether the subject was female and from the 
WTCCC. These variables were used in the analyses to account simultaneously for the sex and 
the study, while limiting the number of covariates. This coding was not needed in the GoRA 
study since controls were group matched on sex.  
 Genomic control was next applied to 591 genome-wide SNP markers that were 
common to WTCCC and GoRA in order to assess the impact of these two covariates on the 
inflation factor λ. SNP markers from the HLA region were excluded because the large 
number of positive associations with RA, which are mostly due to LD, would have inflated 
the genomic control inflation factor. SNP markers from chromosome X were also excluded. 
The inflation factor λ was estimated with and without sex and study.  
 The inflation factors λ were 1.06 in the unadjusted analysis, and 1.08 for the analysis 
adjusted analysis on sex and study. The slight increase after adjusting for sex and study is 
negligible and might be due to variability of the inflation factor in this small set of SNP 
markers. In order to investigate whether the increase in λ might be due to chance, a thousand 
inflation factors based on 591 markers were simulated. This simulation study showed that 
about 26% and 21% of the simulated inflation factors exceeded 1.6 and 1.8 under the null 
hypothesis of no associations, respectively. There was hence no evidence of inflation before 
and after adjusting for sex and study.  
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 The inflation factor within each cohort was however less than the combined GoRA 
and WTCCC. The sex and GoRA/WTCCC indicators were hence entered in the model as 
covariates in order to account for the differences of female to male ratio among the cases and 
controls between the two studies. 
 
 
6.4.1 Findings of single-SNP association analysis adjusted on the SE+, *0101, sex and 
study 
 
 Figure 6.3 presents the single-SNP association test results of the combined GoRA and 
WTCCC datasets after adjustment for the number of SE+ and HLA-DRB1*0101 allele copies, 
sex and study. Crosses above the dashed lines represent 467 markers significant at P < 
8.1x10
-6
, corresponding to a Bonferroni-corrected P-value using a type-I error of 0.05. The 
two SNP markers, rs4678 and rs2442728, which were reported in the analysis of the GoRA 
study were among them. The quantile-quantile (QQ) plot in Figure 6.6 shows a large excess 
of positive associations, which might be due to LD with non-DRB1 causal associations. 
 
 
6.4.2 Findings of the LASSO multi-SNP association analyses 
 
 The penalised value L  of the DE prior distribution was defined using the 
permutation approach as described in Chapter 5. With this method, a L  value of 180 gave 
on average less than one positive result per model, corresponding to P < 1.6x10
-4
 (1/6,182), 
and was selected for the LASSO logistic regression. In this analysis, the penalised parameter
L  was not applied to the covariates, namely the number of SE+ and HLA-DRB1*0101 allele 
copies, sex and study, since previous analysis (Chapter 5) revealed that over-shrinking the SE 
might lead correlated SNPs to be retained in the LASSO model.  
 The LASSO logistic regression identified five associated SNPs in addition to the 
number of SE+ and HLA-DRB1*0101 allele copies, sex and study. Table 6.3 presents the five 
SNP markers that were retained by the LASSO and the association P-values from the single-
SNP analysis after adjustment for the SE, HLA-DRB1*0101 and the sex and study. All SNP 
markers were significantly associated with RA in the single-SNP association analysis at P < 
8.1x10
-6
. Among the five SNPs that were retained in the LASSO model, two markers in HLA-
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DPB1 (rs9277553 and rs3117225) and one marker in TRIM26 (rs3094139) were fully 
imputed in the GoRA and WTCCC datasets. In order to assess the degree of correlation 
between the markers, r
2
 values among these markers were calculated and displayed using 
Haploview ( 
Figure 6.5). None of the selected SNPs were correlated with the number of SE+ allele copies 
or the number of HLA-DRB1*0101 allele copies. Two pairs of highly correlated SNPs (r
2
 > 
0.90) stand out: rs3117225 and rs9277553 in the vicinity of HLA-DPB1, and rs3132671 and 
rs3094139 near TRIM26. None of the five selected markers were retained in the GoRA study 
(Chapter 5). In an exploratory analysis, LD between the six markers that were selected by 
LASSO logistic regression in the GoRA study and the five markers that were retained in this 
analysis were calculated using the combined WTCCC-GoRA dataset (Table 6.4). Although 
marker rs3132472 in MICA was not selected in the GoRA study, this SNP was in LD (r
2
 > 
0.50) with four of the SNPs that were previously selected. The remaining SNPs did not show 
any LD with those selected in the GoRA study.  
 
 
 
Figure 6.3 –log10(P –value) of the single-SNP association tests across the HLA region 
after adjustment for the SE, *0101, sex and study 
 
 
 
 
The y-axis shows the –log10(P-value) for association with RA, and SNP location is shown on 
the x-axis. The dashed and dotted lines correspond to a P-value thresholds of 10
-4
 and 8.1x10
-
6
. The vertical line indicates HLA-DRB1. 
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Figure 6.4 QQplot of the single-SNP association test P-values across the HLA region 
 
 
 
 
 
Table 6.3 Information on the five SNPs selected by the LASSO logistic regression 
Marker 
dbSNP127 
Position(kb) 
NCBI36 
Gene 
(location) 
P
1
 MAF R
2
MACH 
Genotyped 
in 
rs9277553 
 
33163494 
 
HLA-DPB1 
(intron) 
8.5x10
-10
 0.31 0.95 HapMap 
rs3132472 31494110 
MICA 
(3‟UTR) 
6.5x10
-16
 0.15 0.99 
HapMap - 
GoRA 
rs3132671 30286266 
TRIM26 
(intron) 
7.2x10
-10
 0.49 1 
HapMap - 
GoRA - 
WTCCC 
rs3117225 33165689 
HLA-DPB1 
(Intron) 
8.3x10
-10
 0.30 0.94 HapMap 
rs3094139 30305974 
TRIM26 
(Intron) 
6.4x10
-10
 0.49 0.98 HapMap 
 
 
 
 
 
 
 
1
Single-SNP association P after adjustment for the effect of SE+, *0101, sex and study. 
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Figure 6.5 LD using r
2
 among the SNPs selected by the LASSO logistic regression  
 
 
 
 
  
 
 
Table 6.4 r
2
 values between the SNPs retained by the LASSO logistic regression in the 
GoRA study (columns) and the combined WTCCC-GoRA study (rows). 
 
 rs3132671 rs3094139 rs3132472 rs39277553 rs3117225 
1
rs1592409 - - - - - 
rs886422 0.10 0.10 0.74 * * 
rs1264308 0.10 0.10 0.74 * * 
rs4678 0.08 0.08 0.50 * * 
rs7750641 
rs2442728 
0.08 
0.03 
0.08 
0.03 
0.86 
0.27 
* 
* 
* 
* 
 
 
. 
 
 
 
 
6.4.3 Findings of the HLASSO multi-SNP association analyses 
 
 A penalty factor L  of 180, which was derived for the DE prior distribution, was 
applied to the NEG prior distribution in order to control for the per-SNP type I error (Chapter 
SNPs are ordered by map position. 
1
rs1592409 was excluded from the combined WTCCC-GoRA analysis due to large 
differences in mean allele score between the WTCCC and GoRA samples (Ttest P < 10
-4
). 
*r
2 
< 0.01 
Correlation coefficients using r
2
(x100) are shown in the individual boxes. Grey 
shading denotes 0<r
2
< 1 with white boxes corresponding to r
2 
= 0 and black boxes 
corresponding to r
2 
= 1. SNPs are positioned in map order. To illustrate the 
correlation with carriage of the SE and *0101, these two markers are also shown. 
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5). HLASSO logistic regression was applied to the same set of 6,182 SNP markers using a 
prior shape parameter λH of 1. Previous assessment (Chapter 5) revealed that λH = 1 was able 
to retain the important variables, while removing the positive associations due to LD (λH > 1) 
and without favoring SNPs with large effect sizes (λH < 1). 
 Three SNPs were retained in the HLASSO model with the largest posterior mode in 
addition to the number of allele copies of SE+ and HLA-DRB1*0101, sex and study. The 
three markers were as follows: rs3132472, which is upstream of MICA, rs3132671, which is a 
synonymous SNP in TRIM26, and rs3117225, which is a non-coding variant in HLA-DPB1. 
These markers are presented in Table 6.5. All were highly associated with RA in the single-
SNP association analysis after adjustment for the number of SE+ and HLA-DRB1*0101 allele 
copies, sex and study (P < 8.1x10
-6
). These three markers were also selected by LASSO 
logistic regression. These markers were not in LD with each other or with the SE and HLA-
DRB1*0101 ( 
Figure 6.5).  
  
 
 
Table 6.5 Information on the three SNPs selected by the HLASSO logistic regression 
Marker 
dbSNP127 
Position(kb) 
NCBI36 
Gene 
(location) 
P
1
 MAF R 
2
MACH 
Genotyped 
in 
rs3117225 33165689 
HLA-DPB1 
(intron) 
7.2x10
-10
 0.30 0.94 HapMap 
rs3132472 31494110 
MICA 
(3‟UTR) 
6.5x10
-16
 0.15 0.99 
HapMap-
GoRA 
rs3132671 30286266 
TRIM26 
(intron) 
8.3x10
-10
 0.49     1 
HapMap-
GoRA-
WTCCC 
 
 
  
 
 
 
 
 
 
 
 
1
Single-SNP association P after adjustment for the effect of SE+, *0101, sex and study. 
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Figure 6.6 –log10(P –value) of the single-SNP association tests across the HLA region 
after adjustment for the SE, *0101, sex and study 
 
 
 
 
 
 
 
 
Contrary to the LASSO, which selected SNPs in high LD within the same gene, the 
HLASSO selected three independent associations within different genes. Figure 6.6 shows 
the location of the SNPs that were selected by LASSO and HLASSO logistic regression 
across the HLA region. Each marker is represented using the single-SNP association test P-
value adjusted for the number of SE+ and HLA-DRB1*0101 allele copies, sex and study. 
Three genetic regions can be identified. From the telomeric end to the centromeric end, the 
first region includes SNPs in gene TRIM26. The second region encompasses markers near 
MICA and the third region covers the genetic associations in the vicinity of HLA-DPB1. 
 Each SNP marker was analysed in an exploratory logistic regression analysis, which 
included the effects of the three SNPs retained by HLASSO, namely rs3117225, rs3132472 
and rs3132671, in addition to the number of SE+ and *0101 allele counts, the sex and study 
as covariates. The objective of this analysis was to assess the amount of genetic signals that 
Shown are the –log10(P) of the SNPs from an additive single-SNP association test after 
adjustment for the SE and *0101 (grey dots). The position of each SNP on chromosome 6 is 
indicated on the x-axis. Data points above the plain and dashed lines represent markers 
significant at P < 1.6x10
-4
,
 
corresponding to one false positive results among 6,182 tests
 
and P < 
8.1x10
-6, corresponding to a Bonferoni correction with α = 0.05. The vertical line indicates the 
position of HLA-DRB1. The positions of other genes of interest are indicated across the top. 
SNPs highlighted in red are markers selected by both LASSO and HLASSO logistic regression. 
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might remain after accounting for the effects of these three markers. By this approach, twelve 
SNP markers were associated with RA at type-I error α = 10-3, which is not markedly 
different from the expected number of false positive results (= 6). None of these markers 
were highly associated with RA at P < 1.6x10
-4
. These twelve SNPs are presented in Table 
6.6. The location of these markers across the HLA region is also displayed in Figure 6.7.  
 The first eleven makers, which are in LD with each other (r
2
 > 0.5), are located in the 
same genetic region telomeric of MICA. The twelfth association, which is located in an 
unknown gene between HLA-DQB1 and HLA-DPB1, did not show any correlation with these 
eleven SNP markers. None of these markers were correlated with the SE, *0101, or any of 
the three HLASSO SNPs. 
 The proposed model eliminated a large number of positive associations within the 
HLA region that remained even after adjusting for both the effects of the SE+ and *0101 
allele counts (Chapter 4). It therefore seems reasonable to conclude that, among the SNP set 
analysed, rs3117225, rs3132472 and rs3132671 might represent true associations with RA. 
 
 
 
Table 6.6 Markers with P < 10
-4
 in the adjusted analysis on the SE,  
*0101, the sex and the study and the 3 SNPs retained by HLASSO  
Marker 
dbSNP127 
Gene (location) 
Position 
(BP) 
P 
rs3094225 CCHCR1 (exon) 31221031 7.0x10
-4
 
rs130078 CCHCR1(exon) 31226544 6.9x10
-4
 
rs2073723 TCF19 (intron) 31238057 4.9x10
-4
 
rs1065461 POU5F1 (3‟UTR) 31238481 5.1x10-4 
rs3130931 POU5F1 (intron) 31242867 2.0x10
-4
 
rs9263804 POU5F1 (intron) 31243685 5.2x10
-4
 
rs9263805 POU5F1 (intron) 31243714 6.4x10
-4
 
rs3130501 POU5F1 (intron) 31244432 4.7x10
-4
 
rs3130502 POU5F1 (intron) 31244645 5.1x10
-4
 
rs879882 POU5F1 (5‟UTR) 31247431 4.4x10-4 
rs3094188 - 31250224 9.4x10
-4
 
rs6933763 LOC650557 
(intron) 
32830830 3.4x10
-4
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Figure 6.7 –log10(P –value) of the single-SNP association tests across the HLA region 
after adjustment for the SE, *0101, sex and study, and the 3 HLASSO SNPs 
 
 
 
 
 
 
 
 
 
 
 
Table 6.7 Number of SNPs significant at P < 10
-3
, 1.6x10
-4
 and 8.1x10
-6
 in the unadjusted 
and adjusted logistic regression analyses 
P 
Unadjusted 
analysis‡ 
SE adjusted 
analysis*‡ 
SE & *0101 
adjusted 
analysis*‡ 
SE, *0101 & 
HLASSO SNPs 
adjusted analysis*† 
< 10
-3
 2580 1143 935 12 
< 1.6x10
-
4
 
2160 878 689 0 
< 8.1x10
-
6
 
1648 606 467 0 
*Models included also gender and study as covariates. 
‡ Results from the unadjusted and adjusted analyses on the SE and *0101 allele counts are presented in Chapter 
4. 
†The HLASSO SNPs are rs3117225, rs3132472 and rs3132671. 
 
 
 
Shown are the –log10(P) of the SNPs from an additive single-SNP association test after 
adjustment for the SE,*0101, the sex and the study and the 3 SNPs that were retained by 
HLASSO, namely rs3117225, rs3132472 and rs3132671. The position of each SNP on 
chromosome 6 is indicated on the x-axis. Data points above the dashed line represent markers 
significant at P < 10
-3
. The vertical line indicates the position of HLA-DRB1. The positions of 
other genes of interest are indicated across the top. SNPs highlighted in red are the gene-region 
of the markers selected by HLASSO logistic regression. 
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6.4.4 Robustness of the LASSO and HLASSO models 
 
6.4.4.1 Variable selection using bootstrapping 
 
 A bootstrap approach was used to investigate the repeatability of variable-selection by 
LASSO and HLASSO logistic regression. A thousand bootstrap datasets were created by 
sampling with replacement the observations from the original dataset. The penalised logistic 
regression using the DE and NEG prior distributions were performed on each bootstrap 
dataset and the number of times a variable was retained in a thousand models was calculated.  
 In order to accommodate the presence of LD, SNP markers with r
2
 ≥ 0.9 were 
grouped together using the pairwise tagging algorithm in Haploview [144], which is based on 
the computer program Tagger [67]. This pairwise tagging algorithm is similar to the 
Carlson‟s method [66], which is implemented in LDSelect. First, the algorithm selects a SNP 
in LD with the maximum number of markers for a given r
2
 threshold. The SNPs are grouped 
together within a bin. Since the pair-wise associations are not transitive, the correlations 
between the SNP markers are re-evaluated within a bin. This process is repeated until the 
pair-wise correlations between the SNPs within the same bin exceed the r
2
 threshold. Within 
each group, a SNP is then selected as a proxy to represent the set of correlated markers. 
 In the current analysis, SNP markers that were selected by the LASSO and HLASSO 
were identified as the proxies. Interpretation was then based on the number of times each 
SNP group was selected, i.e. not on the selection of individual SNPs.  
 Among a thousand Bootstrap models, the LASSO identified 506 unique markers 
belonging to 268 groups at r
2
 ≥ 0.9 and the HLASSO identified 728 markers belonging to 
391 groups at r
2
 ≥ 0.9. The Bootstrap results are presented in Table 6.8 and Table 6.9 for the 
LASSO and HLASSO logistic regression, respectively. The SNP markers that were selected 
in the penalised models derived from the raw data were consistently ranked among the first 
selected variables. These results were enhanced when groups of correlated SNPs were taken 
into account instead of a unique SNP, suggesting that the penalised variable selection 
approaches were consistent in terms of LD group selected. Both the LASSO and HLASSO 
logistic models most often retained SNP markers in HLA-DPB1, which was selected 80% and 
73% of the time by the LASSO and HLASSO followed by SNPs in MICA ( 58% by the 
LASSO and 35% by the HLASSO) and TRIM26 (33% by the LASSO and 23% by the 
HLASSO) as the genetic regions of interest.  
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Table 6.8 Boostrap results of the five SNPs selected by the LASSO logistic regression 
Marker 
dbSNP127 
Gene (location) Genotyped in 
Bootstrap 
SNP
1
(rank) SNP/proxy
2
(rank) 
rs9277553 
HLA-DPB1 
(intron) 
HapMap 249 (3
rd
) 801 (1
st
) 
 
rs3132472 
MICA 
(3‟UTR) 
HapMap - GoRA 581 (1
st
) 581 (2
nd
) 
rs3132671 
TRIM26 
(intron) 
HapMap - GoRA - WTCCC 125 (6
th
) 327 (3
rd
) 
rs3117225 
HLA-DPB1 
(Intron) 
HapMap 455 (2
nd
) 581 (1
st
)* 
rs3094139 
TRIM26 
(Intron) 
HapMap 188 (5
th
) 327 (3
rd) † 
 
 
 
 
 
 
Table 6.9 Boostrap results of the three SNPs selected by the HLASSO logistic regression 
Marker 
dbSNP127 
Gene (location) Genotyped in Bootstrap 
SNP
2
 
(rank) 
SNP/Proxy
3
 (rank) 
rs3117225 HLA-DPB1 (intron) HapMap 170 (4
th
) 732 (1
st
) 
rs3132472 MICA (3‟UTR) HapMap-GoRA 348 (1st) 348 (2nd) 
rs3132671 TRIM26 (intron) HapMap-GoRA-WTCCC 44 (18
th
) 233 (5
th
) 
 
  
 
  
 Meinshausen and Buhlman [145] introduced Stability Selection to improve penalised 
regression approaches such as LASSO. Stability Selection uses sub-sampling in combination 
with variable selection algorithms. When applied in combination with LASSO this method is 
less sensitive to the penalty parameters and can be used to assess the stability of the retained 
predictors [145].  
 Stability Selection was applied with HLASSO to the combined GoRA/WTCCC study. 
A thousand random sub-samples containing 50% of the cases and 50% controls were drawn 
without replacement from the original dataset. HLASSO was next applied to the sub-datasets 
containing 1,339 cases and 1,498 controls. The number of times a variable was retained in a 
thousand models was used to identify the relevant variables. As with Bootstrap, SNPs with r
2
 
≥ 0.90 were grouped together using the pair-wise tagging algorithm in Haploview [144] and 
1
Frequency and rank of the selected SNP among 1,000 bootstrap models 
2
Frequency and rank of the SNP proxy that was used to tag the LASSO SNPs (r
2≥0.9); the count 
was recorded when pairs of correlated SNPs were selected in different models. 
*markers rs3117225 and rs9277553 were in LD at r
2≥0.9; rs9277553 was used as a proxy. 
†markers rs3094139 and rs3132472 were in LD at r2≥0.9; rs3132472 was used as a proxy. 
 
1
Frequency and rank of the selected SNP among 1000 bootstrap models 
2
Frequency and rank of the SNP proxy that was used to tag the HLASSO SNPs (r
2≥0.9); the 
count was recorded when pairs of correlated SNPs were selected in different models. 
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these groups were treated as a single SNP for frequency counts. HLASSO results were 
assessed for shape parameters λH of 0.5, 1 and 2, and scale parameters γ of 0.0075, 0.01 and 
0.025; only the SE, *0101, sex and study were retained with γ ≤ 0.0075.  Table 6.10 presents 
these results. 
 The number of SNP markers that were selected varied with the values of the prior 
shape and scale parameters. Stability selection in combination with HLASSO is more 
sensitive to the values of the prior penalty parameters than with LASSO as shown in 
Meinshausen and Buhlman [145]. As shape parameter λH increases, less SNPs are selected for 
a fixed value of the scale parameter γ. For small value of λH, the density is more L shaped 
with a sharp peak at zero, flat tails and a transition point close to the origin (cf. Chapter 5, 
Figure 5.7). SNPs with small effect sizes can be retained in the model if they lie just beyond 
the transition point of the NEG density function. The same SNPs will be set to zero and 
rejected from the final model as the shape parameter increases if they are in a region of 
higher curvature and close to the origin.  Eventually, more SNPs would be selected for large 
values of λH because additional SNPs are selected to account for the effects of the markers 
that are shrunk too severely (cf. Chapter 5, Table 5.10).  HLASSO models with a prior shape 
parameter λH of 1 and γ of 0.025 were used in this assessment as an example.  
 
 
Table 6.10 Number ofSNPs that are selected on average among 1000 
subsamples for λH = 0.5, 1 and 2 and γ = 0.0075, 0.01 and 0.025 
 Shape parameter λH 
Scale parameter γ 0.5 1 2 
0.0075 0
*
 0
*
 0
*
 
0.01 1 0
*
 0
*
 
0.025 18 9 3 
*
only the SE, *0101, sex and study were retained  
 
 
 Stability Selection and Bootstrap behaved similarity, apart for SNP rs3132472 in 
MICA. The sub-sampling simulations confirmed that markers in HLA-DPB1 remain the most 
often selected genetic regions under perturbations of the dataset with 80% of replicates 
(Table 6.11).  As with bootstrap, reproducibility was inconclusive for the TRIM26 SNP 
rs3132671 with 24% of replicates. Reproducibility was worse for the MICA SNP rs3132472 
(8%) compared to Bootstrapping (35%), which was the second most selected association in a 
 135 
 
thousand bootstrap models. This SNP had also the lowest single-SNP association P-value 
after adjusting for the effect of SE, *0101, sex and study (P = 6.5x10
-16
). Interestingly, SNP 
rs2517524 in HCG22, which is the third most often retained marker by Stability Selection, 
lies very close to SNP 3132472 in MICA.  
 Hoggart et al. [88] found in simulations that the number of SNPs included in the 
model selected by HLASSO reflects the number of distinct associations.  Although results 
from Boostrapping and sub-sampling are different, they both illustrate that HLASSO logistic 
regression can be used to tag true causal variants and disentangle complex patterns of 
association in regions of high LD.  
 
 
Table 6.11 Stability selection results for SNPs selected by the HLASSO logistic 
regression (in bold) and for group of correlated SNPs selected more than 20% of the 
time   
Marker 
dbSNP127 
Gene (location) Map position (bp) Subsamples 
SNP
2
 
(rank) 
SNP/Proxy
3
 
(rank) 
rs3117225 HLA-DPB1 (intron) 33165689 3 (72
nd
) 782 (1
st
) 
rs6933763 
rs2517524 
LOC650557 (intron)
*
 
HCG22 (3‟UTR) 
32830830 
31133692 
565 (1
st
) 
281 (2
nd
)  
565 (2
st
) 
281 (3
rd
) 
rs3132671 TRIM26 (intron) 30286266 215 (4
th
) 236 (4
th
) 
rs3132472 MICA (3’UTR) 31494110 83 (18th) 83 (21st) 
 
 
6.4.4.2 Model prediction using cross-validation  
 
 
 Ten-fold cross-validation (CV) [70] was used to compare the performance of LASSO 
and HLASSO logistic regression at predicting disease status. The combined GoRA and 
WTCCC dataset was used to specify ten training sub-datasets containing 90% of the data and 
ten test sub-datasets containing the remaining 10%. Cases and controls from the GoRA and 
WTCCC were well-balanced among the training and test samples. The LASSO and HLASSO 
logistic regressions were performed on each of the training samples. The LASSO and 
HLASSO parameter estimates being biased towards zero, they were replaced by the un-
shrunk regression coefficients of the selected variables, obtained from a multi-SNP logistic 
model, in order to assess the prediction error of the fitted models in the test samples. The true 
positive rate (TPR) and false positive rate (FPR) were calculated within each test dataset. The 
averaged receiver operating characteristics (ROC) [146] curve across the 10 trials was used to 
1
Frequency and rank of the selected SNP among 1,000 subsample models 
2
Frequency and rank of the SNP proxy that was used to tag the HLASSO SNPs (r
2≥0.9); the 
count was recorded when pairs of correlated SNPs were selected in different models. 
*
Assigned to an unknown gene. 
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assess the predictive power of the penalised logistic approaches by displaying TPR as a 
function of FPR. Figure 6.8 (a) displays the ROC curves of the LASSO and HLASSO 
models, and a reduced model that includes the number of SE+ and *0101 allele copies, sex 
and study. The area under the average ROC curves were similar among the models: 80%, 
80% and 79% for the LASSO, HLASSO and the reduced model, respectively. Table 6.12 
presents the TPR values at different FPR thresholds. It is noteworthy that the predictive 
performance of both the LASSO and HLASSO models was not highly different from a model 
that included only the effect of the HLA-DRB1 alleles. It has been shown in the literature that 
although there is evidence of RA risk factors that are independent of the well-known SE 
effect, their risks contribute far less than the effect of the HLA-DRB1 SE alleles [29]. It is 
hence not surprising that the additional non-DRB1 SNPs improved the predictive 
performance of the LASSO and HLASSO models by a small amount. In terms of SNP-
selection, the 10 predictive models selected the three markers that were retained in the initial 
analyses most of the time: rs3132472 in MICA was selected in every model; rs3117225 in 
HLA-DPB1 was selected seven times out of ten; rs3132671 was only selected twice but two 
further predictive models included rs9277553 instead, which was highly correlated with 
rs3117225 (r
2 
= 0.99). 
 Large values of the penalty factors have been used to achieve variable selection, 
where the objective is to limit the number of false possible results. However, if prediction is 
the main interest, less stringent values of the prior penalty factors should be considered in 
order to increase the performance of the model by including more positive results. It may 
then be acceptable for the model to include some false positive results provided that the 
coefficients of those variables are small. A thorough exploration of prediction would require 
investigating also changes in the prior shape parameter. Since model selection is the main 
focus of this thesis, only a succinct exploration of prediction is presented. 
 HLASSO and LASSO logistic regressions were performed with prior penalty 
parameters λL = 62, λH = 1 and γ = 0.026. On averaged, 28 and 52 SNP markers were selected 
with these prior penalty settings by HLASSO and LASSO, respectively. The area under the 
average ROC curves improved slightly: 84% for the LASSO and 82% for HLASSO (Figure 
6.8 (b)). In Table 6.12, the LASSO seems to outperform HLASSO since many more SNP 
markers, which are likely to be in LD, were retained in the models, improving the measure of 
the prediction performance. These results suggest that careful choice of the prior penalty 
factors should be assessed when the main interest is in prediction.  
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Figure 6.8 ROC curves showing the averaged performance for predicting RA of the 
LASSO and HLASSO models compared to a reduced model that included the SE, 
*0101, the sex and the study considering penalised models with (a) λL = 180, λH = 1 and γ 
= 0.008 for variable selection and with (b) λL = 62, λH = 1 and γ = 0.026 for model 
prediction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.12 TPR and FPR for HLASSO, LASSO and reduced models with prior penalty 
parameters fixed for variable selection and prediction  
 
Variable Selection 
λL = 180, λH = 1 and γ = 0.008 
Prediction 
λL = 62, λH = 1 and γ = 0.026 TPR 
Reduced model 
FPR 
TPR  
HLASSO 
TPR  
LASSO 
TPR 
HLASSO 
TPR  
LASSO 
5% 37% 36% 40% 45% 35% 
10% 49% 49% 53% 57% 47% 
20% 64% 64% 67% 71% 62% 
50% 88% 88% 89% 91% 87% 
 
 
ROC curves showing TPR (sensitivity) on the y-axis and FPR (1-specificity) on the x-axis for 
predicting case/control status in the combined WTCCC-GoRA study. Each line is the average 
ROC of the 10 models fitted during CV. The solid and dashed curves show the performance of 
the HLASSO and LASSO SNP selection models. The dotted line shows the performance of the 
reduced model that includes the SE, *0101, sex and study. The AUC of the solid, dashed and 
dotted ROC curve is 80%, 80% and 79%, respectively in (a) and 82%, 84% and 79% in (b). 
 
  
(a) (b) 
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6.4.5 Can the HLASSO identify the same associations when the effect at HLA-DRB1 is 
shrunk? 
 
As most association studies are hypothesis-generating, it is of interest to know 
whether the HLASSO logistic regression is able to identify the same genetic signals when the 
penalty factors are also applied to the SE and HLA-DRB1*0101. Table 6.13 presents the four 
SNP markers that were retained. Interestingly, HLA-DRB1*0101, which showed no LD with 
any of these four SNPs (r
2
 < 0.10) (Table 6.15), was not selected in the final model. SNP 
rs2395185, which was not significant in the single-SNP association analysis (P > 0.05), lies 
close to HLA-DRB1 and shows some LD with the SE (r
2
= 0.24,Table 6.14). This marker 
might have been selected to account for some of the SE risk effect. There was however no 
LD among the four selected markers.  
 Overall, the HLASSO identified positive signals within the same genetic regions that 
were reported when no shrinkage was applied on the SE and *0101, i.e. HLA-DPB1, TRIM26 
and MICA. Marker rs3117228 in HLA-DPB1 is in complete LD with marker rs3117225 also 
in HLA-DPB1, which was previously selected (r
2
 = 1, Table 6.15). Marker rs3132668, which 
is not allocated to a gene, is in high LD with marker rs3132671 in TRIM26, which was also 
previously retained by the HLASSO logistic model (r
2
 = 0.99, Table 6.15) and rs3132472 in 
MICA is the same marker that was previously reported.  
 These results suggest that the HLASSO logistic regression can select a set of 
independent markers even when a penalty factor is also applied to a marker with a large 
effect size such as the SE, which is an improvement over the LASSO logistic regression 
(Chapter 5).  
 
 
Table 6.13 SNPs selected by the HLASSO logistic regression 
Marker 
dbSNP127 
Gene (location) P
1
 MAF R 
2
MACH Genotyped in 
rs2395185 * 0.291 0.42 0.99 HapMap-GoRA 
rs3117228 HLA-DPB1(intron) 3.2x10
-9
 0.28 1 HapMap-GoRA 
rs3132472 MICA (3‟UTR) 6.4x10-16 0.22 0.99 HapMap-GoRA 
rs3132668 * 1.4x10
-9
 0.50 1 HapMap-GoRA 
 
 
 
 
 
 
*region with no gene assignment 
1
Single-SNP association P-value after adjustment for the effect of the number of SE+ allele 
copies, the number of HLA-DRB1*0101 allele copies, the sex and the study. 
 139 
 
 
Table 6.14 r
2
 values between the SNPs retained by the HLASSO 
 logistic regression with penalty applied on the SE and *0101 
 rs3132668 rs3132472 rs2395185 SE rs3117228 
rs3132668 1 0.1 * * * 
rs3132472  1 0.05 0.03 * 
rs2395185   1 0.24 * 
SE    1 * 
rs3117228     1 
         *r2 < 0.01 
 
 
 
Table 6.15 r
2
 values between the SNPs retained by the HLASSO  
logistic regression with penalty applied on the SE and *0101  
(columns) and those with no penalty (rows) 
 rs3132668 rs3132472 rs2395185 rs3117228 
rs3132671 0.99 0.09 * * 
rs3132472 0.10 1 0.05 * 
rs3117225 * * * 0.97 
*0101 * * 0.09 * 
                            *r
2
 < 0.01 
 
 
 
 
6.5 Replication Study: The NARAC case-control study   
 
6.5.1 The SE association 
 
 The NARAC case-control study [99], which contains 863 cases and 1,181 controls, 
was used as a replication study. The NARAC dataset cannot be exactly considered as a 
replication study since the RA patients were all anti-CCP+ whereas the GoRA and WTCCC 
included also anti-CCP- cases. The GoRA study included mostly anti-CCP+ subjects 
(85.4%), but no information about the anti-CCP status of the WTCCC RA cases was 
provided. For this reason, the results have to be interpreted with care. High-resolution typing 
(4-digit) was used to define the HLA-DRB1 alleles as SE+ and SE-. HLA-DRB1*0101 was re-
coded to indicate the number of allele copies a subject was carrying. Table 6.16 and Table 
6.17 present the distribution of the number of SE+ and HLA-DRB1*0101 allele copies.  
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Table 6.16 Distribution of the SE in the NARAC study 
 Cases Controls N 
0 SE copy 190 (22%) 794 (67%) 984 
1 SE copy 389 (45%) 342 (29%) 731 
2 SE copies 215 (25%) 38 (3%) 253 
missing 69 (8%) 7 (1%) 76 
N 863 1181 2044 
 
 
 
 
 
Table 6.17 Distribution of *0101 in the NARAC study 
 Cases Controls N 
0 *0101 copy 707 (82%) 1128 (95%) 984 
1 *0101 copy 85 (10%) 40 (3%) 731 
2 *0101 copies 2 (<1%) 6 (1%) 253 
missing 69 (8%) 7 (1%) 76 
N 863 1181 2044 
 
  
 
 As expected the majority of the cases were SE+ and the majority of the controls were 
SE-. There was however fewer RA cases with at least one copy of the SE+ (70%) compared 
to the GoRA study (82%). HLA-DRB1*0101 was also less frequent in the NARAC study: 
10% of the NARAC cases carried at least one copy of *0101 compared to 14% for the GoRA 
cases. The amount of missing genotypes at HLA-DRB1 was also greater among the NARAC 
cases (8%) compared to the NARAC controls (<1%).  
 In order to increase the coverage of the SE and HLA-DRB1*0101 in the NARAC 
study, the SE and *0101 indicator variables were imputed from the HapMap (60 CEU 
parents) using MACH [115]. SNP markers that were retained by the HLASSO model were 
also included in the combined analysis of the GoRA and WTCCC study, i.e. rs3117225, 
rs3132472 and rs3132671, in order to assess whether the same SNP markers were selected by 
HLASSO logistic regression.  
 Table 6.18 displays the OR estimates for the SE and HLA-DRB1*0101, whom missing 
values had been imputed. Both variables were well imputed as shown with the MACH 
estimated R
2
MACH values of 0.98 for the SE+ and 0.97 for *0101.  
 Both the SE and *0101 were highly associated with RA on their own with P = 
1.30x10
-84
 and P = 2.03x10
-7
, respectively. As in the GoRA and the combined WTCCC-
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GoRA study, HLA-DRB1*0101 has a different effect from the number of SE+ allele copies. 
Interestingly, when the SE and *0101 were included in the same model, the effect of HLA-
DRB1*0101 disappeared (P > 0.05). It was noted that high resolution typing was available 
mainly for the subjects with the HLA-DRB1*04 type. This might have contributed to the 
presence of a selection effect, which resulted in the recruitment of mostly HLA-DRB1*04 
samples. In the NARAC dataset, 44% of the cases and 14% of the controls carried at least 
one SE+ HLA-DRB1*04 allele, i.e. *0401, *0404, *0405 or *0408, compared to 6% of the 
cases and 2% of the controls with *0101. In the GoRA study, the distribution of the SE+ 
HLA-DRB1*04 allele was similar to the NARAC study: 40% of the GoRA cases and 15% of 
the GoRA controls carried at least one SE+ HLA-DRB1*04. The HLA-DRB1*0101 was 
however more frequent in both the GoRA cases and controls than among the NARAC cases 
and controls: 15% of the GoRA cases and 11% of the GoRA controls.  
  
 
Table 6.18 OR estimates of the SE and *0101 in the NARAC imputed study 
 R
2
MACH P OR (95%CI) 
univariate effect 
SE+ 
 
0.98 
 
1.3x10
-84
 
 
4.9 (4.2; 5.8) 
univariate effect  
*0101 
 
0.97 
 
2.0x10
-7
 
 
2.5 (1.8; 3.5) 
multivariate effects 
SE+ 
*0101 
 
 
 
5.9x10
-81 
0.090 
 
5.2 (4.4; 6.1) 
0.7 (0.5; 1.1) 
 
 
 
6.5.2 HLASSO logistic regression analysis of the NARAC study 
 
 The number of SE+ and *0101 allele copies were included in the HLASSO logistic 
model in order to stay as close as possible with the previous logistic penalised models. As 
with the combined GoRA and WTCCC analysis, uncertainty in imputation was accounted for 
in the regression analysis by using the expected number of SE+ and *0101 alleles. HLASSO 
logistic regression was applied to 1,625 SNP markers from the HLA region using a prior 
shape parameter λH of 1. The scale parameter γ was selected as a function of the shape 
parameter λH and the LASSO penalty factor λL of 60 to give on average one false positive 
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result (Chapter 5). As before, Gaussian priors with large variance were applied to the SE and 
to HLA-DRB1*0101, in order to give weak constraint to these parameters.  
 Table 6.19 displays the eleven SNP markers that were retained in the final model in 
addition to the SE and *0101. Among these associations, rs3117225 in HLA-DPB1, which 
was fully imputed in the NARAC study, was retained in the HLASSO model. The result 
provides convincing evidence that SNPs near or within HLA-DPB1 might be associated with 
RA susceptibility and more specifically with the anti-CCP+ type of RA. The other SNP 
markers tabulated were not selected in the combined analysis of the WTCCC and GoRA 
study.  
 
 
Table 6.19 Markers selected by the HLASSO logistic regression 
Marker 
dbSNP127 
Gene (location) 
Position 
(kb) 
MAF 
Multivariate Logistic 
Model 
P OR (95%CI) 
rs259937 C6orf2 (intron) 30115472 0.05 1.6x10
-4
 2.0 (1.4; 2.9) 
rs3778638 PSORS1C1 (intron) 31200103 0.20 1.6x10
-7
 0.6 (0.4; 0.7) 
rs2256175 LOC100129668 (intron) 31488428 0.44 2.1x10
-4
 0.7 (0.6; 0.8) 
rs2244839 BAT1 (intron) 31546347 0.24 2.5x10
-3
 0.7 (0.6; 0.9) 
rs10484560 C6orf10 (intron) 32406115 0.10 2.2x10
-5
 1.9 (1.4; 2.6) 
rs2395175 - 32513004 0.29 6.0x10
-12
 3.1 (2.2; 4.2) 
SE HLA-DRB1 32595661 0.32 0.019 1.4 (1.1; 1.8) 
*0101 HLA-DRB1 32595661 0.04 0.273 1.3 (0.8; 2.2) 
rs660895 - 32685358 0.33 3.5x10
-12
 3.2 (2.3; 4.5) 
rs10484561 LOC650557 (intron) 32773398 0.16 4.6x10
-21
 3.6 (2.8; 4.7) 
rs3117225 HLA-DPB1 (intron) 33165689 0.26 3.0x10
-8
 0.5 (0.4; 0.6 
 
 
 In an exploratory analysis, the eleven markers were analysed jointly in a multi-SNP 
logistic regression analysis in order to assess the strength of these effects (Table 6.19). 
Among them, eight SNP markers were significant at P < 6x10
-4
 (1/1,627). Surprisingly, the 
SE and *0101 were not significant in this model. Based on earlier results, the multi-SNP 
association was repeated omitting *0101 and as expected, the SE effect became apparent (P = 
7.2x10
-4
, OR = 1.5, 95%CI = (1.2; 1.9)). 
 In order to assess the degree of correlation among these associations, pairwise r
2
 
values were calculated for the eleven markers (Table 6.20). Two markers, rs2395175 and 
rs660895, which lie very close and on each side of HLA-DRB1, were highly correlated (r
2
 = 
0.72). These two markers were also in moderate LD with the SE with r
2
 = 0.49 for rs660895 
and r
2
 = 0.46 for rs2395175. The SE+/SE- binary classification in the NARAC study, which 
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contained mostly HLA-DRB1*04 alleles, might not have captured entirely the effect at HLA-
DRB1. SNP markers might have been retained due to LD with other HLA-DRB1 alleles.  
 In order to assess LD with the additional two SNP markers, which were identified in 
the combined analysis of the GoRA and WTCCC samples, rs3132472 in MICA and 
rs3132671 in TRIM26, LD between these two markers and the eleven markers selected was 
calculated (Table 6.21). Marker rs3132472 in MICA is in moderate LD with marker 
rs2256175 (r
2
 = 0.31). These two markers, which lie within ~5.6kb from each other in the 
class I HLA region might account for the genetic signal in MICA/BAT1. No association was 
found with SNP markers in TRIM26 and RA in contrast to the combined WTCCC and GoRA 
study. 
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Table 6.20 r
2
 between the eleven SNPs selected by the HLASSO logistic regression in the NARAC study ordered by map position 
 rs259937 rs3778638 rs2256175 rs2244839 rs10484560 rs2395175 SE *0101 rs660895 rs10484561 rs3117225 
rs259937 1 * 0.01 * * * * * * * * 
rs3778638  1 * * * * * * * * * 
rs2256175   1 0.11 * 0.05 0.02 * 0.03 0.01 * 
rs2244839    1 * 0.01 * * * * * 
rs10484560     1 0.03 * 0.09 0.01 0.25 * 
rs2395175      1 0.46 * 0.72 0.06 * 
SE       1 0.1 0.49 * * 
*0101        1 * 0.15 * 
rs660895         1 0.07 * 
rs10484561          1 * 
rs3117225           1 
 
 
Table 6.21 r
2
 between the eleven SNPs selected by the HLASSO logistic regression in the NARAC 
and the three SNP markers that were associated in the combined GoRA and WTCCC study 
 rs3117225 rs3132472 rs3132671 
rs259937 * * * 
rs3778638 * 0.09 * 
rs2256175 * 0.31 0.03 
rs2244839 * 0.13 0.03 
rs10484560 * * * 
rs2395175 * 0.01 0.02 
SE * * * 
*0101 * * * 
rs660895 * * 0.02 
rs10484561 * * * 
rs3117225 1 * * 
      *r2 < 0.01. Markers are ordered by map position. 
*r
2
 < 0.01.  
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6.6 Discussion  
 
 LASSO logistic regression selected five SNPs associated with RA. Among them, 
three markers were also retained by the HLASSO penalised model: rs3117225 in HLA-DPB1, 
rs3132472 in MICA and rs3132671 in TRIM26. The two SNP markers that were selected only 
by the LASSO, rs304139 in TRIM26 and rs9277553 in HLA-DPB1, were in high LD (r
2 
= 
0.99) with markers rs3132671 in TRIM26 and rs3117225 in HLA-DPB1, respectively. These 
results suggest that the HLASSO approach can identify independent associations in SNP 
dense region such as the HLA complex, which is characterised by the presence of LD.  
 Markers in HLA-DPB1, MICA and TRIM26 were consistently selected among a 
thousand bootstrap models. When correlation among markers was taken into account, genetic 
signals in HLA-DPB1 were retained 80% and 73% of the time by the LASSO and HLASSO 
logistic regressions, respectively. Markers in MICA were selected 58% and 35% of the time 
and markers in TRIM26 were selected 33% by the LASSO and 23% of the time by the 
HLASSO. 
 In order to investigate whether the observed associations were due to LD with alleles 
at HLA-DRB1, pair-wise r
2
 values were calculated for the SNP markers selected by the 
LASSO and HLASSO and the alleles at HLA-DRB1 using the GoRA and WTCCC controls. 
Table 6.22 presents the r
2
 values between alleles at HLA-DRB1 with frequency > 2% in 
controls and the five SNPs. Interestingly, it emerged that rs3132472 was in LD with HLA-
DRB1*0301 (r
2 
= 0.50), which was the most common SE- allele in the GoRA study. The 
assessment presented in Chapter 4 revealed that association with that *0301 was well 
accounted for by the SE+/SE- classification in the GoRA study. Unfortunately, this 
association could not be assessed in the combined GoRA and WTCCC data since the 4-digit 
HLA typing was only available for some of the WTCCC control samples. Although MICA 
has been reported as having a DRB1-independent association with RA in a Spanish family-
based study [147], the association involving rs3132472 might have arisen through the indirect 
effect of HLA-DRB1*0301 in the combined GoRA and WTCCC study.  
 The association involving SNPs in TRIM26 is also intriguing. Although no genetic 
association has been reported between markers in TRIM26 and RA, there is biological 
evidence that genes from the TRIM family might be involved in autoimmune diseases. This 
class of genes have protein-degrading functions that are involved in normal cell growth and 
immune functions [119, 148]. Furthermore, there was no LD between the selected markers 
and alleles at HLA-DRB1 in the GoRA study.  
 146 
 
 
 
 Table 6.22 r
2 
values between the SNPs selected by the LASSO and  
HLASSO logistic regression and the HLA-DRB1 alleles 
1 
DRB1 alleles
 
SNP selected by LASSO and HLASSO 
rs3132671 rs3094139 rs3132472 rs9277553 rs3117225 
*0101 0.01 * * * * 
*0103 * * * * * 
*0301 0.05 0.06 0.51 0.01 0.01 
*0401 * * 0.02 * * 
*0403 * * * * * 
*0404 * * * * * 
*0701 * * 0.02 * * 
*0801 * * * * * 
*0901 * * * * * 
*1101 * * * * * 
*1201 * * * * * 
*1301 * * * * * 
*1302 * * * * * 
*1401 * * * * * 
*1501 * * 0.01 0.01 0.01 
  
 
 
 In contrast to TRIM26 and MICA, the association of RA with rs3117225 in HLA-
DPB1 was replicated in the NARAC study. It is noted that the NARAC study included only 
anti-CCP+ RA patients. These antibodies are found in the sera of most patients with RA; de 
Vries et al. [148] reported that anti-CCP+ patients represent about 2/3 of the RA patients in 
an average population. The GoRA study included mostly anti-CCP+ RA patients (85%) but 
no information was given with regard to the WTCCC RA cases.  
 Although, subjects from the NARAC study were different from the GoRA and 
WTCCC studies, they expected to show similar genetic association because anti-CCP+ is 
thought to be induced by RA. It has been shown in mice model that anti-CCP+ might 
influence the progression of RA rather than inducing the disease [149]. The infusion of anti-
CCP+ into animals with RA led to an exacerbation of the disease whereas a reduction of anti-
CCP+ levels was associated with a less severe form of RA, suggesting that the presence of 
anti-CCP+ was linked with RA severity rather than RA susceptibility. In addition, none of the 
alleles at HLA-DRB1 was correlated with this marker in the GoRA controls (Table 6.22). In 
1
 HLA-DRB1 alleles with frequency > 2% in the GoRA controls 
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summary, there is convincing evidence of the presence of a causal locus in HLA-DPB1 
beyond the effect of HLA-DRB1, which might contribute to the risk of RA.  
 The current analysis of the combined WTCCC and GoRA study is the first large-scale 
analysis of SNP markers from the HLA region where genetic imputation has been used to 
combine samples from different platforms. Imputation-based approaches use LD between 
markers to infer genotypes at missing loci, making them less accurate in regions of low LD. 
In an exploratory analysis, 5% of the genotypes were hidden in order to assess the robustness 
of the imputation process. The results showed that less than 1% of the markers were poorly 
imputed. The presence of long segments of LD (Chapter 1) in the HLA region may have 
improved the performance of the genotype imputation. 
 The precision of the imputed data may be disputed if the samples are not well-
matched between studies. In the current analysis, all subjects were of European ancestry and 
recruited in the UK. The RA cases were recruited using the same inclusion criteria in both 
studies. The Devlin & Roeder genomic control approach [101] showed modest evidence of 
population substructure among the combined WTCCC and GoRA samples. Furthermore, the 
effect of study was included as covariate in the regression analyses in order to account for the 
potential effect of ascertainment bias.  
 It is important to take into account the uncertainty of the imputed data. There is no 
consensus on the best approach to follow. de Bakker et al. [143] suggested that one should 
minimize the effects of imputation error by restricting the analysis to SNP markers that are at 
least genotyped in one platform. This would defeat the purpose of this analysis, which is to 
increase the genetic coverage of the HLA region by including SNP markers from HapMap. 
They also proposed the removal of SNP markers that were estimated to have poor imputation 
performance, using for instance the estimated R
2
MACH and this approach was taken here. A 
more stringent threshold than the recommended value by Li et al. [115] (R
2
MACH
 
> 0.3) was 
applied since most of the markers from the HLA region were imputed from the HapMap 
samples. In addition, an allele score based on the estimated imputation probabilities of each 
genotype was constructed in order to take into account the uncertainty of the imputation in 
the regression model. Care was thus taken to ensure that the LASSO and HLASSO 
associations were not caused by an artefact of the imputation process.  
 The findings from this analysis show that the LASSO and HLASSO logistic 
regression approaches provide a substantial benefit, both in terms of detecting several causal 
variants simultaneously and in the reduction of false positive associations and associations 
solely due to LD with other associated loci. Furthermore, by using bootstrapping, HLASSO 
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can infer the number of causal loci. Traditionally, bootstrapping has been used for asymptotic 
inference of standard errors and confidence intervals. In this experiment, 1,000 bootstrap 
models were used to assess the consistency in SNP selection, i.e. the number of times each 
SNP marker was selected. The present assessment revealed that the HLASSO performed 
consistently in identifying markers that carry the same genetic information. There is hence 
convincing evidence that a locus in HLA-DPB1 might play an important role in RA 
susceptibility. Further large-scale analyses are required to elucidate the complex relationship 
between HLA-DPB1, anti-CCP+ and RA. The results from the 10-fold cross-validation 
suggest however that these associations contribute far less than the effect of the HLA-DRB1 
in predicting disease in individuals. 
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Chapter 7. Conclusions and Further Work 
 
 
 
 
7.1 Summary of the findings  
 
 Many autoimmune and inflammatory diseases have been associated with 
markers from the HLA region. However, because of the presence of LD and the high 
degree of polymorphism, the true underlying determinants of HLA-driven diseases 
remain unknown. Multi-SNP association methods using penalised logistic regression 
via the LASSO can assist genetic epidemiologists in locating disease-associated loci 
from the HLA region and in turn help to disentangle the genetic basis of complex 
human diseases. In this thesis, the objective was to identify risk loci from the HLA 
region associated with RA in addition to the effect of the well-known HLA-DRB1 
association.  
 Single-SNP and multi-SNP regression methods were applied to data from the 
GoRA study, which included approximately 1,000 cases and 1,000 controls using 
2,302 SNPs spanning the HLA region, together with genotypes from HLA-DRB1. 
Genotype imputation was also used as a means to jointly analyse the WTCCC and 
GoRA studies, which together comprised 6,575 subjects and 6,182 part-imputed SNPs 
from the HLA region. The NARAC study, which included 863 cases and 1,181 
controls, was used to evaluate these findings. 
 This analysis confirmed the well-known association of the SE with RA in both 
the GoRA and the WTCCC studies. The effect of HLA-DRB1 on RA is complex, as a 
number of authors have pointed out [36, 46, 105-107, 148]. The picture is 
complicated by the different strengths of association conferred by different SE alleles 
[41]. In Chapter 3, the inclusion of the number of risk allele copies at HLA-
DRB1*0101 improved the model of association with RA over the usual model, which 
only includes the number of SE+ allele copies. This improvement was observed in 
both the GoRA and the WTCCC datasets. The number of HLA-DRB1*0101 and SE+ 
allele copies were hence included in the regression models to account for the effect of 
HLA-DRB1. The effect of HLA-DRB1*0101 was however not different from the other 
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SE+ alleles in the NARAC study, probably due to the over-representation of HLA-
DRB1*04 alleles compared to *0101 alleles among the cases and controls.  
 Inference using single-SNP analysis identified a large number of associations 
in the GoRA study, even after adjustment for the effect of the number of SE+ and 
*0101 allele copies (Chapter 4). The number of true causal variants underlying these 
signals is very likely to be much less than the number of positive associations. 
Stepwise logistic regression was attempted but failed due to numerical and 
computational issues. The stepwise procedures could not find an optimal model 
because of the presence of a large number of correlated predictors. Instead, backward 
stepwise logistic regression was applied to the set of markers that were singly 
significant either in the non-adjusted or in the adjusted single-SNP analyses. Although 
these stepwise approaches are unstable in the presence of multicollinearity as is the 
case here, two markers stand out: rs2442728, which is upstream of HLA-B and 
rs4678, which encodes a non-synonymous change in VARS2; both SNPs are located in 
the class I HLA region. 
 Alternatively, the LASSO was applied as a variable selection approach for 
multi-SNP association analysis of a case-control study. With the LASSO, estimation 
of the parameters is performed while applying a penalty that either shrinks the 
regression coefficients or sets them to zero. This is equivalent to applying a DE prior 
distribution to the coefficients, with a mode at zero corresponding to the prior belief 
that the effect sizes of most of the markers are close to zero [73]. Parameter inference 
is based on the posterior mode, with non-zero values indicating marker-disease 
associations. A generalisation of the LASSO called HLASSO, which uses the NEG 
prior distribution in place of the DE, was also investigated. The NEG distribution has 
a sharper peak and flatter tails compared to the DE (Chapter 5). 
 LASSO logistic regression was first assessed by applying the same amount of 
shrinkage to the SNP markers and the SE+ and *0101 allele counts. The LASSO 
logistic regression identified fewer positive results than the standard and commonly-
used single-SNP analysis in the GoRA study. At first sight, it seemed that LD was 
better handled by this method but these results showed that the DE prior did not 
account entirely for the strong effect of the SE as three SNP markers in LD with the 
SE were selected. Although the number of SE+ allele copies was included in the 
model, the posterior mode was shrunk too severely by the penalty factor, causing 
SNPs with no effects and in LD with the SE to be selected. When the DE prior was 
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not applied on the SE and *0101, the LASSO selected six SNPs that were 
independent of the SE and *0101 effect. Among these markers were the three markers 
that were identified in the single-SNP association analyses (Chapter 4): rs4678 in 
VARS2, rs2442728 in HLA-B and rs1592409, which is upstream of an unknown gene. 
Interestingly, these markers exhibited inter-correlation. 
 When the NEG prior distribution was used, the regression coefficients of the 
selected parameters were less shrunk, preventing SNPs with zero effect from being 
selected merely due to LD. HLASSO logistic regression identified fewer positive 
results than LASSO. Four SNP markers were selected in addition to the SE and HLA-
DRB1*0101 in the GoRA study. Surprisingly, the three SNP markers stated above, 
rs4678, rs244278 and rs1592409, were also retained in the HLASSO logistic model. 
In addition, the model retained rs3130188, which is located upstream of HLA-DPB1. 
These SNPs were not correlated with each other, in contrast to those that were 
retained by LASSO logistic regression.  
 The LASSO and HLASSO were next applied to the combined GoRA and 
WTCCC study (Chapter 6). The results from HLASSO logistic regression were 
sparser but similar to the LASSO, i.e. SNPs within the same gene region were 
identified: HLA-DPB1 (rs3117225), MICA (rs3132472) and TRIM26 (rs3132671). 
The LASSO logistic regression included two additional SNPs also in HLA-DPB1 
(rs9277553) and TRIM26 (rs3094139) that showed LD with the disease-associated 
markers already identified within the same genes. In both models, the robustness of 
the retained variables was verified by bootstrapping. Markers in HLA-DPB1 were 
consistently selected across the 1,000 bootstrap models by both the penalised 
methods. The marker-disease associations in MICA and TRIM26 were questionable 
since these were retained less frequently compared to those in HLA-DPB1. In contrast 
to the LASSO, the HLASSO selected SNPs that give the same genetic information, 
i.e. SNPs in high LD with each other, each time in different models, suggesting that 
the HLASSO can infer the number of causal variants that might be associated with 
RA and refine the location of the causal elements.  
 Variants in HLA-DPB1 have recently been associated with RA in two 
association studies [33, 52]. These studies identified HLA-DPB1 as a DRB1-
independent risk locus associated with the presence of anti-CCP+, a clinical subtype 
of RA. Further analyses revealed that the associated marker rs3117225 in HLA-DPB1 
was in high LD with the marker rs3117213 that was reported by Ding et al. [33], also 
 152 
 
in HLA-DPB1 (r
2 
= 0.96). This finding suggests that a variant in HLA-DPB1 might be 
involved in the pathogenesis of RA in addition to the effect of HLA-DRB1.  
 The class II HLA-DP molecule is a glycoprotein composed of two 
polymorphic polypeptide chains, the α chain and the highly polymorphic β chain. The 
role of the HLA-DP molecule is to trigger an immune response through antigen 
presentation. Alleles at HLA-DPB1 have been implicated in a number of autoimmune 
diseases such as juvenile chronic arthritis [150], graft-versus-host disease [151], 
Grave‟s disease [152], Type I diabetes [153] and more recently systemic sclerosis 
[154]. There is hence strong evidence that the class II classical HLA marker HLA-
DPB1 might play an important role in autoimmune diseases.  
 Although there is evidence of additional RA risk loci in the HLA region that 
are independent of the HLA-DRB1 alleles, the cross-validation analysis revealed that 
these associations contribute far less than the well-known SE risk effect in the 
combined WTCCC and GoRA study. This finding was also observed by Plenge et al. 
[29]. Further large-scale analyses are required to elucidate the complex relationship 
between HLA-DPB1 and RA susceptibility. High-resolution typing of HLA-DPB1 
would permit one for instance to assess whether these associations are restricted to 
specific HLA-DPB1 RA risk alleles.  
 
 
7.2 Discussion on the LASSO and HLASSO logistic regression 
 
 The LASSO and HLASSO regression approaches showed apparent benefit in 
the reduction of positive associations. The main challenge of these penalised 
regression approaches is choosing the proper amount of penalty, i.e. the DE or NEG 
prior distribution of the parameters, for consistent variable selection. The choice of 
prior is important as it can lead to different MAP estimates. No established 
methodology has been developed to select optimal values for the prior parameters. As 
is the case with any prior specification approach, there is reliance instead on the 
statistician‟s judgement, an uneasy situation when there is so much scope to introduce 
selection bias and distort the results.  
 Permutation using a bracketing and a bisecting approach provided a good 
alternative for estimating the DE penalty factor λL, while controlling for the per-SNP 
type-I error rate. With respect to the NEG distribution, this assessment showed that a 
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shape parameter λH of 1 allowed identification of the important SNPs, while removing 
associations that are due to LD.  
 Overall, the LASSO and HLASSO may be useful for identifying risk loci that 
deserve further investigation in a densely genotyped region of high LD, through the 
derivation of sparse models. An important application of the HLASSO is to infer the 
number of causal loci that might be associated with the endpoint. The main 
disadvantage of both methods is the provision of shrunk estimates that are biased 
towards the origin and cannot be used in prediction. Instead, the shrunk estimates may 
be ranked by order of importance, which can provide a good alternative to P-values. 
Alternatively, the regression coefficients of those predictors can be obtained by 
applying a traditional multi-SNP logistic regression model [86]. In addition, 
bootstrapping can be used to identify the set of important loci by assessing the 
frequency with which each SNP is selected and the robustness of the SNP selection 
process.  
 
 
7.3 Areas for further investigation  
 
 Recently, Meinshausen and Buhlmann [145] proposed Stability Selection, 
which is based on sub-sampling in combination with variable selection algorithms. 
Their method addresses the two main challenges of penalised regression, namely the 
selection of the appropriate penalty factor and assessing the stability of the retained 
predictors. With Stability Selection, sub-samples are drawn without replacement and 
variable selection methodology such as the LASSO is applied many times. The 
frequencies of with which each predictor is selected, are used to identify the relevant 
variables. Bootstrapping can be used in place of sub-sampling.  
 At first sight, their approach seems equivalent to the combined penalised 
logistic regression/boostrapping method used here, but the advantage of Stability 
Selection is the choice of a set of penalty factors, which are determined for a desired 
expected number of false positives. Furthermore, they showed that the solutions of 
Stability Selection are less sensitive to the choice of the penalty factors than are those 
from LASSO. In addition, they proposed the use of randomised LASSO, which 
introduces random penalty weights to the estimation of the regression parameters. 
They showed that sub-sampling in conjunction with randomised LASSO improved 
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the selection of the relevant predictors substantially over the LASSO in the presence 
of multi-collinearity. It will be of interest to apply Stability Selection to the combined 
GoRA and WTCCC studies using HLASSO and compare the selection of the prior 
parameters and the robustness of the models derived. 
 Since the LASSO and HLASSO can include a large number of covariates, 
another application that deserves further investigation is the use of the LASSO and 
HLASSO to correct for population stratification. Setakis et al. [155] reported through 
a simulation study that the inclusion of genome-wide null markers as covariates, i.e. a 
set of non-associated SNP in low LD, could protect against false positive results by 
soaking up the effect of population stratification. Further work can be performed to 
assess whether this approach could refine the identification of the causal elements 
from the HLA region, especially when combining samples from different platform 
using genotype imputation techniques. Necessary resources would include access to 
WGA data for the GoRA study. 
 The proposed penalised logistic approaches are Bayesian-inspired methods in 
the sense that parameter estimates are based on the posterior mode rather than the full 
distribution. As a result, both approaches are computationally faster than Bayesian 
methods. A number of authors have explored the Bayesian version of the LASSO. 
These have often used the Gibbs sampler, which is a computationally demanding 
sampling procedure in presence of a large number of predictors [126, 156-160]. With 
the advances of technology and Markov Chain Monte Carlo (MCMC) algorithms that 
generate posterior samples, Bayesian methods can be applied to markers from densely 
genotyped regions [156]. Hans [157] applied the Bayesian LASSO regression and 
showed that the approach yielded a reduction of the prediction error compared to 
standard LASSO procedures. Yi et al. [156] applied the Bayesian LASSO to a set of 
127 candidate markers in a quantitative trait analysis using MCMC techniques. They 
showed that the Bayesian approaches performed well in identifying the positive 
signals. Unlike the Bayesian-inspired methods, Yi et al. [156] extended the Bayesian 
LASSO model to account for the uncertainty in the penalty factors by considering 
these parameters as unknowns and estimating them along with the other parameters, 
which might provide a substantial benefit compared to traditional approaches that rely 
on arbitrary criteria. It will hence be of interest to apply the Bayesian LASSO to the 
WTCCC and GoRA dataset and extend this approach to the NEG prior distribution. 
The Bayesian approaches being computationally intensive, one possibility is to 
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explore the posterior distribution of the set of selected SNP markers and assess the 
gain of using a fully Bayesian approach at the expense of time compared to a 
regression approach.  
 Overall, SNP selection using the LASSO and HLASSO are promising multi-
SNP association methods for the identification of causal variants. These penalised 
regression approaches can deal with the presence of LD and with cases in which the 
number of predictors exceeds the number of observations, as is the case in genetic 
association studies. This provides a substantial benefit compared to single-SNP 
association analyses in which true causal elements are often inconspicuous among 
many other positive association results.   
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Appendix  
 
Markers with P < 10
-4
 in the SE and *0101 adjusted analysis (additive model) 
Marker 
dbSNP127 
Position (kb) 
NCBI 36 
Gene (location) 
SE and *0101 
adjusted P 
SE  
adjusted P 
rs1059612 30816934 FLOT1 (intron) 1.3x10
-5
 3.7 x10
-5
 
rs1235162 29645203 UBD (5'-UTR) 3.5x10
-5
 7.4 x10
-5
 
rs1264308 30987966 GTF2H4 (intron) 1.0 x10
-6
 3.3 x10
-6
 
rs1264341 30910444 DDR1 (5'-UTR) 1.3 x10
-6
 4.3 x10
-6
 
rs1265178 31269208 HCG27 (5'-UTR) 9.4 x10
-5
 1.4x10
-4
 
rs1800629 31651010 TNF (5'-UTR) 8.4 x10
-5
 2.7x10
-4
 
rs2157678 30236928 TRIM10 (5'-UTR) 4.5 x10
-5
 8.4 x10
-5
 
rs2249464 30996140 VARS2L (coding) 8.3 x10
-5
 2.2x10
-4
 
rs2442728 31427334 HLA-B (3'-UTR) 7.3 x10
-6
 1.8 x10
-5
 
rs2524069 31352768 HLA-C (5'-UTR) 1.1 x10
-5
 3.4 x10
-5
 
rs2532934 31002738 VARS2L (3'-UTR) 8.5 x10
-5
 2.1x10
-4
 
rs2844657 30937501 DDR1 (5'-UTR) 1.2 x10
-6
 5.0 x10
-6
 
rs2857595 31676448 NCR3 (5'-UTR) 6.8 x10
-5
 3.1x10
-4
 
rs3094014 31541537 HCP5 (3'-UTR) 8.0 x10
-5
 1.5x10
-4
 
rs3094061 30429168 RPP21 (3'-UTR) 2.3 x10
-5
 5.7 x10
-5
 
rs3094064 30404232 TRIM39 (intron) 1.6 x10
-5
 4.1 x10
-5
 
rs3095338 30839380 IER3 (5'-UTR) 9.6 x10
-6
 2.6 x10
-5
 
rs3129820 30451548 RPP21 (3'-UTR) 6.8 x10
-5
 1.5x10
-4
 
rs3129973 30829122 IER3 (5'-UTR) 1.2 x10
-5
 3.3 x10
-5
 
rs3130247 30623022 GNL1 (coding) 1.3 x10
-5
 3.4 x10
-5
 
rs3130352 30436336 RPP21 (3'-UTR) 1.5 x10
-5
 3.8 x10
-5
 
rs3130364 30427133 RPP21 (3'-UTR) 2.5 x10
-5
 6.5 x10
-5
 
rs3130374 30429315 RPP21 (3'-UTR) 2.2 x10
-5
 5.1 x10
-5
 
rs3130380 30387109 TRIM39 (5'-UTR) 1.4 x10
-5
 3.1 x10
-5
 
rs3130557 31202682 PSORS1C (intron) 3.1 x10
-6
 9.8 x10
-6
 
rs3130673 30854498 IER3 (5'-UTR) 2.5x10
-5
 8.3 x10
-5
 
rs3130782 31022822 LOC7297 (5'-UTR) 1.3 x10
-5
 4.0 x10
-5
 
rs3130955 31162490 C6orf15 (3'-UTR) 3.9 x10
-5
 2.6 x10
-5
 
rs3131934 31039823 LOC6465 (5'-UTR) 3.0 x10
-6
 1.0 x10
-5
 
rs3132450 31704117 BAT2 (intron) 3.1 x10
-5
 4.3 x10
-5
 
rs3132472 31494110 MICA (3'-UTR) 2.2 x10
-6
 6.2 x10
-6
 
rs3132571 31013292 SFTPG (5'-UTR) 2.5 x10
-5
 4.4 x10
-5
 
rs3132579 31048968 LOC6465 (3'-UTR) 8.7 x10
-6
 3.0x10
-5
 
rs3132580 31028103 DPCR1 (coding) 4.3 x10
-6
 1.1x10
-5
 
rs3132610 30652380 ABCF1 (intron) 1.4 x10
-5
 3.1 x10
-5
 
rs389419 29629424 UBD (3'-UTR) 9.3 x10
-5
 2.0x10
-4
 
rs404240 29631936 UBD (coding) 6.5 x10
-5
 1.4x10
-4
 
rs4678 31001920 VARS2L (coding) 5.0 x10
-7
 1.7 x10
-6
 
rs753725 30998850 VARS2L(intron) 5.4 x10
-5
 1.5x10
-4
 
rs7750641 31237289 TCF19 (coding) 2.2 x10
-6
 6.6 x10
-6
 
rs886422 30972258 DDR1 (intron) 9.6 x10
-7
 3.0 x10
-6
 
rs9261290 30146626 RNF39 (coding) 1.6x10
-5
 4.1 x10
-5
 
rs1592409 29599902 LOC729653(3'-UTR) 6.3x10
-5
 8.2x10
-5
 
rs3130123 30460626 RPP21 (3'-UTR) 5.8x10
-5
 1.3x10
-4
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Markers with P < 10
-4
 in the SE and *0101 adjusted analysis (general model) 
Marker 
dbSNP127 
Position (kb) 
NCBI 36 
Gene (location) 
SE and *0101 
adjusted P 
SE  
adjusted P 
rs1059612 30816934 FLOT1 (intron) 7.6x10
-5
 2.0x10
-4
 
rs1235162 29645203 UBD (5'-UTR) 7.2x10
-5
 1.8x10
-4
 
rs1264308 30987966 GTF2H4 (intron) 6.5x10
-6
 2.0x10
-5
 
rs1264341 30910444 DDR1 (5'-UTR) 8.3x10
-6
 2.6x10
-5
 
rs2442728 31427334 HLA-B (3'-UTR) 1.3x10
-5
 3.0x10
-5
 
rs2524069 31352768 HLA-C (5'-UTR) 5.9x10
-5
 1.6x10
-4
 
rs2844657 30937501 DDR1 (5'-UTR) 6.9 x10
-6
 2.7x10
-5
 
rs3094064 30404232 TRIM39 (intron) 9.2 x10
-5
 2.2x10
-4
 
rs3095338 30839380 IER3 (5'-UTR) 5.5 x10
-5
 1.1x10
-4
 
rs3129973 30829122 IER3 (5'-UTR) 6.4Ex10
-5
 1.6x10
-4
 
rs3130247 30623022 GNL1 (coding) 7.5 x10
-5
 1.9x10
-4
 
rs3130352 30436336 RPP21 (3'-UTR) 7.8 x10
-5
 1.9x10
-4
 
rs3130374 30429315 RPP21 (3'-UTR) 9.9 x10
-5
 2.1x10
-4
 
rs3130380 30387109 TRIM39 (5'-UTR) 7.6 x10
-5
 1.6x10
-4
 
rs3130557 31202682 PSORS1C1 (intron) 1.8 x10
-5
 5.5x10
-5
 
rs3130782 31022822 LOC729778 (5'-UTR) 7.2 x10
-5
 1.9x10
-4
 
rs3131934 31039823 LOC646570 (5'-UTR) 1.6 x10
-5
 5.4x10
-5
 
rs3132472 31494110 MICA (3'-UTR) 1.3 x10
-5
 3.4 x10
-5
 
rs3132571 31013292 SFTPG (5'-UTR) 5.1 x10
-5
 8.7 x10
-5
 
rs3132579 31048968 LOC646570 (3'-UTR) 3.3 x10
-5
 1.1x10
-4
 
rs3132580 31028103 DPCR1 (coding) 2.6 x10
-5
 6.4 x10
-5
 
rs3132610 30652380 ABCF1 (intron) 6.5 x10
-5
 1.5x10
-4
 
rs4678 31001920 VARS2 (coding) 1.2 x10
-6
 4.3x10
-6
 
rs7750641 31237289 TCF19 (coding) 1.3 x10
-5
 3.8 x10
-5
 
rs886422 30972258 DDR1 (intron) 6.1 x10
-6
 1.8 x10
-5
 
rs9261290 30146626 RNF39 (coding) 7.6 x10
-5
 1.9x10
-4
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